Neoplasms
Conditions
Keywords
ICOS receptor agonist antibody, Pembrolizumab, KEYNOTE-478, GSK3359609, Cohort expansion, Dose escalation, Dostarlimab, Cobolimab, Bintrafusp alfa
Brief summary
GSK3359609 is an anti-Inducible T cell Co-Stimulator (ICOS) receptor agonist antibody intended for the treatment of cancers of different histology. This is a first-time-in-human (FTIH), open-label, multicenter study designed to investigate the safety, pharmacology, and preliminary antitumor activity in participants with selected, advanced or recurrent solid tumors with the aim to establish recommended dose(s) of GSK3359609 for further exploration as monotherapy and in combination with pembrolizumab or chemotherapy regimens. The study is comprised of two primary parts, each composed of two phases: Part 1: GSK3359609 monotherapy with Part 1A as dose escalation phase and Part 1B as cohort expansion phase; Part 2: GSK3359609 combination therapy with Part 2A pembrolizumab or GSK3174998 or chemotherapy or pembrolizumab plus chemotherapy or dostarlimab plus cobolimab or Bintrafusp alfa combination dose escalation phase and Part 2B expansion phase with pembrolizumab. The primary objective of the study is to determine the safety, tolerability, maximum tolerated dose or the maximum administered dose of GSK3359609 alone or in combination.
Interventions
DRUGfeladilimab (GSK3359609)
DRUGGSK3174998
DRUGPembrolizumab
DRUGDocetaxel
DRUGPemetrexed
DRUGFluorouracil (5-FU) plus carboplatin or cisplatin
DRUGDostarlimab
DRUGCobolimab
DRUGBintrafusp alfa
Sponsors
Merck Sharp & Dohme LLC
GlaxoSmithKline
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 93 Years
Healthy volunteers
No
Inclusion criteria
* Capable of giving signed, written informed consent. * Male or female, age 18 to 93 years (at the time consent is obtained). * Histological or cytological documentation of an invasive malignancy that was diagnosed as locally advanced/metastatic or relapsed/refractory and is of one of the following tumor types: bladder/urothelial cancer of the upper and lower urinary tract; cervical; colorectal (includes appendix); esophagus, squamous cell; head and neck carcinoma; melanoma; malignant pleural mesothelioma (MPM); non-small-cell lung cancer (NSCLC), prostate; Microsatellite Instability-High/deficient mismatch repair (MSI-H/dMMR) tumor (Part 1B and Part 2B) and Human Papilloma Virus (HPV)-positive or Epstein-Barr (EBV)-positive tumor (Part 1B and Part 2B). * Disease that has progressed after standard therapy for the specific tumor type, or for which standard therapy has proven to be ineffective, intolerable, or is considered inappropriate, or if no further standard therapy exists; exceptions are in these tumor types in which pembrolizumab single agent may be a standard: NSCLC, head and neck squamous cell cancer (HNSCC), bladder/urothelial cancer, MSI-H/dMMR cancers and melanoma and cervical cancer. In Part 2B pembrolizumab combination expansion cohorts, prior treatment with anti-Programmed cell death protein 1(PD-1)/ Ligand-1 (L1) may not be required. 1) Participants must not have received more than 5 prior lines of therapy for advanced disease including both standards of care and investigational therapies. 2) Participants who received prior PD-1/L1 therapy must fulfill the following requirements (Part 1B \[except PK/PD cohort\]/ Part 2B):a) Have achieved a CR, PR or SD and subsequently had disease progression while still on PD-1/L1 therapy; b) Have received at least 2 doses of an approved PD-1/L1 inhibitor (by any regulatory authority), c) Have demonstrated disease progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 within 18 weeks from the last dose of the PD-1/L1 inhibitor. The initial evidence of disease progression is to be confirmed by a second assessment no less than four weeks from the date of the first documented Progressive Disease (PD) (the confirmatory scan could be the Baseline eligibility scan for this study). 3) In Part 2A 5-fluorouracil (FU)/platinum combination with GSK3359609 and pembrolizumab cohort, participants must not have received prior systemic therapy administered in the recurrent or metastatic setting (with the exception of systemic therapy given as part of multimodal treatment for locally advanced disease). * Archival tumor tissue obtained at any time from the initial diagnosis to study entry; a fresh tumor biopsy using a procedure that is safe for the participant on a lesion not previously irradiated unless lesion progressed will be required if archival tissue is unavailable. * Agree to undergo a pre-treatment and on treatment biopsy and have disease amenable to biopsy required in pharmacokinetic (PK) / pharmacodynamics (PD), dose randomized HNSCC, Melanoma dose expansion and Biomarker cohorts.. * Measurable disease per RECIST version 1.1. Palpable lesions that are not measurable by radiographic or photographic evaluations may not be utilized as the only measurable lesion. Any measurable lesion biopsied at Screening cannot be followed as a target/index lesion unless agreed upon by GlaxoSmithKline (GSK). * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1. * Life expectancy of at least 12 weeks. * Adequate organ function. * QT interval corrected for heart rate according to Fridericia's formula (QTcF) \<450 milliseconds (msec) or QTcF \<480 msec for participants with bundle branch block. * A female participant is eligible to participate if she is not pregnant (as confirmed by a negative serum beta-human chorionic gonadotrophin \[beta-hCG\] test in females of reproductive potential), and not lactating or reproductive potential agrees to follow one of the options listed in protocol from 30 days prior to the first dose of study medication and until 120 days after the last dose of study treatment. * Male participants with female partners of child bearing potential must agree to use one of the methods of contraception specified in protocol from time of first dose of study treatment until 120 days after the last dose of study treatment. * Documented HPV/ EBV-positive tumor as determined by a local laboratory for Part 1B and Part 2B pembrolizumab combination viral-positive expansion cohorts only. * Documented MSI-H or dMMR-positive tumor as determined by local laboratory for Part 1B and Part 2B pembrolizumab combination MSI-H/dMMR expansion cohorts only. * ICOS expression result using an analytically validated immunohistochemistry (IHC) assay by central laboratory for Part 1B biomarker cohort only. * Gene expression (GEX) result using an analytically validated method by central laboratory (Part 1B Biomarker Cohort only). * PD-L1 combined positive score (CPS) \<1 using the Food and Drug Administration (FDA) approved PD-L1 IHC 22C3 pharmdx assay by central laboratory testing for Part 2B HNSCC PD-L1 CPS \<1 Cohort. Documented test result from FDA approved PD-L1 IHC 22C3 pharmDx assay in local laboratory, if available, may be accepted in lieu of the central laboratory test result.
Exclusion criteria
* Prior treatment with the following therapies: • Anticancer therapy within 30 days or 5 half-lives of the drug, whichever is shorter. At least 14 days must have elapsed between the last dose of prior anticancer agent and the first dose of study drug is administered. • Part 2B (GSK3359609/pembrolizumab combination): prior pembrolizumab washout is not required. • Prior radiation therapy: permissible if at least one non-irradiated measurable lesion is available for assessment according to RECIST version 1.1 or if a solitary measurable lesion was irradiated, objective progression is documented. A wash out of at least two weeks before start of study drug for radiation of any intended use to the extremities for bone metastases and 4 weeks for radiation to the chest, brain, or visceral organs is required. • Investigational therapy within 30 days or 5 half-lives of the investigational product (whichever is shorter). At least 14 days must have elapsed between the last dose of investigational agent and the first dose of study drug is administered. * Prior allogeneic or autologous bone marrow transplantation or other solid organ transplantation. * Toxicity from previous anticancer treatment * Invasive malignancy or history of invasive malignancy other than disease under study within the last two years except: Any other invasive malignancy for which the participant was definitively treated, has been disease-free for \<=2 years and in the opinion of the principal investigator and GSK Medical Monitor will not affect the evaluation of the effects of the study treatment on the currently targeted malignancy, may be included in this clinical trial; and curatively treated non-melanoma skin cancer. * Central nervous system (CNS) metastases, with the following exception: • Participants who have previously-treated CNS metastases, are asymptomatic, and have no requirement for steroids at least 14 days prior to first dose of study drug. Participants with carcinomatous meningitis or leptomeningeal spread are excluded regardless of clinical stability. * Received transfusion of blood products (including platelets or red blood cells) or administration of colony stimulating factors (including granulocyte colony-stimulating factor \[G-CSF\], granulocyte-macrophage colony-stimulating factor, recombinant erythropoietin) within 14 days prior to the first dose of GSK3359609. * Major surgery \<=4 weeks before the first dose of study treatment. Participants must have also fully recovered from any surgery (major or minor) and/or its complications before initiating study treatment. * Active autoimmune disease that has required systemic treatment within the last two years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. * Concurrent medical condition requiring the use of systemic immunosuppressive medications within 7 days before the first dose of study treatment. Physiologic doses of corticosteroids for treatment of endocrinopathies or steroids with minimal systemic absorption, including topical, inhaled, or intranasal corticosteroids may be continued if the participant is on a stable dose. * Condition requiring treatment with strong inhibitors/inducers of cytochrome p (CYP) 450 3A4 within 7 days prior to first dose of chemotherapy (requirement applies to participants enrolled to Part 2 chemotherapy combination with docetaxel). * Active infection requiring systemic therapy, known human immunodeficiency virus infection, or positive test for hepatitis B active infection or hepatitis C active infection. * Current active liver or biliary disease (with the exception of Gilbert's syndrome or asymptomatic gallstones, liver metastases, or otherwise stable chronic liver disease per investigator assessment). * Recent history (within the past 6 months) of acute diverticulitis, inflammatory bowel disease, intra-abdominal abscess, or gastrointestinal obstruction that required surgery. * Receipt of any live vaccine within 4 weeks prior to first dose of study treatment. * Recent history of allergen desensitization therapy within 4 weeks of starting study treatment. * History of severe hypersensitivity to monoclonal antibodies or to the chemotherapies under investigation including any ingredient used in the formulation. * History or evidence of cardiac abnormalities. * History of (current and past) idiopathic pulmonary fibrosis, pneumonitis (for past pneumonitis exclusion only if steroids were required for treatment), interstitial lung disease, or organizing pneumonia. Note: post-radiation changes in the lung related to prior radiotherapy and/or asymptomatic radiation-induced pneumonitis not requiring treatment may be permitted if agreed by the investigator and Medical Monitor. * Recent history (within 6 months) of uncontrolled symptomatic ascites or pleural effusions. * Any serious and/or unstable pre-existing medical, psychiatric disorder, or other condition that could interfere with the participant's safety, obtaining informed consent, or compliance to the study procedures.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Part 1A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Up to approximately 367 weeks | An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, or is a congenital anomaly/birth defect, other situations which involve medical or scientific judgment or is associated with liver injury and impaired liver function. SAEs are subset of AEs. A summary of number of participants with any AEs and SAEs is presented. AEs were coded using the Medical Dictionary for Regulatory Affairs (MedDRA dictionary). |
| Part 1A: Number of Participants With Dose Limiting Toxicity (DLT) | Up to 28 days | DLT is an AE that is considered by the investigator to be clinically relevant and attributed to the study therapy during the 28-day DLT period and meets at least one of the DLT criteria: Febrile neutropenia; Grade 4 neutropenia of \>7 days in duration or requiring Granulocyte Colony-stimulating Factor (G-CSF), anemia, thrombocytopenia, non-hematologic toxicity; Grade 3 thrombocytopenia with bleeding, pneumonitis, toxicity that does not resolve to Grade 1 or baseline within 3 days; Grade 2 ocular toxicity; Toxicity that results in permanent discontinuation of feladilimab during the first four weeks of treatment; any other event which in the judgment of the investigator and GSK Medical Monitor is considered to be a DLT. |
| Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Baseline (Day 1) and up to approximately 367 weeks | Blood samples were collected for analysis of clinical chemistry parameters. Laboratory parameters were graded according to CTCAE v4.03. Grade (G) 0: None; G1: mild; G2: moderate; G3: severe or medically significant; G4: life-threatening consequences. Higher grade indicates greater severity and increase in grade was defined relative to Baseline grade. Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Only grade change data is presented for Baseline (B) and Worst-Case Post-Baseline (WCPB) as G0, G1, G2, G3, G4, and missing (M) here as Parameter name, B GX, WCPB GX where X=grade digit. |
| Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Up to approximately 367 weeks | Normal ranges were 0.1 to 0.3 micromoles (umol)/liter (L) (direct bilirubin); 6 to 8.3 grams/L (protein); 100 to 250 international units (IU)/L (Lactate Dehydrogenase(LDH)); 2.3 - 4.1 picomoles/L (Free Triiodothyronine(T3)); 4.6 to 11.2 picomoles/L (Free Thyroxine(T4)); 0 and 0.04 microgram (ug)/L (Troponin I); 0 - 0.01 ug/L (Troponin T); 0.45 to 4.5 milliunits (Mu)/L (Thyrotropin(TSH)); and 6 to 24 millimoles/L (Urea). Participants were counted in worst case category that their value changes to low, normal or no change \[NC\] or high), unless there is NC in their category. Participants whose laboratory value category was unchanged (e.g. High to High) or whose value became normal, were recorded in To Normal or No Change category. Participants were counted twice if participant had values that changed To Low and To High, so percentages may not add to 100%. |
| Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Baseline (Day 1) and up to approximately 367 weeks | Blood samples were collected for analysis of hematology parameters. Laboratory parameters were graded according to CTCAE v4.03. Grade (G) 0: None; G1: mild; G2: moderate; G3: severe or medically significant; G4: life-threatening consequences. Higher grade indicates greater severity and increase in grade was defined relative to Baseline grade. Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Only grade change data is presented for Baseline (B) and Worst-Case Post-Baseline (WCPB) as G0, G1, G2, G3, G4, and missing (M) here as Parameter name, B GX, WCPB GX where X=grade digit. |
| Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Up to approximately 367 weeks | Normal ranges were 0.01 to 0.3\*10\^9 cells/L (basophils), 0 to 500 cells /L (eosinophils), 41 to 50 percentage of red blood cells (RBC) in blood (hematocrit), 1,000 - 4,800 lymphocytes per microliter (µL) of blood (lymphocytes), 80-100 femtoliters (fl) (erythrocytes, mean corpuscular volume), 2 to 8 percentage of WBC (monocytes), 40 to 60 cells/mcL (neutrophils) and Women: 4.2 to 5.4 million RBC/ microliter (mcL) of blood and Men: 4.7 to 6.1 million RBC/ mcL (erythrocytes count). Participants were counted in worst case category that their value changes to low, normal or no change \[NC\] or high), unless there is NC in their category. Participants whose laboratory value category was unchanged (e.g. High to High) or whose value became normal, were recorded in To Normal or No Change category. Participants were counted twice if participant had values that changed To Low and To High, so percentages may not add to 100%. |
| Part 1A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Up to approximately 367 weeks | Urine samples were collected to assess urine glucose, ketones and occult blood using dipstick method. The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as negative, trace, 1+, 2+, 3+ indicating proportional concentrations in the urine sample. Baseline (Day 1) was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Result for urinalysis parameters were recorded as no change/decreased and any increase. |
| Part 1A: Number of Participants With Dose Modifications of Feladilimab | Up to approximately 367 weeks | Number of participants with dose modifications (including dose delays, dose escalations and infusion interruptions) were reported for Feladilimab. |
| Part 2A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Up to approximately 367 weeks | An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that, at any dose results in death, Is life-threatening, Requires inpatient hospitalization or prolongation of existing hospitalization, Results in persistent disability/incapacity or Is a congenital anomaly/birth defect, Other situations which involve medical or scientific judgment or is associated with liver injury and impaired liver function. SAEs are subset of AEs. A summary of number of participants with any AEs and SAEs is presented. AEs were coded using the MedDRA dictionary. |
| Part 2A: Number of Participants With Dose Limiting Toxicity (DLT) | Up to 28 days | DLT is an AE that is considered by the investigator to be clinically relevant and attributed to the study therapy during the 28-day DLT period and meets at least one of the DLT criteria: Febrile neutropenia; Grade 4 neutropenia of \>7 days in duration or requiring Granulocyte Colony-stimulating Factor (G-CSF), anemia, thrombocytopenia, non-hematologic toxicity; Grade 3 thrombocytopenia with bleeding, pneumonitis, toxicity that does not resolve to Grade 1 or baseline within 3 days; Grade 2 ocular toxicity; Toxicity that results in permanent discontinuation of feladilimab monotherapy or in combination during the first four weeks of treatment; any other event which in the judgment of the investigator and GSK Medical Monitor is considered to be a DLT. |
| Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Baseline (Day 1) and up to approximately 367 weeks | Blood samples were collected for analysis of clinical chemistry parameters. Laboratory parameters were graded according to CTCAE v4.03. Grade (G) 0: None; G1: mild; G2: moderate; G3: severe or medically significant; G4: life-threatening consequences. Higher grade indicates greater severity and increase in grade was defined relative to Baseline grade. Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Only grade change data is presented for Baseline (B) and Worst-Case Post-Baseline (WCPB) as G0, G1, G2, G3, G4, and missing (M) here as Parameter name, B GX, WCPB GX where X=grade digit. |
| Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Up to approximately 367 weeks | Normal ranges were 6 to 8.3 grams/L (protein); 100 to 250 international units (IU)/L (Lactate Dehydrogenase(LDH)); 2.3 - 4.1 picomoles/L (Free Triiodothyronine(T3)); 4.6 to 11.2 picomoles/L (Free Thyroxine(T4)); 0 and 0.04 microgram (ug)/L (Troponin I); 0 - 0.01 ug/L (Troponin T); 0.45 to 4.5 milliunits (Mu)/L (Thyrotropin(TSH)); and 6 to 24 millimoles/L (Urea). Participants were counted in worst case category that their value changes to low, normal or no change \[NC\] or high), unless there is NC in their category. Participants whose laboratory value category was unchanged (e.g. High to High) or whose value became normal, were recorded in To Normal or No Change category. Participants were counted twice if participant had values that changed To Low and To High, so percentages may not add to 100%. |
| Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Baseline (Day 1) and up to approximately 367 weeks | Blood samples were collected for analysis of hematology parameters. Laboratory parameters were graded according to CTCAE v4.03. Grade (G) 0: None; G1: mild; G2: moderate; G3: severe or medically significant; G4: life-threatening consequences. Higher grade indicates greater severity and increase in grade was defined relative to Baseline grade. Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Only grade change data is presented for Baseline (B) and Worst-Case Post-Baseline (WCPB) as G0, G1, G2, G3, G4, and missing (M) here as Parameter name, B GX, WCPB GX where X=grade digit. |
| Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Up to approximately 367 weeks | Normal ranges were 0.01 to 0.3\*10\^9 cells/L (basophils), 0 to 500 cells /L (eosinophils), 41 to 50 percentage of RBC in blood (hematocrit), 2 to 8 percentage of WBC (monocytes), 40 to 60 cells/mcL (neutrophils) and Women: 4.2 to 5.4 million RBC/mcL of blood and Men: 4.7 to 6.1 million RBC/ mcL (erythrocytes count). Participants were counted in worst case category that their value changes to low, normal or no change \[NC\] or high), unless there is NC in their category. Participants whose laboratory value category was unchanged (e.g. High to High) or whose value became normal, were recorded in To Normal or No Change category. Participants were counted twice if participant had values that changed To Low and To High, so percentages may not add to 100%. |
| Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Up to approximately 367 weeks | Urine samples were collected to assess urine glucose, ketones and occult blood using dipstick method. The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as negative, trace, 1+, 2+, 3+ indicating proportional concentrations in the urine sample. Baseline (Day 1) was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Result for urinalysis parameters were recorded as no change/decreased and any increase. |
| Part 2A: Number of Participants With Dose Modifications of Feladilimab | Up to approximately 367 weeks | Number of participants with dose modifications (including dose delays, dose escalations, and infusion interruptions) were reported for Feladilimab |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Part 1A: Overall Survival (OS) | Up to approximately 367 weeks | OS was defined as the interval between the date of first assigned study therapy/randomization and date of death due to any cause. |
| Part 1A: Progression-free Survival (PFS) | Up to approximately 367 weeks | PFS was defined as the interval between the date of first dose of study treatment (or date of randomization for randomized cohorts) and the date of disease progression according to radiological response from investigator assessment, or death due to any cause, whichever occurs earlier. Disease progression was defined as the date of radiological disease progression based on imaging data per RECIST v1.1 |
| Part 1A: Time to Overall Response (TTR) | Up to approximately 367 weeks | TTR was defined as the time from date of first dose of study treatment/randomization to the date of first documented confirmed (=4 weeks) CR or PR. CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 mm. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters. |
| Part 1A: Duration of Response (DOR) | Up to approximately 367 weeks | DOR was defined as the interval of time in months from the date of the first documented evidence of a response (confirmed CR or PR) to the date of first documented evidence of disease progression according to radiological response from investigator assessment per RECIST v1.1, or date of last adequate assessment of response or the date of death due to any cause (whichever occurs earlier). CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 mm. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters. Disease progression was defined as the date of radiological disease progression based on imaging data per RECIST v1.1. |
| Part 2A: Overall Response Rate (ORR) | Up to approximately 367 weeks | ORR was defined as the percentage of participants with irCR or irPR per irRECIST. irCR is defined as disappearance of all target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimeters (mm). irPR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters. |
| Part 2A: Disease Control Rate (DCR) | Up to approximately 367 weeks | DCR was defined as percentage of participants with best overall response of irCR or irPR at any time + irSD meeting the minimum time criteria from the start of treatment until irPD or death due to any cause or the start of new anticancer therapy/crossover. irCR defined as disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \<10 mm. irPR defined as at least 30% decrease in the sum of diameters of target lesions, taking as a reference, the baseline sum of the diameters. irSD defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease. IrPD defined as the date of radiological disease progression based on imaging data per irRECIST. A one-week visit window was considered in the duration of irSD, i.e. a minimum of 8 weeks (irSD\>=9 weeks) and 17 weeks (irSD\>=18 weeks) were considered. |
| Part 2A: Overall Survival (OS) | Up to approximately 367 weeks | OS was defined as the interval between the date of first assigned study therapy/randomization and date of death due to any cause. |
| Part 2A: Progression-free Survival (PFS) | Up to approximately 367 weeks | PFS was defined as the interval between the date of first dose of study treatment (or date of randomization for randomized cohorts) and the date of disease progression according to radiological response from investigator assessment, or death due to any cause, whichever occurs earlier. Disease Progression was defined as the date of radiological disease progression based on imaging data per RECIST v1.1. |
| Part 2A: Time to Overall Response (TTR) | Up to approximately 367 weeks | TTR was defined as the time from date of first dose of study treatment/randomization to the date of first documented confirmed (=4 weeks) CR or PR. CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 mm. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters. |
| Part 2A: Duration of Response (DOR) | Up to approximately 367 weeks | DOR was defined as the interval of time in months from the date of the first documented evidence of a response (confirmed CR or PR) to the date of first documented evidence of disease progression according to radiological response from investigator assessment per RECIST v1.1, or date of last adequate assessment of response or the date of death due to any cause (whichever occurs earlier). CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 mm. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters. Disease progression is defined as the date of radiological disease progression based on imaging data per RECIST v1.1. |
| Part 1B: Overall Response Rate (ORR) | Up to approximately 367 weeks | ORR was defined as the percentage of participants with a confirmed irCR or confirmed irPR per irRECIST. irCR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. irPR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters. |
| Part 1B: Disease Control Rate (DCR) | Up to approximately 367 weeks | DCR was defined as percentage of participants with best overall response of irCR or irPR at any time + irSD meeting the minimum time criteria from the start of treatment until irPD or death due to any cause or the start of new anticancer therapy/crossover. irCR is defined as disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \<10 mm. irPR defined as at least 30% decrease in the sum of diameters of target lesions, taking as a reference, the baseline sum of the diameters. irSD defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease. IrPD defined as the date of radiological disease progression based on imaging data per irRECIST. A one-week visit window was considered in the duration of irSD, i.e. a minimum of 8 weeks (irSD\>=9 weeks) and 17 weeks (irSD\>=18 weeks) were considered. |
| Part 1B: Overall Survival (OS) | Up to approximately 367 weeks | OS was defined as the interval between the date of first assigned study therapy/randomization and date of death due to any cause. |
| Part 1B: Progression-free Survival (PFS) | Up to approximately 367 weeks | PFS was defined as the interval between the date of first dose of study treatment (or date of randomization for randomized cohorts) and the date of disease progression according to radiological response from investigator assessment, or death due to any cause, whichever occurs earlier. Disease progression was defined as the date of radiological disease progression based on imaging data per RECIST v1.1. |
| Part 1B: Time to Overall Response (TTR) | Up to approximately 367 weeks | TTR was defined as the time from date of first dose of study treatment/randomization to the date of first documented confirmed (=4 weeks) CR or PR. CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 mm. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters. |
| Part 1B: Duration of Response (DOR) | Up to approximately 367 weeks | DOR was defined as the interval of time in months from the date of the first documented evidence of a response (confirmed CR or PR) to the date of first documented evidence of disease progression according to radiological response from investigator assessment per RECIST v1.1, or date of last adequate assessment of response or the date of death due to any cause (whichever occurs earlier). CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 mm. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters. Disease progression is defined as the date of radiological disease progression based on imaging data per RECIST v1.1. |
| Part 2B: Overall Response Rate (ORR) | Up to approximately 367 weeks | ORR was defined as the percentage of participants with a confirmed irCR or confirmed irPR per irRECIST. irCR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. irPR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters. |
| Part 2B: Disease Control Rate (DCR) | Up to approximately 367 weeks | DCR was defined as the percentage of participants with a best overall response of irCR or irPR at any time plus irSD meeting the minimum time criteria from the start of treatment until irPD or death due to any cause or the start of new anticancer therapy/crossover. irCR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. irPR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters. irSD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease. irPD is defined as the date of radiological disease progression based on imaging data per irRECIST. A one-week visit window was considered in the duration of irSD, i.e. a minimum of 8 weeks (irSD\>=9 weeks) and 17 weeks (irSD\>=18 weeks) were considered. |
| Part 2B: Overall Survival (OS) | Up to approximately 367 weeks | OS was defined as the interval between the date of first assigned study therapy/randomization and date of death due to any cause. |
| Part 2B: Progression-free Survival (PFS) | Up to approximately 367 weeks | PFS was defined as the interval between the date of first dose of study treatment (or date of randomization for randomized cohorts) and the date of disease progression according to radiological response from investigator assessment, or death due to any cause, whichever occurs earlier. Disease progression was defined as the date of radiological disease progression based on imaging data per RECIST v1.1. |
| Part 2B: Time to Overall Response (TTR) | Up to approximately 367 weeks | TTR was defined as the time from date of first dose of study treatment/randomization to the date of first documented confirmed (=4 weeks) CR or PR. CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 mm. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters. |
| Part 2B: Duration of Response (DOR) | Up to approximately 367 weeks | DOR was defined as the interval of time in months from the date of the first documented evidence of a response (confirmed CR or PR) to the date of first documented evidence of disease progression according to radiological response from investigator assessment per RECIST v1.1, or date of last adequate assessment of response or the date of death due to any cause (whichever occurs earlier). CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters. Disease progression is defined as the date of radiological disease progression based on imaging data per RECIST v1.1 |
| Part 1A: Maximum Observed Plasma Concentration (Cmax) and Minimum Observed Plasma Concentration (Ctau) of Feladilimab | Pre-dose; end of infusion (EOI); 0.5, 1, 2, 4, 6, 8, 24, 48-72, 96-120 hours POST EOI; week 1; week 2; Pre-dose and 0.5 hours POST EOI in week 3; week 4; week 5; Pre-dose and 0.5 hours POST EOI in week 6, 9, 12 15; Pre-dose in week 21 and 33 | Blood samples were collected for Pharmacokinetic (PK) analysis. PK analysis was calculated based on standard non-compartmental method. |
| Part 1A: Area Under the Concentration-time Curve From Time 0 to 504 Hours After Dosing [AUC (0-504h)] of Feladilimab | Pre-dose; end of infusion (EOI); 0.5, 1, 2, 4, 6, 8, 24, 48-72, 96-120 hours post-EOI; week 1; week 2; Pre-dose and 0.5 hours post-EOI in week 3; week 4; week 5; Pre-dose and 0.5 hours post-EOI in week 6, 9, 12 15; Pre-dose in week 21 and 33 | Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method. |
| Part 2A: Ctau of Pembrolizumab | Pre-dose and 24 hours post-EOI on day 1; week 1; week 2; Pre-dose in week 3; week 4; week 5; Pre-dose in week 9, 15, 18, 21, 33, 45, 57, 69, 81 and 93 | Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method. |
| Part 2A: AUC (0-504h) of Pembrolizumab | Pre-dose and 24 hours post-EOI on day 1; week 1; week 2; Pre-dose in week 3; week 4; week 5; Pre-dose in week 9, 15, 18, 21, 33, 45, 57, 69, 81 and 93 | Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method. |
| Part 2A: Cmax and Ctau of GSK3174998 | Pre-dose and 24 hours post-EOI on day 1; week 1; week 2; Pre-dose in week 3; week 4; week 5; Pre-dose in week 9, 15, 18, 21, 33, 45, 57, 69, 81 and 93 | Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method. |
| Part 2A: AUC (0-504 h) of GSK3174998 | Pre-dose and 24 hours post-EOI on day 1; week 1; week 2; Pre-dose in week 3; week 4; week 5; Pre-dose in week 9, 15, 18, 21, 33, 45, 57, 69, 81 and 93 | Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method. |
| Part 1B: Cmax and Ctau of Feladilimab | Pre-dose; end of infusion (EOI); 0.5, 1, 2, 4, 6, 8, 24, 48-72, 96-120 hours post-EOI; week 1; week 2; Pre-dose and 0.5 hours post-EOI in week 3; week 4; week 5; Pre-dose and 0.5 hours post-EOI in week 6, 9, 12 15; Pre-dose in week 21, 33 and 45 | Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method. |
| Part 1B: AUC (0-504 h) of Feladilimab | Pre-dose; end of infusion (EOI); 0.5, 1, 2, 4, 6, 8, 24, 48-72, 96-120 hours post-EOI; week 1; week 2; Pre-dose and 0.5 hours post-EOI in week 3; week 4; week 5; Pre-dose and 0.5 hours post-EOI in week 6, 9, 12 15; Pre-dose in week 21, 33 and 45 | Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method. |
| Part 2B: Cmax and Ctau of Feladilimab | Pre-dose; EOI; 0.5, 1, 2, 4, 6, 8, 24, 48-72, 96-120 hours post-EOI; week 1; week 2; Pre-dose and 0.5 hours post-EOI in week 3; week 4; week 5; Pre-dose and 0.5, 4 hours post-EOI in week 6, 9, 12 and15; Pre-dose in week 18, 21, 33, 45, 57, 69, 81 and 93 | Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method. |
| Part 2B: AUC (0-504 h) of Feladilimab | Pre-dose; EOI; 0.5, 1, 2, 4, 6, 8, 24, 48-72, 96-120 hours post-EOI; week 1; week 2; Pre-dose and 0.5 hours post-EOI in week 3; week 4; week 5; Pre-dose and 0.5, 4 hours post-EOI in week 6, 9, 12 and15; Pre-dose in week 18, 21, 33, 45, 57, 69, 81 and 93 | Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method. |
| Part 2B: AUC (0-1008 h) of Feladilimab | Pre-dose; EOI; 0.5, 1, 2, 4, 6, 8, 24, 48-72, 96-120 hours post-EOI; week 1; week 2; Pre-dose and 0.5 hours post-EOI in week 3; week 4; week 5; Pre-dose and 0.5, 4 hours post-EOI in week 6, 9, 12 and15; Pre-dose in week 18, 21, 33, 45, 57, 69, 81 and 93 | Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method. |
| Part 2B: Cmax and Ctau of Pembrolizumab | Pre-dose; EOI; 0.5, 1, 2, 4, 6, 8, 24, 48-72, 96-120 hours post-EOI; week 1; week 2; Pre-dose and 0.5 hours post-EOI in week 3; week 4; week 5; Pre-dose and 0.5, 4 hours post-EOI in week 6, 9, 12 and15; Pre-dose in week 18, 21, 33, 45, 57, 69, 81 and 93 | Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method. |
| Part 1B: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Up to approximately 367 weeks | An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that, at any dose results in death, Is life-threatening, Requires inpatient hospitalization or prolongation of existing hospitalization, Results in persistent disability/incapacity or Is a congenital anomaly/birth defect, Other situations which involve medical or scientific judgment or is associated with liver injury and impaired liver function. SAEs are subset of AEs. A summary of number of participants with any AEs and SAEs is presented. AEs were coded using the MedDRA dictionary. |
| Part 1A: Number of Participants With Positive Results in Anti-drug Antibody (ADA) Test by Feladilimab Dose Level | Up to approximately 367 weeks | Serum samples collected and tested for the presence of ADA with a screening assay. |
| Part 2A: Number of Participants With Positive Results in ADA Test by Feladilimab in Combination With GSK3174998 Dose Level | Up to approximately 367 weeks | Serum samples collected and tested for the presence of ADA with a screening assay. |
| Part 2A: Number of Participants With Positive Results in ADA Test by Feladilimab Dose Level in Combination With Pembrolizumab | Up to approximately 367 weeks | Serum samples collected and tested for the presence of ADA with a screening assay. |
| Part 2A: Number of Participants With Positive Results in ADA in Pembrolizumab | Up to approximately 367 weeks | Serum samples collected and tested for the presence of ADA with a screening assay. |
| Part 2A: Number of Participants With Positive Results in ADA in GSK3174998 | Up to approximately 367 weeks | Serum samples collected and tested for the presence of ADA with a screening assay. |
| Part 2A: Number of Participants With Positive Results in ADA Test by Feladilimab Combination With Chemotherapies Dose Level | Up to approximately 367 weeks | Serum samples collected and tested for the presence of ADA with a screening assay. |
| Part 1B: Number of Participants With Positive Results in ADA Test by Feladilimab Dose Level | Up to approximately 367 weeks | Serum samples collected and tested for the presence of ADA with a screening assay. |
| Part 2B: Number of Participants With Positive Results in ADA Test by Feladilimab Dose Level | Up to approximately 367 weeks | Serum samples collected and tested for the presence of ADA with a screening assay. |
| Part 2B: Number of Participants With Positive Results in ADA in Pembrolizumab | Up to approximately 367 weeks | Serum samples collected and tested for the presence of ADA with a screening assay. |
| Part 1A: Receptor Occupancy of Feladilimab | Up to approximately 367 weeks | Blood samples were collected to assess the cluster of differentiation 4 (CD4+) and cluster of differentiation 8 (CD8+) receptor occupancy by Feladilimab as a pharmacodynamic analysis. It was assessed using validated flow cytometry assay. |
| Part 2A: Receptor Occupancy of Feladilimab | Up to approximately 367 weeks | Blood samples were collected to assess the cluster of differentiation 4 (CD4+) and cluster of differentiation 8 (CD8+) receptor occupancy by Feladilimab as a pharmacodynamic analysis. It was assessed using validated flow cytometry assay. |
| Part 1B: Receptor Occupancy of Feladilimab | Up to approximately 367 weeks | Blood samples were collected to assess the cluster of differentiation 4 (CD4+) and cluster of differentiation 8 (CD8+) receptor occupancy by Feladilimab as a pharmacodynamic analysis. It was assessed using validated flow cytometry assay. |
| Part 2B: Receptor Occupancy of Feladilimab | Up to approximately 367 weeks | Blood samples were collected to assess the cluster of differentiation 4 (CD4+) and cluster of differentiation 8 (CD8+) receptor occupancy by Feladilimab as a pharmacodynamic analysis. It was assessed using validated flow cytometry assay. |
| Part 2B: AUC (0-504h) of Pembrolizumab | Pre-dose; EOI; 0.5, 1, 2, 4, 6, 8, 24, 48-72, 96-120 hours post-EOI; week 1; week 2; Pre-dose and 0.5 hours post-EOI in week 3; week 4; week 5; Pre-dose and 0.5, 4 hours post-EOI in week 6, 9, 12 and15; Pre-dose in week 18, 21, 33, 45, 57, 69, 81 and 93 | Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method. |
| Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Baseline (Day 1) and up to approximately 367 weeks | Blood samples were collected for analysis of clinical chemistry parameters. Laboratory parameters were graded according to CTCAE v4.03. Grade (G) 0: None; G1: mild; G2: moderate; G3: severe or medically significant; G4: life-threatening consequences. Higher grade indicates greater severity and increase in grade was defined relative to Baseline grade. Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Only grade change data is presented for Baseline (B) and Worst-Case Post-Baseline (WCPB) as G0, G1, G2, G3, G4, and missing (M) here as Parameter name, B GX, WCPB GX where X=grade digit. |
| Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Up to approximately 367 weeks | Normal ranges were 6 to 8.3 grams/L (protein); 100 to 250 international units (IU)/L (Lactate Dehydrogenase(LDH)); 2.3 - 4.1 picomoles/L (Free Triiodothyronine(T3)); 4.6 to 11.2 picomoles/L (Free Thyroxine(T4)); 0 and 0.04 microgram (ug)/L (Troponin I); 0 - 0.01 ug/L (Troponin T); 0.45 to 4.5 milliunits (Mu)/L (Thyrotropin(TSH)); and 6 to 24 millimoles/L (Urea). Participants were counted in worst case category that their value changes to low, normal or no change \[NC\] or high), unless there is NC in their category. Participants whose laboratory value category was unchanged (e.g. High to High) or whose value became normal, were recorded in To Normal or No Change category. Participants were counted twice if participant had values that changed To Low and To High, so percentages may not add to 100% |
| Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Baseline (Day 1) and up to approximately 367 weeks | Blood samples were collected for analysis of hematology parameters. Laboratory parameters were graded according to CTCAE v4.03. Grade (G) 0: None; G1: mild; G2: moderate; G3: severe or medically significant; G4: life-threatening consequences. Higher grade indicates greater severity and increase in grade was defined relative to Baseline grade. Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Only grade change data is presented for Baseline (B) and Worst-Case Post-Baseline (WCPB) as G0, G1, G2, G3, G4, and missing (M) here as Parameter name, B GX, WCPB GX where X=grade digit. |
| Part 1B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Up to approximately 367 weeks | Normal ranges were 0.01 to 0.3\*10\^9 cells/L (basophils), 0 to 500 cells /L (eosinophils), 41 to 50 percentage of RBC in blood (hematocrit), 2 to 8 percentage of WBC (monocytes), and Women: 4.2 to 5.4 million RBC/ mcL of blood and Men: 4.7 to 6.1 million RBC/ mcL (erythrocyte count). Participants were counted in worst case category that their value changes to low, normal or no change \[NC\] or high), unless there is NC in their category. Participants whose laboratory value category was unchanged (e.g. High to High) or whose value became normal, were recorded in To Normal or No Change category. Participants were counted twice if participant had values that changed To Low and To High, so percentages may not add to 100%. |
| Part 1B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Up to approximately 367 weeks | Urine samples were collected to assess urine glucose, ketones and occult blood using dipstick method. The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as negative, trace, 1+, 2+, 3+ indicating proportional concentrations in the urine sample. Baseline (Day 1) was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Result for urinalysis parameters were recorded as no change/decreased and any increase. |
| Part 1B: Number of Participants With Dose Modifications of Feladilimab | Up to approximately 367 weeks | Number of participants with dose modifications (including dose delays, dose escalation and infusion interruptions) were reported for Feladilimab. |
| Part 2B: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Up to approximately 367 weeks | An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, Results in persistent disability/incapacity or is a congenital anomaly/birth defect, other situations which involve medical or scientific judgment or is associated with liver injury and impaired liver function. SAEs are subset of AEs. A summary of number of participants with any AEs and SAEs is presented. AEs were coded using the MedDRA dictionary. |
| Part 1A: Overall Response Rate (ORR) | Up to approximately 367 weeks | ORR was defined as the percentage of participants with immune-related confirmed complete response (irCR) or ir confirmed partial response (irPR) per Immune-related Response Evaluation Criteria in Solid Tumors Criteria (irRECIST). irCR is defined as disappearance of all target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 millimeters (mm). irPR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters. |
| Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Baseline (Day 1) and up to approximately 367 weeks | Blood samples were collected for analysis of clinical chemistry parameters. Laboratory parameters were graded according to CTCAE v4.03. Grade (G) 0: None; G1: mild; G2: moderate; G3: severe or medically significant; G4: life-threatening consequences. Higher grade indicates greater severity and increase in grade was defined relative to Baseline grade. Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Only grade change data is presented for Baseline (B) and Worst-Case Post-Baseline (WCPB) as G0, G1, G2, G3, G4, and missing (M) here as Parameter name, B GX, WCPB GX where X=grade digit. |
| Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Up to approximately 367 weeks | Normal ranges were 0.1 to 0.3 micromoles (umol)/liter (L) (direct bilirubin); 6 to 8.3 grams/L (protein); 100 to 250 international units (IU)/L (Lactate Dehydrogenase(LDH)); 2.3 - 4.1 picomoles/L (Free Triiodothyronine(T3)); 4.6 to 11.2 picomoles/L (Free Thyroxine(T4)); 0 and 0.04 microgram (ug)/L (Troponin I); 0 - 0.01 ug/L (Troponin T); 0.45 to 4.5 milliunits (Mu)/L (Thyrotropin(TSH)); 24-204 ug/L (creatine kinase); and 6 to 24 millimoles/L (Urea). Participants were counted in worst case category that their value changes to low, normal or no change \[NC\] or high), unless there is NC in their category. Participants whose laboratory value category was unchanged (e.g. High to High) or whose value became normal, were recorded in To Normal or No Change category. Participants were counted twice if participant had values that changed To Low and To High, so percentages may not add to 100%. |
| Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Baseline (Day 1) and up to approximately 367 weeks | Blood samples were collected for analysis of hematology parameters. Laboratory parameters were graded according to CTCAE v4.03. Grade (G) 0: None; G1: mild; G2: moderate; G3: severe or medically significant; G4: life-threatening consequences. Higher grade indicates greater severity and increase in grade was defined relative to Baseline grade. Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Only grade change data is presented for Baseline (B) and Worst-Case Post-Baseline (WCPB) as G0, G1, G2, G3, G4, and missing (M) here as Parameter name, B GX, WCPB GX where X=grade digit. |
| Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Up to approximately 367 weeks | Normal ranges were 0.01 to 0.3\*10\^9 cells/L (basophils), 0 to 500 cells/L(eosinophils), 41 to 50 percentage of RBC in blood (hematocrit), 1,000 - 4,800 lymphocytes per microliter (µL) of blood (lymphocytes), 80-100 fl (erythrocytes, mean corpuscular volume), 2 to 8 percentage of WBC (monocytes), 40 to 60 cells/mcL (neutrophils) and Women: 4.2 to 5.4 million RBC/ mcL of blood and Men: 4.7 to 6.1 million RBC/ mcL (erythrocytes count). Participants were counted in worst case category that their value changes to low, normal or no change \[NC\] or high), unless there is NC in their category. Participants whose laboratory value category was unchanged (e.g. High to High) or whose value became normal, were recorded in To Normal or No Change category. Participants were counted twice if participant had values that changed To Low and To High, so percentages may not add to 100%. |
| Part 2B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Up to approximately 367 weeks | Urine samples were collected to assess urine glucose, ketones and occult blood using dipstick method. The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as negative, trace, 1+, 2+, 3+ indicating proportional concentrations in the urine sample. Baseline (Day 1) was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Result for urinalysis parameters were recorded as no change/decreased and any increase. |
| Part 2B: Number of Participants With Dose Modifications of Feladilimab | Up to approximately 367 weeks | Number of participants with dose modifications (including dose delays, dose escalations, and infusion interruptions) were reported for Feladilimab. |
| Part 1A: Disease Control Rate (DCR) | Up to approximately 367 weeks | DCR was defined as percentage of participants with best overall response of irCR or irPR at any time + ir stable disease (irSD) meeting the minimum time criteria from the start of treatment until ir disease progression (irPD) or death due to any cause or the start of new anticancer therapy/crossover. irCR is defined as disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \<10 mm. irPR defined as at least 30% decrease in the sum of diameters of target lesions, taking as a reference, the baseline sum of the diameters. irSD defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease. IrPD defined as the date of radiological disease progression based on imaging data per irRECIST. A one-week visit window was considered in the duration of irSD, i.e. a minimum of 8 weeks (irSD\>=9 weeks) and 17 weeks (irSD\>=18 weeks) were considered. |
Countries
Australia, Canada, China, France, Italy, Japan, Netherlands, Spain, United States
Participant flow
Pre-assignment details
A total of 829 participants were enrolled.
Participants by arm
| Arm | Count |
|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) Participants with advanced solid tumors received 0.001 mg/kg feladilimab intravenous (IV) infusion once in a three week (Q3W) of each 21-day Cycle up to until disease progression, unacceptable toxicity, or withdrawal of consent, or for up to maximum of 35 cycles. | 1 |
| Part 1A: Fela 0.003 mg/kg Participants with advanced solid tumors received 0.003 mg/kg feladilimab IV infusion Q3W of each 21-day Cycle up to until disease progression, unacceptable toxicity, or withdrawal of consent, or for up to maximum of 35 cycles. | 1 |
| Part 1A: Fela 0.010 mg/kg Participants with advanced solid tumors received 0.010 mg/kg feladilimab IV infusion Q3W of each 21-day Cycle up to until disease progression, unacceptable toxicity, or withdrawal of consent, or for up to maximum of 35 cycles. | 2 |
| Part 1A: Fela 0.030 mg/kg Participants with advanced solid tumors received 0.030 mg/kg feladilimab IV infusion Q3W of each 21-day Cycle up to until disease progression, unacceptable toxicity, or withdrawal of consent, or for up to maximum of 35 cycles. | 7 |
| Part 1A: Fela 0.100 mg/kg Participants with advanced solid tumors received 0.100 mg/kg feladilimab IV infusion Q3W of each 21-day Cycle up to until disease progression, unacceptable toxicity, or withdrawal of consent, or for up to maximum of 35 cycles. | 24 |
| Part 1A: Fela 0.300 mg/kg Participants with advanced solid tumors received 0.300 mg/kg feladilimab IV infusion Q3W of each 21-day Cycle up to until disease progression, unacceptable toxicity, or withdrawal of consent, or for up to maximum of 35 cycles. | 25 |
| Part 1A: Fela 1.000 mg/kg Participants with advanced solid tumors received 1.000 mg/kg feladilimab IV infusion Q3W of each 21-day Cycle up to until disease progression, unacceptable toxicity, or withdrawal of consent, or for up to maximum of 35 cycles. | 15 |
| Part 1A: Fela 3.000 mg/kg Participants with advanced solid tumors received 3.000 mg/kg feladilimab IV infusion Q3W of each 21-day Cycle up to until disease progression, unacceptable toxicity, or withdrawal of consent, or for up to maximum of 35 cycles. | 27 |
| Part 1A: Fela 10.000 mg/kg Participants with advanced solid tumors received 10.000 mg/kg feladilimab IV infusion Q3W of each 21-day Cycle up to until disease progression, unacceptable toxicity, or withdrawal of consent, or for up to maximum of 35 cycles. | 7 |
| Part 1B: Fela 0.300 mg/kg Participants with advanced solid tumors received 0.300 mg/kg feladilimab IV infusion Q3W of each 21-day Cycle up to until disease progression, unacceptable toxicity, or withdrawal of consent, or for up to maximum of 35 cycles. | 39 |
| Part 1B: Fela 1.000 mg/kg Participants with advanced solid tumors received 1.000 mg/kg feladilimab IV infusion Q3W of each 21-day Cycle up to until disease progression, unacceptable toxicity, or withdrawal of consent, or for up to maximum of 35 cycles. | 115 |
| Part 1B: Fela 24 mg Participants with advanced solid tumors received 24 mg feladilimab IV infusion Q3W of each 21-day Cycle up to until disease progression, unacceptable toxicity, or withdrawal of consent, or for up to maximum of 35 cycles. | 59 |
| Part 2A: Fela 0.010 mg/kg + Pembrolizumab (Pembro) 200 mg Participants with advanced solid tumors received 0.010 mg/kg feladilimab IV infusion in combination with 200 mg of pembro IV infusion Q3W of each 21-day Cycle up to until disease progression, unacceptable toxicity, or withdrawal of consent, or for up to maximum of 35 cycles. | 5 |
| Part 2A: Fela 0.030 mg/kg + Pembro 200 mg Participants with advanced solid tumors received 0.030 mg/kg feladilimab IV infusion in combination with 200 mg of pembro IV infusion Q3W of each 21-day Cycle up to until disease progression, unacceptable toxicity, or withdrawal of consent, or for up to maximum of 35 cycles. | 5 |
| Part 2A: Fela 0.100 mg/kg + Pembro 200 mg Participants with advanced solid tumors received 0.100 mg/kg feladilimab IV infusion in combination with 200 mg of pembro IV infusion Q3W of each 21-day Cycle up to until disease progression, unacceptable toxicity, or withdrawal of consent, or for up to maximum of 35 cycles. | 5 |
| Part 2A: Fela 0.300 mg/kg + Pembro 200 mg Participants with advanced solid tumors received 0.300 mg/kg feladilimab IV infusion in combination with 200 mg of pembro IV infusion Q3W of each 21-day Cycle up to until disease progression, unacceptable toxicity, or withdrawal of consent, or for up to maximum of 35 cycles. | 8 |
| Part 2A: Fela 1.000 mg/kg + Pembro 200 mg Participants with advanced solid tumors received 1.000 mg/kg feladilimab IV infusion in combination with 200 mg of pembro IV infusion Q3W of each 21-day Cycle up to until disease progression, unacceptable toxicity, or withdrawal of consent, or for up to maximum of 35 cycles. | 11 |
| Part 2A: Fela 3.000 mg/kg + Pembro 200 mg Participants with advanced solid tumors received 3.000 mg/kg feladilimab IV infusion in combination with 200 mg of pembro IV infusion Q3W of each 21-day Cycle up to until disease progression, unacceptable toxicity, or withdrawal of consent, or for up to maximum of 35 cycles. | 11 |
| Part 2A: Fela 8 mg + GSK3174998 8 mg Participants with advanced solid tumors received 8 mg feladilimab IV infusion in combination with 8 mg of GSK3174998 IV infusion Q3W of each 21-day Cycle up to until disease progression, unacceptable toxicity, or withdrawal of consent, or for up to maximum of 35 cycles. | 1 |
| Part 2A: Fela 8 mg + GSK3174998 24 mg Participants with advanced solid tumors received 8 mg feladilimab IV infusion in combination with 24 mg of GSK3174998 IV infusion Q3W of each 21-day Cycle up to until disease progression, unacceptable toxicity, or withdrawal of consent, or for up to maximum of 35 cycles. | 4 |
| Part 2A: Fela 24 mg + GSK3174998 24 mg Participants with advanced solid tumors received 24 mg feladilimab IV infusion in combination with 24 mg of GSK3174998 IV infusion Q3W of each 21-day Cycle up to until disease progression, unacceptable toxicity, or withdrawal of consent, or for up to maximum of 35 cycles. | 16 |
| Part 2A: Fela 80 mg + GSK3174998 24 mg Participants with advanced solid tumors received 80 mg feladilimab IV infusion in combination with 24 mg of GSK3174998 IV infusion Q3W of each 21-day Cycle up to until disease progression, unacceptable toxicity, or withdrawal of consent, or for up to maximum of 35 cycles. | 4 |
| Part 2A: Fela 80 mg + GSK3174998 80 mg Participants with advanced solid tumors received 80 mg feladilimab IV infusion in combination with 80 mg of GSK3174998 IV infusion Q3W of each 21-day Cycle up to until disease progression, unacceptable toxicity, or withdrawal of consent, or for up to maximum of 35 cycles. | 3 |
| Part 2A: Fela 24 mg + Chemotherapy Participants with advanced solid tumors received 24 mg feladilimab IV infusion in combination with chemotherapy Q3W of each 21-day Cycle up to until disease progression, unacceptable toxicity, or withdrawal of consent, or for up to maximum of 35 cycles. | 6 |
| Part 2A: Fela 80 mg + Chemotherapy Participants with advanced solid tumors received 80 mg feladilimab IV infusion in combination with chemotherapy Q3W of each 21-day Cycle up to until disease progression, unacceptable toxicity, or withdrawal of consent, or for up to maximum of 35 cycles. | 36 |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy Participants with advanced solid tumors received 24 mg feladilimab IV infusion in combination with chemotherapy and 200 mg of pembro IV infusion Q3W of each 21-day Cycle up to until disease progression, unacceptable toxicity, or withdrawal of consent, or for up to maximum of 35 cycles. | 13 |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy Participants with advanced solid tumors received 80 mg feladilimab IV infusion in combination with chemotherapy and 200 mg of pembro IV infusion Q3W of each 21-day Cycle up to until disease progression, unacceptable toxicity, or withdrawal of consent, or for up to maximum of 35 cycles. | 22 |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg Participants with advanced solid tumors received 24 mg feladilimab IV infusion in combination with 500 mg dostarlimab and 300 mg cobolimab IV infusion Q3W of each 21-day Cycle up to until disease progression, unacceptable toxicity, or withdrawal of consent, or for up to maximum of 35 cycles. | 1 |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg Participants with advanced solid tumors received 24 mg feladilimab IV infusion in combination with 2400 mg bintrafusp alfa IV infusion Q3W of each 21-day Cycle up to until disease progression, unacceptable toxicity, or withdrawal of consent, or for up to maximum of 35 cycles. | 4 |
| Part 2B: Fela 0.100 mg/kg + Pembro 200 mg Participants with advanced solid tumors received 0.100 mg/kg feladilimab IV infusion in combination with 200 mg of pembro IV infusion every 3 Week (Q3W) of each 21-day Cycle up to until disease progression, unacceptable toxicity, or withdrawal of consent, or for up to maximum of 35 cycles. | 14 |
| Part 2B: Fela 0.300 mg/kg + Pembro 200 mg Participants with advanced solid tumors received 0.300 mg/kg feladilimab IV infusion in combination with 200 mg of pembro IV infusion Q3W of each 21-day Cycle up to until disease progression, unacceptable toxicity, or withdrawal of consent, or for up to maximum of 35 cycles. | 255 |
| Part 2B: Fela 1.000 mg/kg + Pembro 200 mg Participants with advanced solid tumors received 1.000 mg/kg feladilimab IV infusion in combination with 200 mg of pembro IV infusion Q3W of each 21-day Cycle up to until disease progression, unacceptable toxicity, or withdrawal of consent, or for up to maximum of 35 cycles. | 44 |
| Part 2B: Fela 3.000 mg/kg + Pembro 200 mg Participants with advanced solid tumors received 3.000 mg/kg feladilimab IV infusion in combination with 200 mg of pembro IV infusion Q3W of each 21-day Cycle up to until disease progression, unacceptable toxicity, or withdrawal of consent, or for up to maximum of 35 cycles. | 23 |
| Part 2B: Fela 24 mg + Pembro 200 mg Participants with advanced solid tumors received 24 mg feladilimab IV infusion in combination with 200 mg of pembro IV infusion Q3W of each 21-day Cycle up to until disease progression, unacceptable toxicity, or withdrawal of consent, or for up to maximum of 35 cycles. | 4 |
| Part 2B: Fela 48 mg + Pembro 400 mg Participants with advanced solid tumors received 48 mg feladilimab IV infusion in combination with 400 mg of pembro IV infusion Q6W of each 42-day Cycle up to until disease progression, unacceptable toxicity, or withdrawal of consent, or for up to maximum of 35 cycles. | 6 |
| Part 2B: Fela 160 mg + Pembro 400 mg Participants with advanced solid tumors received 160 mg feladilimab IV infusion in combination with 400 mg of pembro IV infusion Q6W of each 42-day Cycle up to until disease progression, unacceptable toxicity, or withdrawal of consent, or for up to maximum of 35 cycles. | 5 |
| Part 2B: Fela 80 mg + Pembro 200 mg Participants with advanced solid tumors received 80 mg feladilimab IV infusion in combination with 200 mg of pembro IV infusion Q3W of each 21-day Cycle up to until disease progression, unacceptable toxicity, or withdrawal of consent, or for up to maximum of 35 cycles. | 1 |
| Total | 829 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 | FG006 | FG007 | FG008 | FG009 | FG010 | FG011 | FG012 | FG013 | FG014 | FG015 | FG016 | FG017 | FG018 | FG019 | FG020 | FG021 | FG022 | FG023 | FG024 | FG025 | FG026 | FG027 | FG028 | FG029 | FG030 | FG031 | FG032 | FG033 | FG034 | FG035 | FG036 | FG037 | FG038 | FG039 | FG040 | FG041 | FG042 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Crossover/ Re-treatment Phase | Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 14 | 32 | 2 | 1 | 0 |
| Crossover/ Re-treatment Phase | Lost to Follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 0 | 0 |
| Crossover/ Re-treatment Phase | Physician Decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 |
| Crossover/ Re-treatment Phase | Site Closed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 2 | 0 | 0 | 0 |
| Escalation Phase | Death | 1 | 1 | 2 | 7 | 18 | 17 | 11 | 21 | 3 | 0 | 0 | 0 | 2 | 4 | 5 | 6 | 6 | 7 | 1 | 3 | 13 | 3 | 2 | 4 | 31 | 7 | 13 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Escalation Phase | Lost to Follow-up | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 2 | 0 | 1 | 2 | 1 | 0 | 0 | 1 | 1 | 3 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Escalation Phase | Participants were crossed over OR were re-treated following progression | 0 | 0 | 0 | 0 | 5 | 2 | 2 | 4 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Escalation Phase | Physician Decision | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Escalation Phase | Site Closed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 0 | 1 | 0 | 0 | 0 | 3 | 1 | 3 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Escalation Phase | Withdrawal by Subject | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Expansion Phase | Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 25 | 69 | 48 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12 | 202 | 31 | 17 | 2 | 3 | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Expansion Phase | Lost to Follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 19 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Expansion Phase | Participants were crossed over OR were re-treated following progression | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10 | 36 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Expansion Phase | Physician Decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Expansion Phase | Site Closed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 4 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Expansion Phase | Withdrawal by Subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 4 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Baseline characteristics
| Characteristic | Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Fela 0.003 mg/kg | Part 1A: Fela 0.010 mg/kg | Part 1A: Fela 0.030 mg/kg | Part 1A: Fela 0.100 mg/kg | Part 1A: Fela 0.300 mg/kg | Part 1A: Fela 1.000 mg/kg | Part 1A: Fela 3.000 mg/kg | Part 1A: Fela 10.000 mg/kg | Part 1B: Fela 0.300 mg/kg | Part 1B: Fela 1.000 mg/kg | Part 1B: Fela 24 mg | Part 2A: Fela 0.010 mg/kg + Pembrolizumab (Pembro) 200 mg | Part 2A: Fela 0.030 mg/kg + Pembro 200 mg | Part 2A: Fela 0.100 mg/kg + Pembro 200 mg | Part 2A: Fela 0.300 mg/kg + Pembro 200 mg | Part 2A: Fela 1.000 mg/kg + Pembro 200 mg | Part 2A: Fela 3.000 mg/kg + Pembro 200 mg | Part 2A: Fela 8 mg + GSK3174998 8 mg | Part 2A: Fela 8 mg + GSK3174998 24 mg | Part 2A: Fela 24 mg + GSK3174998 24 mg | Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2B: Fela 0.100 mg/kg + Pembro 200 mg | Part 2B: Fela 0.300 mg/kg + Pembro 200 mg | Part 2B: Fela 1.000 mg/kg + Pembro 200 mg | Part 2B: Fela 3.000 mg/kg + Pembro 200 mg | Part 2B: Fela 24 mg + Pembro 200 mg | Part 2B: Fela 48 mg + Pembro 400 mg | Part 2B: Fela 160 mg + Pembro 400 mg | Part 2B: Fela 80 mg + Pembro 200 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Customized 18 - 93 years | 1 Participants | 1 Participants | 2 Participants | 7 Participants | 24 Participants | 25 Participants | 15 Participants | 27 Participants | 7 Participants | 39 Participants | 115 Participants | 59 Participants | 5 Participants | 5 Participants | 5 Participants | 8 Participants | 11 Participants | 11 Participants | 1 Participants | 4 Participants | 16 Participants | 4 Participants | 3 Participants | 6 Participants | 36 Participants | 13 Participants | 22 Participants | 1 Participants | 4 Participants | 14 Participants | 255 Participants | 44 Participants | 23 Participants | 4 Participants | 6 Participants | 5 Participants | 1 Participants | 829 Participants |
| Race/Ethnicity, Customized HISPANIC OR LATINO | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 2 Participants | 4 Participants | 4 Participants | 1 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 1 Participants | 0 Participants | 1 Participants | 1 Participants | 0 Participants | 2 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 1 Participants | 8 Participants | 1 Participants | 1 Participants | 1 Participants | 0 Participants | 0 Participants | 1 Participants | 33 Participants |
| Race/Ethnicity, Customized Missing | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 2 Participants | 3 Participants | 1 Participants | 3 Participants | 0 Participants | 4 Participants | 13 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 2 Participants | 0 Participants | 0 Participants | 0 Participants | 2 Participants | 21 Participants | 4 Participants | 7 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 66 Participants |
| Race/Ethnicity, Customized NOT HISPANIC OR LATINO | 1 Participants | 1 Participants | 2 Participants | 7 Participants | 22 Participants | 22 Participants | 14 Participants | 23 Participants | 7 Participants | 33 Participants | 98 Participants | 55 Participants | 4 Participants | 4 Participants | 5 Participants | 8 Participants | 10 Participants | 11 Participants | 0 Participants | 3 Participants | 15 Participants | 3 Participants | 2 Participants | 5 Participants | 34 Participants | 11 Participants | 21 Participants | 1 Participants | 4 Participants | 11 Participants | 226 Participants | 39 Participants | 15 Participants | 3 Participants | 5 Participants | 5 Participants | 0 Participants | 730 Participants |
| Sex: Female, Male Female | 1 Participants | 0 Participants | 1 Participants | 4 Participants | 11 Participants | 14 Participants | 4 Participants | 11 Participants | 2 Participants | 18 Participants | 47 Participants | 25 Participants | 1 Participants | 2 Participants | 2 Participants | 3 Participants | 4 Participants | 5 Participants | 0 Participants | 1 Participants | 8 Participants | 0 Participants | 3 Participants | 1 Participants | 13 Participants | 1 Participants | 5 Participants | 0 Participants | 0 Participants | 2 Participants | 115 Participants | 15 Participants | 4 Participants | 0 Participants | 0 Participants | 2 Participants | 0 Participants | 325 Participants |
| Sex: Female, Male Male | 0 Participants | 1 Participants | 1 Participants | 3 Participants | 13 Participants | 11 Participants | 11 Participants | 16 Participants | 5 Participants | 21 Participants | 68 Participants | 34 Participants | 4 Participants | 3 Participants | 3 Participants | 5 Participants | 7 Participants | 6 Participants | 1 Participants | 3 Participants | 8 Participants | 4 Participants | 0 Participants | 5 Participants | 23 Participants | 12 Participants | 17 Participants | 1 Participants | 4 Participants | 12 Participants | 140 Participants | 29 Participants | 19 Participants | 4 Participants | 6 Participants | 3 Participants | 1 Participants | 504 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk | EG008 affected / at risk | EG009 affected / at risk | EG010 affected / at risk | EG011 affected / at risk | EG012 affected / at risk | EG013 affected / at risk | EG014 affected / at risk | EG015 affected / at risk | EG016 affected / at risk | EG017 affected / at risk | EG018 affected / at risk | EG019 affected / at risk | EG020 affected / at risk | EG021 affected / at risk | EG022 affected / at risk | EG023 affected / at risk | EG024 affected / at risk | EG025 affected / at risk | EG026 affected / at risk | EG027 affected / at risk | EG028 affected / at risk | EG029 affected / at risk | EG030 affected / at risk | EG031 affected / at risk | EG032 affected / at risk | EG033 affected / at risk | EG034 affected / at risk | EG035 affected / at risk | EG036 affected / at risk | EG037 affected / at risk | EG038 affected / at risk | EG039 affected / at risk | EG040 affected / at risk | EG041 affected / at risk | EG042 affected / at risk |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 1 / 1 | 1 / 1 | 2 / 2 | 7 / 7 | 18 / 24 | 17 / 25 | 11 / 15 | 21 / 27 | 3 / 7 | 25 / 39 | 69 / 115 | 48 / 59 | 2 / 5 | 4 / 5 | 5 / 5 | 6 / 8 | 6 / 11 | 7 / 11 | 1 / 1 | 3 / 4 | 13 / 16 | 3 / 4 | 2 / 3 | 4 / 6 | 31 / 36 | 7 / 13 | 13 / 22 | 0 / 1 | 1 / 4 | 12 / 14 | 202 / 255 | 31 / 44 | 17 / 23 | 2 / 4 | 3 / 6 | 3 / 5 | 1 / 1 | 1 / 1 | 14 / 19 | 32 / 42 | 2 / 2 | 1 / 1 | 0 / 1 |
| other Total, other adverse events | 1 / 1 | 1 / 1 | 2 / 2 | 7 / 7 | 19 / 24 | 23 / 25 | 12 / 15 | 17 / 27 | 6 / 7 | 32 / 39 | 101 / 115 | 51 / 59 | 5 / 5 | 5 / 5 | 5 / 5 | 5 / 8 | 8 / 11 | 10 / 11 | 0 / 1 | 4 / 4 | 14 / 16 | 3 / 4 | 3 / 3 | 6 / 6 | 36 / 36 | 13 / 13 | 22 / 22 | 1 / 1 | 4 / 4 | 13 / 14 | 236 / 255 | 40 / 44 | 21 / 23 | 4 / 4 | 5 / 6 | 4 / 5 | 1 / 1 | 1 / 1 | 15 / 19 | 26 / 42 | 1 / 2 | 1 / 1 | 1 / 1 |
| serious Total, serious adverse events | 0 / 1 | 0 / 1 | 1 / 2 | 2 / 7 | 6 / 24 | 8 / 25 | 4 / 15 | 12 / 27 | 1 / 7 | 9 / 39 | 44 / 115 | 19 / 59 | 3 / 5 | 2 / 5 | 3 / 5 | 2 / 8 | 3 / 11 | 4 / 11 | 0 / 1 | 2 / 4 | 5 / 16 | 2 / 4 | 1 / 3 | 4 / 6 | 13 / 36 | 3 / 13 | 17 / 22 | 0 / 1 | 1 / 4 | 3 / 14 | 126 / 255 | 17 / 44 | 7 / 23 | 1 / 4 | 2 / 6 | 2 / 5 | 1 / 1 | 0 / 1 | 4 / 19 | 12 / 42 | 1 / 2 | 0 / 1 | 0 / 1 |
Outcome results
Primary
Part 1A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, or is a congenital anomaly/birth defect, other situations which involve medical or scientific judgment or is associated with liver injury and impaired liver function. SAEs are subset of AEs. A summary of number of participants with any AEs and SAEs is presented. AEs were coded using the Medical Dictionary for Regulatory Affairs (MedDRA dictionary).
Time frame: Up to approximately 367 weeks
Population: All Treated population included all participants who received at least one dose of feladilimab.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any AEs | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any SAEs | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any AEs | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any SAEs | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any AEs | 2 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any SAEs | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any AEs | 7 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any SAEs | 2 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any AEs | 22 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any SAEs | 6 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any SAEs | 8 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any AEs | 24 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any SAEs | 4 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any AEs | 13 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any AEs | 21 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any SAEs | 12 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any AEs | 6 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any SAEs | 1 Participants |
Primary
Part 1A: Number of Participants With Dose Limiting Toxicity (DLT)
DLT is an AE that is considered by the investigator to be clinically relevant and attributed to the study therapy during the 28-day DLT period and meets at least one of the DLT criteria: Febrile neutropenia; Grade 4 neutropenia of \>7 days in duration or requiring Granulocyte Colony-stimulating Factor (G-CSF), anemia, thrombocytopenia, non-hematologic toxicity; Grade 3 thrombocytopenia with bleeding, pneumonitis, toxicity that does not resolve to Grade 1 or baseline within 3 days; Grade 2 ocular toxicity; Toxicity that results in permanent discontinuation of feladilimab during the first four weeks of treatment; any other event which in the judgment of the investigator and GSK Medical Monitor is considered to be a DLT.
Time frame: Up to 28 days
Population: DLT Evaluable Population included All Treated Population in the dose escalation phase or PK/PD cohorts, who completed the 28-day DLT observation period or experienced a DLT during the determinative period (28 days).
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Dose Limiting Toxicity (DLT) | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Dose Limiting Toxicity (DLT) | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Dose Limiting Toxicity (DLT) | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Dose Limiting Toxicity (DLT) | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Dose Limiting Toxicity (DLT) | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Dose Limiting Toxicity (DLT) | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Dose Limiting Toxicity (DLT) | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Dose Limiting Toxicity (DLT) | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Dose Limiting Toxicity (DLT) | 0 Participants |
Primary
Part 1A: Number of Participants With Dose Modifications of Feladilimab
Number of participants with dose modifications (including dose delays, dose escalations and infusion interruptions) were reported for Feladilimab.
Time frame: Up to approximately 367 weeks
Population: All treated population
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Dose Modifications of Feladilimab | Dose Delays | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Dose Modifications of Feladilimab | Dose Escalations | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Dose Modifications of Feladilimab | infusion interruptions | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Dose Modifications of Feladilimab | infusion interruptions | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Dose Modifications of Feladilimab | Dose Delays | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Dose Modifications of Feladilimab | Dose Escalations | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Dose Modifications of Feladilimab | Dose Delays | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Dose Modifications of Feladilimab | infusion interruptions | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Dose Modifications of Feladilimab | Dose Escalations | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Dose Modifications of Feladilimab | Dose Escalations | 2 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Dose Modifications of Feladilimab | infusion interruptions | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Dose Modifications of Feladilimab | Dose Delays | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Dose Modifications of Feladilimab | Dose Escalations | 3 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Dose Modifications of Feladilimab | infusion interruptions | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Dose Modifications of Feladilimab | Dose Delays | 2 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Dose Modifications of Feladilimab | Dose Delays | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Dose Modifications of Feladilimab | infusion interruptions | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Dose Modifications of Feladilimab | Dose Escalations | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Dose Modifications of Feladilimab | Dose Escalations | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Dose Modifications of Feladilimab | infusion interruptions | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Dose Modifications of Feladilimab | Dose Delays | 2 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Dose Modifications of Feladilimab | infusion interruptions | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Dose Modifications of Feladilimab | Dose Delays | 3 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Dose Modifications of Feladilimab | Dose Escalations | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Dose Modifications of Feladilimab | Dose Delays | 1 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Dose Modifications of Feladilimab | infusion interruptions | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Dose Modifications of Feladilimab | Dose Escalations | 0 Participants |
Primary
Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline
Normal ranges were 0.1 to 0.3 micromoles (umol)/liter (L) (direct bilirubin); 6 to 8.3 grams/L (protein); 100 to 250 international units (IU)/L (Lactate Dehydrogenase(LDH)); 2.3 - 4.1 picomoles/L (Free Triiodothyronine(T3)); 4.6 to 11.2 picomoles/L (Free Thyroxine(T4)); 0 and 0.04 microgram (ug)/L (Troponin I); 0 - 0.01 ug/L (Troponin T); 0.45 to 4.5 milliunits (Mu)/L (Thyrotropin(TSH)); and 6 to 24 millimoles/L (Urea). Participants were counted in worst case category that their value changes to low, normal or no change \[NC\] or high), unless there is NC in their category. Participants whose laboratory value category was unchanged (e.g. High to High) or whose value became normal, were recorded in To Normal or No Change category. Participants were counted twice if participant had values that changed To Low and To High, so percentages may not add to 100%.
Time frame: Up to approximately 367 weeks
Population: All Treated Population. Only those participants with data available at specified categories have been analyzed.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Normal or No Change | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Normal or No Change | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To High | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Normal or No Change | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Normal or No Change | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Low | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To High | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Normal or No Change | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Low | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Low | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To High | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To High | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Low | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To High | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To Normal or No Change | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Low | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To Low | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To High | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To High | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Low | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To High | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Normal or No Change | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Low | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Normal or No Change | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Normal or No Change | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To High | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Low | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To High | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Low | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Low | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Normal or No Change | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To High | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Normal or No Change | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To Low | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To Normal or No Change | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To High | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Normal or No Change | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Normal or No Change | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Normal or No Change | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To High | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Low | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Low | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To High | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To High | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Low | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Normal or No Change | 2 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Normal or No Change | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To High | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Low | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Low | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To High | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To High | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To Low | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To High | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Normal or No Change | 6 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Low | 2 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To High | 3 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Low | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Normal or No Change | 5 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To High | 2 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To High | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Normal or No Change | 5 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Low | 3 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Low | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Normal or No Change | 4 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Normal or No Change | 3 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To High | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Low | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To Normal or No Change | 3 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Direct Bilirubin (umol/L), To Low | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Direct Bilirubin (umol/L), To Normal or No Change | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Direct Bilirubin (umol/L), To High | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Lactate Dehydrogenase (IU/L), To Low | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Lactate Dehydrogenase (IU/L), To Normal or No Change | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Lactate Dehydrogenase (IU/L), To High | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Low | 6 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Normal or No Change | 18 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To High | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Low | 5 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Normal or No Change | 12 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To High | 2 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Low | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Normal or No Change | 19 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To High | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To Low | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To Normal or No Change | 6 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To High | 2 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To Low | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To Normal or No Change | 8 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To High | 3 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Low | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Normal or No Change | 18 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To High | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Low | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Normal or No Change | 12 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To High | 6 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Normal or No Change | 21 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Low | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Lactate Dehydrogenase (IU/L), To Normal or No Change | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To Normal or No Change | 8 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To Low | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Lactate Dehydrogenase (IU/L), To Low | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Normal or No Change | 16 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Lactate Dehydrogenase (IU/L), To High | 2 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To High | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To Normal or No Change | 10 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Low | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Low | 7 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Low | 3 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To High | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Normal or No Change | 15 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To High | 2 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To High | 6 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To High | 3 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To High | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To High | 2 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Normal or No Change | 21 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Low | 6 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Normal or No Change | 11 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To Low | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Normal or No Change | 7 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To Low | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To High | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To Normal or No Change | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To High | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Lactate Dehydrogenase (IU/L), To Normal or No Change | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To Low | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To Normal or No Change | 8 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Lactate Dehydrogenase (IU/L), To Low | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To High | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Normal or No Change | 8 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Low | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Low | 2 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Normal or No Change | 10 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To High | 4 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To High | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Normal or No Change | 9 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To High | 3 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Low | 2 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Low | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Lactate Dehydrogenase (IU/L), To High | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Normal or No Change | 10 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To High | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Low | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To Low | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Low | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To High | 2 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To High | 1 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To Normal or No Change | 8 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Low | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Normal or No Change | 15 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To High | 3 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Normal or No Change | 20 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To High | 6 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Normal or No Change | 21 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Normal or No Change | 21 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Low | 2 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To Normal or No Change | 10 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To Low | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Low | 3 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Low | 1 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To High | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Normal or No Change | 22 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To High | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To High | 4 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To High | 1 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To High | 3 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Normal or No Change | 7 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Normal or No Change | 2 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Normal or No Change | 5 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Normal or No Change | 5 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Low | 1 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To High | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To High | 1 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To Low | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Low | 1 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To Low | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To Normal or No Change | 2 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Low | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To High | 1 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To High | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To Normal or No Change | 2 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Low | 1 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Normal or No Change | 5 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Low | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To High | 1 Participants |
Primary
Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters
Blood samples were collected for analysis of clinical chemistry parameters. Laboratory parameters were graded according to CTCAE v4.03. Grade (G) 0: None; G1: mild; G2: moderate; G3: severe or medically significant; G4: life-threatening consequences. Higher grade indicates greater severity and increase in grade was defined relative to Baseline grade. Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Only grade change data is presented for Baseline (B) and Worst-Case Post-Baseline (WCPB) as G0, G1, G2, G3, G4, and missing (M) here as Parameter name, B GX, WCPB GX where X=grade digit.
Time frame: Baseline (Day 1) and up to approximately 367 weeks
Population: All Treated Population. Only those participants with data available at specified categories have been analyzed.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 1 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 2 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 1 | 3 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 3 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 1 | 2 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 1 | 2 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 2 | 2 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 2 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 1 | 3 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 1 | 2 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 2 | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 1 | 10 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Missing, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Missing, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 0 | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 3 | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Missing, Grade 0 | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 1 | 3 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Missing, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Missing, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Missing, Grade 1 | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 2 | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 2 | 2 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Missing, Grade 0 | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Missing, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Missing, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Missing, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 3 | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Missing, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Missing, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Missing, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 4 | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 1 | 2 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 1 | 4 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 2 | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 2 | 6 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Missing, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Missing, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 1 | 6 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 3 | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 3 | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 0 | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 2 | 3 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 0 | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 1 | 5 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 3 | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 1 | 6 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 1 | 5 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 1 | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 4 | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Missing, Grade 0 | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Missing, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Missing, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Missing, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Missing, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 1 | 3 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 1 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 0 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 0 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 1 | 7 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 2 | 2 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 1 | 4 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 3 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 1 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 1 | 2 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 4 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 1 | 7 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 3 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 1 | 2 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 3 | 2 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 2 | 4 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 1 | 5 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 2 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 3 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 2 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 2 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 3 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 2 | 3 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 1 | 5 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 1 | 4 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 4 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 2 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 3 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 1 | 6 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 0 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 0 | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 1 | 7 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 2 | 2 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 0 | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 2 | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 1 | 6 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 2 | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 1 | 3 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 1 | 4 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 3 | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 0 | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 1 | 4 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 0 | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 3 | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 3 | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 1 | 3 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 1 | 3 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 1 | 2 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 3 | 1 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 1 | 3 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 0 | 1 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 3 | 1 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 1 | 9 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 4 | 1 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 1 | 6 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 1 | 2 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 3 | 1 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 1 | 4 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 4 | 1 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 1 | 2 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 2 | 1 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 1 | 5 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 1 | 9 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 1 | 3 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 1 | 11 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 0 | 1 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 2 | 1 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 2 | 1 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 1 | 3 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 3 | 1 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 1 | 2 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 2 | 1 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 2 | 1 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 1 | 4 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 4 | 0 Participants |
Primary
Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters
Blood samples were collected for analysis of hematology parameters. Laboratory parameters were graded according to CTCAE v4.03. Grade (G) 0: None; G1: mild; G2: moderate; G3: severe or medically significant; G4: life-threatening consequences. Higher grade indicates greater severity and increase in grade was defined relative to Baseline grade. Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Only grade change data is presented for Baseline (B) and Worst-Case Post-Baseline (WCPB) as G0, G1, G2, G3, G4, and missing (M) here as Parameter name, B GX, WCPB GX where X=grade digit.
Time frame: Baseline (Day 1) and up to approximately 367 weeks
Population: All Treated Population. Only those participants with data available at specified categories have been analyzed.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 1 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 1 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 0 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 2 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 2 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 3 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 1 | 3 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 2 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 3 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 2 | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 2 | 3 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 2 | 2 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Missing, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Missing, Grade 3 | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Missing, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Missing, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Missing, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 3 | 2 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Missing, Grade 0 | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Missing, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Missing, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Missing, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Missing, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 1 | 5 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 3 | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 2 | 4 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 1 | 8 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 1 | 3 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 2 | 5 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 3 | 2 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Missing, Grade 0 | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Missing, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Missing, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Missing, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Missing, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 4 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 2 | 5 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 2 | 3 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 0 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 3 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 3 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 2 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 1 | 4 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 2 | 2 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 2 | 2 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 1 | 5 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 3 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 3 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 2 | 3 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 3 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 0 | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 1 | 2 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 2 | 2 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 3 | 2 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 1 | 2 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 2 | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 1 | 2 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 2 | 2 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 3 | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 2 | 2 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 2 | 3 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 0 | 1 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 3 | 1 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 2 | 1 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 3 | 1 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 3 | 1 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 1 | 6 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 3 | 1 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 1 | 6 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 3 | 3 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 2 | 2 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 3 | 1 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 4 | 1 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 1 | 3 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 1 | 2 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 2 | 1 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 2 | 2 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 1 | 0 Participants |
Primary
Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline
Normal ranges were 0.01 to 0.3\*10\^9 cells/L (basophils), 0 to 500 cells /L (eosinophils), 41 to 50 percentage of red blood cells (RBC) in blood (hematocrit), 1,000 - 4,800 lymphocytes per microliter (µL) of blood (lymphocytes), 80-100 femtoliters (fl) (erythrocytes, mean corpuscular volume), 2 to 8 percentage of WBC (monocytes), 40 to 60 cells/mcL (neutrophils) and Women: 4.2 to 5.4 million RBC/ microliter (mcL) of blood and Men: 4.7 to 6.1 million RBC/ mcL (erythrocytes count). Participants were counted in worst case category that their value changes to low, normal or no change \[NC\] or high), unless there is NC in their category. Participants whose laboratory value category was unchanged (e.g. High to High) or whose value became normal, were recorded in To Normal or No Change category. Participants were counted twice if participant had values that changed To Low and To High, so percentages may not add to 100%.
Time frame: Up to approximately 367 weeks
Population: All Treated Population. Only those participants with data available at specified categories have been analyzed.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To High | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To High | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Normal or No Change | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To High | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Normal or No Change | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Low | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Normal or No Change | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Low | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Low | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To High | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Normal or No Change | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To High | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Low | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Normal or No Change | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Low | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To High | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Low | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Low | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Normal or No Change | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Low | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To High | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Normal or No Change | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Normal or No Change | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To High | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To High | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Low | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To High | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Normal or No Change | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Normal or No Change | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Low | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To High | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Normal or No Change | 2 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Low | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Low | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Normal or No Change | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Low | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Normal or No Change | 2 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Low | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To High | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Low | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To High | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Normal or No Change | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To High | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To High | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Normal or No Change | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Normal or No Change | 7 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Low | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Normal or No Change | 5 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To High | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To High | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To High | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Low | 2 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To High | 2 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Normal or No Change | 5 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To High | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Normal or No Change | 6 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Low | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Low | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Normal or No Change | 7 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Low | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To High | 5 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Low | 7 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To High | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Normal or No Change | 17 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Normal or No Change | 24 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Lymphocytes, To Normal or No Change | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Lymphocytes, To High | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Normal or No Change | 14 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Low | 3 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Normal or No Change | 20 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To High | 3 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To High | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Neutrophils, To High | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Neutrophils, To Normal or No Change | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Neutrophils, To Low | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To High | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Low | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Normal or No Change | 18 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Low | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Low | 10 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Lymphocytes, To Low | 2 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Low | 7 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Low | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Normal or No Change | 24 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To High | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Low | 2 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Normal or No Change | 20 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To High | 4 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Normal or No Change | 18 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To High | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Lymphocytes, To Low | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Lymphocytes, To Normal or No Change | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Lymphocytes, To High | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Low | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Normal or No Change | 21 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To High | 3 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Neutrophils, To Low | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Neutrophils, To Normal or No Change | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Neutrophils, To High | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Low | 7 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Normal or No Change | 18 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To High | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To High | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Lymphocytes, To Low | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Neutrophils, To High | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To High | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Lymphocytes, To High | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Normal or No Change | 10 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Low | 2 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To High | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To High | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Low | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Normal or No Change | 13 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, Mean Corpuscular Volume, To Low | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Lymphocytes, To Normal or No Change | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Low | 2 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, Mean Corpuscular Volume, To Normal or No Change | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To High | 3 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Normal or No Change | 11 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, Mean Corpuscular Volume, To High | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Normal or No Change | 14 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Normal or No Change | 11 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Neutrophils, To Low | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Low | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Low | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Neutrophils, To Normal or No Change | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To High | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To High | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Normal or No Change | 21 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Normal or No Change | 21 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Low | 6 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To High | 6 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Low | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To High | 5 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Normal or No Change | 21 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Low | 2 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Low | 3 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To High | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Normal or No Change | 24 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Normal or No Change | 22 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Low | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Normal or No Change | 6 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Normal or No Change | 7 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To High | 1 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To High | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To High | 1 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Normal or No Change | 3 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To High | 1 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Low | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Low | 2 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Normal or No Change | 6 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Normal or No Change | 5 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Low | 3 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Low | 1 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To High | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Low | 0 Participants |
Primary
Part 1A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline
Urine samples were collected to assess urine glucose, ketones and occult blood using dipstick method. The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as negative, trace, 1+, 2+, 3+ indicating proportional concentrations in the urine sample. Baseline (Day 1) was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Result for urinalysis parameters were recorded as no change/decreased and any increase.
Time frame: Up to approximately 367 weeks
Population: All treated population. Only those participants with data available at specified categories have been analyzed.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, No Change/Decreased | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, any increase | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, any increase | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, No Change/Decreased | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, No Change/Decreased | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, any increase | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, any increase | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, No Change/Decreased | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, any increase | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, any increase | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, No Change/Decreased | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, No Change/Decreased | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, No Change/Decreased | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, No Change/Decreased | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, any increase | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, any increase | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, No Change/Decreased | 2 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, any increase | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, any increase | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, No Change/Decreased | 7 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, No Change/Decreased | 6 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, any increase | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, No Change/Decreased | 5 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, any increase | 2 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, No Change/Decreased | 23 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, No Change/Decreased | 17 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, No Change/Decreased | 19 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, any increase | 4 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, any increase | 6 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, any increase | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, any increase | 4 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, No Change/Decreased | 22 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, No Change/Decreased | 18 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, any increase | 7 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, No Change/Decreased | 21 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, any increase | 3 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, No Change/Decreased | 10 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, any increase | 2 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, any increase | 6 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, any increase | 4 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, No Change/Decreased | 8 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, No Change/Decreased | 12 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, No Change/Decreased | 15 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, any increase | 12 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, No Change/Decreased | 15 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, any increase | 2 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, any increase | 12 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, No Change/Decreased | 25 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, any increase | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, No Change/Decreased | 7 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, No Change/Decreased | 7 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, any increase | 2 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, No Change/Decreased | 5 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, any increase | 0 Participants |
Primary
Part 2A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that, at any dose results in death, Is life-threatening, Requires inpatient hospitalization or prolongation of existing hospitalization, Results in persistent disability/incapacity or Is a congenital anomaly/birth defect, Other situations which involve medical or scientific judgment or is associated with liver injury and impaired liver function. SAEs are subset of AEs. A summary of number of participants with any AEs and SAEs is presented. AEs were coded using the MedDRA dictionary.
Time frame: Up to approximately 367 weeks
Population: All Treated population
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any AEs | 5 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any SAEs | 3 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any SAEs | 2 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any AEs | 5 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any SAEs | 3 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any AEs | 5 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any AEs | 5 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any SAEs | 2 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any AEs | 8 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any SAEs | 3 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any SAEs | 4 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any AEs | 10 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any AEs | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any SAEs | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any AEs | 4 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any SAEs | 2 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any SAEs | 5 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any AEs | 15 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any AEs | 4 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any SAEs | 2 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any SAEs | 1 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any AEs | 3 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any SAEs | 4 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any AEs | 6 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any SAEs | 13 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any AEs | 36 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any AEs | 13 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any SAEs | 3 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any AEs | 22 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any SAEs | 17 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any AEs | 1 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any SAEs | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any AEs | 4 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any SAEs | 1 Participants |
Primary
Part 2A: Number of Participants With Dose Limiting Toxicity (DLT)
DLT is an AE that is considered by the investigator to be clinically relevant and attributed to the study therapy during the 28-day DLT period and meets at least one of the DLT criteria: Febrile neutropenia; Grade 4 neutropenia of \>7 days in duration or requiring Granulocyte Colony-stimulating Factor (G-CSF), anemia, thrombocytopenia, non-hematologic toxicity; Grade 3 thrombocytopenia with bleeding, pneumonitis, toxicity that does not resolve to Grade 1 or baseline within 3 days; Grade 2 ocular toxicity; Toxicity that results in permanent discontinuation of feladilimab monotherapy or in combination during the first four weeks of treatment; any other event which in the judgment of the investigator and GSK Medical Monitor is considered to be a DLT.
Time frame: Up to 28 days
Population: DLT Evaluable Population. As pre-specified in the protocol, only specified treatment arms were planned and hence there are 0 participants analyzed for rest of the arms.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Dose Limiting Toxicity (DLT) | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Dose Limiting Toxicity (DLT) | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Dose Limiting Toxicity (DLT) | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Dose Limiting Toxicity (DLT) | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Dose Limiting Toxicity (DLT) | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Dose Limiting Toxicity (DLT) | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Dose Limiting Toxicity (DLT) | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Dose Limiting Toxicity (DLT) | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Dose Limiting Toxicity (DLT) | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Dose Limiting Toxicity (DLT) | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Dose Limiting Toxicity (DLT) | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Dose Limiting Toxicity (DLT) | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Dose Limiting Toxicity (DLT) | 2 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Dose Limiting Toxicity (DLT) | 1 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Dose Limiting Toxicity (DLT) | 3 Participants |
Primary
Part 2A: Number of Participants With Dose Modifications of Feladilimab
Number of participants with dose modifications (including dose delays, dose escalations, and infusion interruptions) were reported for Feladilimab
Time frame: Up to approximately 367 weeks
Population: All Treated population
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Dose Modifications of Feladilimab | Dose delays | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Dose Modifications of Feladilimab | Dose escalations | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Dose Modifications of Feladilimab | Infusion interruptions | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Dose Modifications of Feladilimab | Dose escalations | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Dose Modifications of Feladilimab | Dose delays | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Dose Modifications of Feladilimab | Infusion interruptions | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Dose Modifications of Feladilimab | Dose escalations | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Dose Modifications of Feladilimab | Dose delays | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Dose Modifications of Feladilimab | Infusion interruptions | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Dose Modifications of Feladilimab | Dose delays | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Dose Modifications of Feladilimab | Infusion interruptions | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Dose Modifications of Feladilimab | Dose escalations | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Dose Modifications of Feladilimab | Infusion interruptions | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Dose Modifications of Feladilimab | Dose escalations | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Dose Modifications of Feladilimab | Dose delays | 2 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Dose Modifications of Feladilimab | Dose escalations | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Dose Modifications of Feladilimab | Dose delays | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Dose Modifications of Feladilimab | Infusion interruptions | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Dose Modifications of Feladilimab | Dose escalations | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Dose Modifications of Feladilimab | Dose delays | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Dose Modifications of Feladilimab | Infusion interruptions | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Dose Modifications of Feladilimab | Infusion interruptions | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Dose Modifications of Feladilimab | Dose delays | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Dose Modifications of Feladilimab | Dose escalations | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Dose Modifications of Feladilimab | Dose escalations | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Dose Modifications of Feladilimab | Dose delays | 1 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Dose Modifications of Feladilimab | Infusion interruptions | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Dose Modifications of Feladilimab | Dose delays | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Dose Modifications of Feladilimab | Dose escalations | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Dose Modifications of Feladilimab | Infusion interruptions | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Dose Modifications of Feladilimab | Dose escalations | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Dose Modifications of Feladilimab | Dose delays | 1 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Dose Modifications of Feladilimab | Infusion interruptions | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Dose Modifications of Feladilimab | Dose delays | 1 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Dose Modifications of Feladilimab | Infusion interruptions | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Dose Modifications of Feladilimab | Dose escalations | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Dose Modifications of Feladilimab | Infusion interruptions | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Dose Modifications of Feladilimab | Dose escalations | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Dose Modifications of Feladilimab | Dose delays | 4 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Dose Modifications of Feladilimab | Dose escalations | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Dose Modifications of Feladilimab | Infusion interruptions | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Dose Modifications of Feladilimab | Dose delays | 7 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Dose Modifications of Feladilimab | Infusion interruptions | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Dose Modifications of Feladilimab | Dose escalations | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Dose Modifications of Feladilimab | Dose delays | 11 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Dose Modifications of Feladilimab | Dose delays | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Dose Modifications of Feladilimab | Infusion interruptions | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Dose Modifications of Feladilimab | Dose escalations | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Dose Modifications of Feladilimab | Infusion interruptions | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Dose Modifications of Feladilimab | Dose delays | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Dose Modifications of Feladilimab | Dose escalations | 0 Participants |
Primary
Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline
Normal ranges were 6 to 8.3 grams/L (protein); 100 to 250 international units (IU)/L (Lactate Dehydrogenase(LDH)); 2.3 - 4.1 picomoles/L (Free Triiodothyronine(T3)); 4.6 to 11.2 picomoles/L (Free Thyroxine(T4)); 0 and 0.04 microgram (ug)/L (Troponin I); 0 - 0.01 ug/L (Troponin T); 0.45 to 4.5 milliunits (Mu)/L (Thyrotropin(TSH)); and 6 to 24 millimoles/L (Urea). Participants were counted in worst case category that their value changes to low, normal or no change \[NC\] or high), unless there is NC in their category. Participants whose laboratory value category was unchanged (e.g. High to High) or whose value became normal, were recorded in To Normal or No Change category. Participants were counted twice if participant had values that changed To Low and To High, so percentages may not add to 100%.
Time frame: Up to approximately 367 weeks
Population: All Treated Population. Only those participants with data available at specified categories have been analyzed.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Normal or No Change | 3 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Normal or No Change | 2 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To High | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Low | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To High | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To Low | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To High | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To High | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Low | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To Normal or No Change | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Low | 2 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To Low | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Low | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Low | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To Normal or No Change | 2 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To High | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Normal or No Change | 3 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To High | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Normal or No Change | 2 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Normal or No Change | 3 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To High | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Normal or No Change | 3 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Low | 2 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To Normal or No Change | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Normal or No Change | 5 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Normal or No Change | 5 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To Low | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Low | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To Low | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To High | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To High | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To High | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Normal or No Change | 3 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To High | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Low | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Normal or No Change | 5 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To Normal or No Change | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Low | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To High | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To High | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To High | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Low | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To High | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To High | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Low | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To Low | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To High | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To Low | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Low | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Low | 2 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Normal or No Change | 3 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To High | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Low | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Normal or No Change | 2 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Normal or No Change | 2 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To High | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Normal or No Change | 3 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Normal or No Change | 3 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Low | 2 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To High | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To High | 3 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To Normal or No Change | 2 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To Normal or No Change | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Normal or No Change | 6 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To High | 3 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To Low | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Low | 3 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To High | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Normal or No Change | 3 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To Normal or No Change | 2 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To Normal or No Change | 3 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To High | 2 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To Low | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Low | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To High | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To High | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Low | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Normal or No Change | 6 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Normal or No Change | 5 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Low | 2 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To High | 3 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To High | 2 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Low | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Normal or No Change | 4 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Normal or No Change | 8 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Normal or No Change | 4 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Low | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To High | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Normal or No Change | 8 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To Low | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To High | 2 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To Low | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To Normal or No Change | 4 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To High | 4 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Low | 2 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To High | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Low | 4 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Normal or No Change | 4 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To High | 2 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Low | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To High | 3 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To Normal or No Change | 2 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Low | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Normal or No Change | 6 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To High | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Normal or No Change | 6 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To High | 4 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To Normal or No Change | 3 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To High | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Low | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Normal or No Change | 6 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Normal or No Change | 6 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Normal or No Change | 10 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To High | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Normal or No Change | 9 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To High | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Low | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To High | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Low | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To High | 3 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To Normal or No Change | 3 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Low | 2 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To Low | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To High | 3 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Low | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To Low | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To High | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Low | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To High | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Normal or No Change | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To High | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Normal or No Change | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To High | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Low | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To High | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Normal or No Change | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Normal or No Change | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Low | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Low | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Normal or No Change | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Low | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Normal or No Change | 2 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Normal or No Change | 1 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Low | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To High | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Low | 1 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Low | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Low | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To High | 1 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To High | 1 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To High | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Normal or No Change | 2 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Low | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Normal or No Change | 2 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Normal or No Change | 4 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To High | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To Low | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To Normal or No Change | 1 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To High | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Lactate Dehydrogenase (IU/L), To Normal or No Change | 2 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Normal or No Change | 8 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To Low | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Low | 3 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Normal or No Change | 9 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Normal or No Change | 13 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To High | 4 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To Normal or No Change | 3 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To High | 1 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Lactate Dehydrogenase (IU/L), To Low | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To High | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Lactate Dehydrogenase (IU/L), To High | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To High | 2 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To High | 3 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Low | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To Low | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To High | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Low | 2 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Low | 2 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To Normal or No Change | 8 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Normal or No Change | 10 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Low | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To High | 1 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Normal or No Change | 12 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Normal or No Change | 2 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Lactate Dehydrogenase (IU/L), To Low | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Lactate Dehydrogenase (IU/L), To Normal or No Change | 2 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Lactate Dehydrogenase (IU/L), To High | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Low | 2 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Normal or No Change | 2 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To High | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Low | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Low | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Normal or No Change | 1 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To High | 1 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Low | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To High | 2 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Normal or No Change | 2 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To High | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Low | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Normal or No Change | 2 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To High | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To Low | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To Normal or No Change | 2 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To High | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To Normal or No Change | 1 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Normal or No Change | 3 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Lactate Dehydrogenase (IU/L), To Normal or No Change | 1 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Lactate Dehydrogenase (IU/L), To Low | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Low | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Lactate Dehydrogenase (IU/L), To High | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To High | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Low | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Normal or No Change | 2 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To High | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To Normal or No Change | 1 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To High | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Low | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To High | 1 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Normal or No Change | 2 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To High | 1 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Normal or No Change | 1 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Normal or No Change | 3 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To High | 1 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Low | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To Low | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To High | 1 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Low | 1 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To Low | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Low | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Normal or No Change | 2 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Normal or No Change | 3 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To High | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Low | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To High | 3 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Low | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To High | 2 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Normal or No Change | 3 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To High | 1 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Low | 2 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To Low | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To High | 2 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To High | 1 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Low | 1 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Normal or No Change | 3 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To Normal or No Change | 4 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Normal or No Change | 1 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Normal or No Change | 17 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Normal or No Change | 26 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To High | 3 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Lactate Dehydrogenase (IU/L), To Low | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To Low | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Normal or No Change | 18 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To Low | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Low | 1 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Lactate Dehydrogenase (IU/L), To Normal or No Change | 1 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To High | 6 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To High | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Lactate Dehydrogenase (IU/L), To High | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Normal or No Change | 23 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To High | 1 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Low | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Low | 2 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To High | 6 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Normal or No Change | 31 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Low | 16 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To High | 1 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To Normal or No Change | 12 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Low | 5 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To High | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To Normal or No Change | 11 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To Low | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Normal or No Change | 12 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Low | 2 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To High | 1 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Low | 6 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Normal or No Change | 6 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To High | 3 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To Normal or No Change | 9 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To High | 1 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To Normal or No Change | 2 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To High | 1 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Normal or No Change | 3 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Low | 4 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Normal or No Change | 7 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Lactate Dehydrogenase (IU/L), To Low | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To Low | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Low | 1 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Low | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Normal or No Change | 11 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To High | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To High | 1 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To High | 8 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Lactate Dehydrogenase (IU/L), To High | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Lactate Dehydrogenase (IU/L), To Normal or No Change | 1 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To High | 5 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Normal or No Change | 12 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Low | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Normal or No Change | 18 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To High | 3 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To High | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Normal or No Change | 17 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Low | 5 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Low | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To High | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Lactate Dehydrogenase (IU/L), To Low | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Normal or No Change | 14 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To Normal or No Change | 2 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Low | 2 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To High | 2 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To High | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To Low | 3 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Normal or No Change | 9 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To Normal or No Change | 9 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Low | 12 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To High | 6 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Lactate Dehydrogenase (IU/L), To High | 2 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Lactate Dehydrogenase (IU/L), To Normal or No Change | 3 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To Low | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Low | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To High | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Normal or No Change | 1 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To High | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To High | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Normal or No Change | 1 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To Normal or No Change | 1 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Normal or No Change | 1 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To High | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To High | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Low | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Normal or No Change | 1 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Normal or No Change | 1 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Low | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Low | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To Low | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To High | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Low | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To High | 1 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Normal or No Change | 3 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Normal or No Change | 2 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Normal or No Change | 1 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To Low | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To High | 2 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To High | 2 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To Normal or No Change | 3 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To Low | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To Normal or No Change | 2 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Low | 2 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Normal or No Change | 4 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To High | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Lactate Dehydrogenase (IU/L), To High | 2 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Low | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Lactate Dehydrogenase (IU/L), To Low | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Low | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Low | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To High | 1 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Low | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Lactate Dehydrogenase (IU/L), To Normal or No Change | 1 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Normal or No Change | 3 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To High | 1 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To High | 0 Participants |
Primary
Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters
Blood samples were collected for analysis of clinical chemistry parameters. Laboratory parameters were graded according to CTCAE v4.03. Grade (G) 0: None; G1: mild; G2: moderate; G3: severe or medically significant; G4: life-threatening consequences. Higher grade indicates greater severity and increase in grade was defined relative to Baseline grade. Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Only grade change data is presented for Baseline (B) and Worst-Case Post-Baseline (WCPB) as G0, G1, G2, G3, G4, and missing (M) here as Parameter name, B GX, WCPB GX where X=grade digit.
Time frame: Baseline (Day 1) and up to approximately 367 weeks
Population: All Treated Population. Only those participants with data available at specified categories have been analyzed.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 1 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 2 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 3 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 1 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 2 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 1 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 1 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 2 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 1 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 1 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 1 | 2 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 4 | 2 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 2 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 2 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 2 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 1 | 3 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 1 | 2 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 1 | 2 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 1 | 3 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 4 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 3 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 3 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 3 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 1 | 2 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 2 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 2 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 2 | 2 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 4 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 2 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 1 | 5 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 1 | 2 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 0 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 1 | 2 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 1 | 2 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 1 | 3 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 1 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 1 | 5 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 1 | 2 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 3 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 2 | 2 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 1 | 3 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 3 | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 1 | 2 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 2 | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 1 | 3 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 1 | 2 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 1 | 3 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 1 | 5 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 0 | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 2 | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 1 | 6 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 1 | 4 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 3 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 4 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 0 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 1 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 0 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 1 | 2 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 1 | 6 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 1 | 2 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 4 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 2 | 2 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 2 | 2 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 0 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 1 | 3 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 1 | 2 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 1 | 2 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 1 | 2 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 2 | 1 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 1 | 4 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 3 | 1 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 1 | 2 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 4 | 1 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 1 | 2 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 1 | 2 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 0 | 1 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 1 | 1 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 3 | 1 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 3 | 1 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 2 | 2 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 3 | 1 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 2 | 1 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 2 | 1 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 1 | 6 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 1 | 2 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 3 | 1 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 3 | 1 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 2 | 1 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 1 | 1 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 1 | 2 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 1 | 1 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 1 | 1 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 0 | 1 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 3 | 1 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 1 | 1 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 2 | 1 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 3 | 1 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 4 | 1 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 1 | 2 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 1 | 2 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 1 | 1 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 3 | 1 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 1 | 1 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 3 | 1 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 2 | 1 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 0 | 1 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 3 | 1 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 2 | 1 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 0 | 1 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 2 | 1 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 2 | 1 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 1 | 1 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 1 | 1 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 1 | 2 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 1 | 1 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 3 | 5 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 1 | 7 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 1 | 5 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 1 | 5 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 1 | 7 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 2 | 1 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 3 | 1 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 2 | 4 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 3 | 1 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 2 | 2 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Missing, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Missing, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 0 | 2 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Missing, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Missing, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Missing, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Missing, Grade 0 | 1 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 0 | 1 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Missing, Grade 0 | 1 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 2 | 4 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 1 | 4 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 1 | 2 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Missing, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Missing, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Missing, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Missing, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 1 | 5 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 2 | 1 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 1 | 4 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 1 | 1 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 0 | 1 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 1 | 10 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 2 | 1 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 2 | 1 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 2 | 1 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 1 | 8 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Missing, Grade 0 | 1 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 1 | 2 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 1 | 6 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 0 | 1 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Missing, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Missing, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 3 | 1 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 2 | 5 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 1 | 1 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 0 | 1 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 2 | 5 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Missing, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Missing, Grade 1 | 1 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Missing, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Missing, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 1 | 12 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Missing, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 4 | 1 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 3 | 1 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 3 | 1 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 2 | 1 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 2 | 2 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 3 | 1 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 2 | 2 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 0 | 1 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 1 | 3 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Missing, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 1 | 9 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 2 | 2 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 1 | 1 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 0 | 2 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 1 | 2 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 2 | 1 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 3 | 1 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 3 | 1 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 2 | 1 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 1 | 1 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 2 | 1 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 2 | 2 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 1 | 4 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 1 | 5 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 2 | 3 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 2 | 1 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 2 | 2 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 3 | 1 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 1 | 1 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 2 | 1 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 3 | 1 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 1 | 2 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 1 | 5 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 2 | 1 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 1 | 1 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 1 | 5 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 1 | 5 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 1 | 9 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 0 | 1 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 4 | 1 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 1 | 3 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 2 | 1 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 1 | 5 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 1 | 2 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 1 | 3 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 4 | 1 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 2 | 1 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 1 | 2 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 2 | 1 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 1 | 1 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 0 | 1 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 1 | 7 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 1 | 1 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 3 | 1 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 0 | 1 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 4 | 1 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 2 | 1 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 2 | 3 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 4 | 1 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 0 | 1 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 1 | 12 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 1 | 9 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 3 | 1 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 1 | 6 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 3 | 1 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 3 | 3 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 4 | 1 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 3 | 1 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 1 | 2 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 3 | 1 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 1 | 5 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 2 | 1 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 1 | 3 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 3 | 1 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Missing, Grade 4 | 1 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Missing, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Missing, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Missing, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Missing, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 1 | 2 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 1 | 1 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 4 | 1 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 3 | 1 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 3 | 4 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 2 | 1 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 1 | 1 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 1 | 6 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 2 | 1 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 2 | 1 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 3 | 1 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 2 | 1 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 1 | 1 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 1 | 2 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 1 | 1 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 1 | 3 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 3 | 1 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 2 | 0 Participants |
Primary
Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters
Blood samples were collected for analysis of hematology parameters. Laboratory parameters were graded according to CTCAE v4.03. Grade (G) 0: None; G1: mild; G2: moderate; G3: severe or medically significant; G4: life-threatening consequences. Higher grade indicates greater severity and increase in grade was defined relative to Baseline grade. Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Only grade change data is presented for Baseline (B) and Worst-Case Post-Baseline (WCPB) as G0, G1, G2, G3, G4, and missing (M) here as Parameter name, B GX, WCPB GX where X=grade digit.
Time frame: Baseline (Day 1) and up to approximately 367 weeks
Population: All Treated Population. Only those participants with data available at specified categories have been analyzed.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 1 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 1 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 2 | 2 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 2 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 2 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 2 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 3 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 2 | 3 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 2 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 1 | 2 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 2 | 2 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 2 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 1 | 2 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 3 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 4 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 3 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 1 | 2 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 2 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 3 | 2 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 3 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 0 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 3 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 2 | 2 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 1 | 2 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 2 | 2 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 3 | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 1 | 2 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 1 | 4 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 3 | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 4 | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 3 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 1 | 2 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 2 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 1 | 2 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 1 | 2 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 2 | 2 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 2 | 1 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 2 | 1 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 4 | 1 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 3 | 1 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 2 | 4 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 2 | 2 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 1 | 3 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 3 | 1 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 2 | 2 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 3 | 1 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 4 | 1 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 1 | 1 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 1 | 1 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 4 | 1 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 4 | 1 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 3 | 1 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 2 | 1 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 3 | 1 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 1 | 1 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 2 | 1 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 1 | 1 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 2 | 1 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 2 | 1 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 1 | 2 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 2 | 1 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 3 | 2 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 3 | 1 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 3 | 2 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 3 | 1 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 3 | 1 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 2 | 2 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 3 | 2 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 1 | 2 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 2 | 1 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 1 | 1 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 2 | 1 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 3 | 1 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 2 | 1 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 2 | 1 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 1 | 1 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 2 | 4 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 1 | 1 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 4 | 1 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 1 | 8 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 2 | 9 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 4 | 1 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 2 | 1 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 3 | 3 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 3 | 4 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 1 | 13 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 3 | 13 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 4 | 1 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 4 | 1 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 4 | 8 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 2 | 8 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 1 | 4 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 3 | 1 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 3 | 2 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 3 | 5 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 2 | 1 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 3 | 5 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 2 | 11 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 2 | 7 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 2 | 3 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 1 | 5 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 4 | 3 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 3 | 8 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 3 | 1 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 3 | 4 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 2 | 1 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 3 | 1 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 3 | 1 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 2 | 2 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 2 | 3 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 3 | 2 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 4 | 1 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 3 | 5 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 1 | 2 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 2 | 6 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 2 | 2 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 2 | 4 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 3 | 1 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 4 | 1 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 2 | 2 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 2 | 2 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 3 | 1 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 3 | 3 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 4 | 2 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 1 | 6 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 3 | 1 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 1 | 1 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 2 | 5 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 4 | 1 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 3 | 7 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 4 | 2 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 2 | 7 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 2 | 3 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 1 | 4 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 3 | 1 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 4 | 4 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 2 | 3 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 2 | 4 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 3 | 4 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 3 | 3 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 3 | 2 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 1 | 1 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 3 | 4 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 3 | 1 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 3 | 3 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 1 | 5 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 3 | 10 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 1 | 2 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 2 | 3 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 2 | 3 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 4 | 2 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 3 | 1 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 1 | 1 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 2 | 1 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 2 | 1 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 0 | 1 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 1 | 1 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 3 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 4 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 3 | 0 Participants |
Primary
Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline
Normal ranges were 0.01 to 0.3\*10\^9 cells/L (basophils), 0 to 500 cells /L (eosinophils), 41 to 50 percentage of RBC in blood (hematocrit), 2 to 8 percentage of WBC (monocytes), 40 to 60 cells/mcL (neutrophils) and Women: 4.2 to 5.4 million RBC/mcL of blood and Men: 4.7 to 6.1 million RBC/ mcL (erythrocytes count). Participants were counted in worst case category that their value changes to low, normal or no change \[NC\] or high), unless there is NC in their category. Participants whose laboratory value category was unchanged (e.g. High to High) or whose value became normal, were recorded in To Normal or No Change category. Participants were counted twice if participant had values that changed To Low and To High, so percentages may not add to 100%.
Time frame: Up to approximately 367 weeks
Population: All Treated Population. Only those participants with data available at specified categories have been analyzed.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To High | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Low | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Normal or No Change | 5 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Low | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To High | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To High | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Normal or No Change | 4 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Normal or No Change | 4 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Low | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Low | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To High | 2 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Normal or No Change | 4 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Normal or No Change | 3 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Low | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To High | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Normal or No Change | 3 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Low | 2 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Low | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Normal or No Change | 4 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To High | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Normal or No Change | 4 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Low | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Normal or No Change | 3 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To High | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To High | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To High | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Normal or No Change | 2 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Low | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Low | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To High | 2 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Normal or No Change | 4 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Neutrophils, To High | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Normal or No Change | 5 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Normal or No Change | 5 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Low | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Low | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To High | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Low | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To High | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Normal or No Change | 3 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Low | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Neutrophils, To Normal or No Change | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To High | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Neutrophils, To Low | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To High | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Low | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Normal or No Change | 5 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To High | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Low | 3 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Low | 3 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Normal or No Change | 4 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Normal or No Change | 6 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Low | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To High | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To High | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To High | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Low | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Normal or No Change | 5 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Low | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Normal or No Change | 5 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Normal or No Change | 5 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To High | 4 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To High | 3 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Low | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Normal or No Change | 8 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Low | 6 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Normal or No Change | 4 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To High | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Normal or No Change | 11 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To High | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To High | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Low | 4 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Normal or No Change | 9 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To High | 2 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To High | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Normal or No Change | 6 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Low | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Low | 3 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Low | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Normal or No Change | 8 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Low | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Normal or No Change | 9 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Normal or No Change | 9 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To High | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To High | 3 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Normal or No Change | 8 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Low | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Low | 3 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Low | 2 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Normal or No Change | 11 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To High | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To High | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To High | 2 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Low | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Low | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To High | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Normal or No Change | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To High | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Normal or No Change | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Low | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Normal or No Change | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To High | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Low | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Low | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To High | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Normal or No Change | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Normal or No Change | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To High | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Low | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Normal or No Change | 4 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To High | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Normal or No Change | 4 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To High | 1 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Low | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Normal or No Change | 3 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To High | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Low | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Normal or No Change | 3 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Low | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To High | 1 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Normal or No Change | 4 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To High | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Low | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To High | 4 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Low | 3 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Normal or No Change | 9 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Low | 2 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Low | 2 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Low | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Normal or No Change | 11 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To High | 1 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Normal or No Change | 12 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Normal or No Change | 13 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Normal or No Change | 11 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To High | 1 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Low | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To High | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To High | 3 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Normal or No Change | 4 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Low | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Low | 2 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Normal or No Change | 4 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Low | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Low | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To High | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To High | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Normal or No Change | 3 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To High | 1 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To High | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Normal or No Change | 4 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Low | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To High | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Normal or No Change | 2 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Normal or No Change | 1 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Low | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Normal or No Change | 3 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To High | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Low | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Normal or No Change | 3 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To High | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Low | 2 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To High | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Low | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Normal or No Change | 3 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To High | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Low | 2 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Normal or No Change | 1 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To High | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To High | 1 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Normal or No Change | 2 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Low | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To High | 1 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Normal or No Change | 1 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To High | 3 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Normal or No Change | 5 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Low | 3 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Low | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Normal or No Change | 3 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To High | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To High | 0 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Low | 3 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Normal or No Change | 2 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Low | 1 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Normal or No Change | 23 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Low | 17 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Low | 10 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Low | 6 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Normal or No Change | 21 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To High | 1 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Normal or No Change | 16 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Low | 2 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Low | 15 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To High | 12 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To High | 2 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Normal or No Change | 19 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To High | 3 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To High | 3 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Normal or No Change | 23 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Low | 1 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Normal or No Change | 6 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To High | 6 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Low | 2 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Low | 9 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Low | 7 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To High | 6 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Normal or No Change | 7 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Low | 7 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Normal or No Change | 4 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To High | 3 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Normal or No Change | 9 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Normal or No Change | 4 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To High | 0 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To High | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Low | 9 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To High | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Normal or No Change | 12 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Normal or No Change | 6 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To High | 6 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To High | 13 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Normal or No Change | 12 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Low | 6 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To High | 0 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Low | 13 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To High | 1 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Normal or No Change | 8 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Normal or No Change | 17 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Low | 3 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Low | 10 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To High | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Normal or No Change | 1 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Normal or No Change | 1 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To High | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To High | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To High | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Normal or No Change | 1 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To High | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Low | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Low | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Low | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Normal or No Change | 1 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Low | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Low | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Normal or No Change | 1 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To High | 1 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Low | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To High | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Normal or No Change | 2 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Normal or No Change | 2 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Low | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Low | 2 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To High | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Low | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Low | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Normal or No Change | 4 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Normal or No Change | 4 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Normal or No Change | 2 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To High | 2 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To High | 2 Participants |
Primary
Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline
Urine samples were collected to assess urine glucose, ketones and occult blood using dipstick method. The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as negative, trace, 1+, 2+, 3+ indicating proportional concentrations in the urine sample. Baseline (Day 1) was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Result for urinalysis parameters were recorded as no change/decreased and any increase.
Time frame: Up to approximately 367 weeks
Population: All treated population. Only those participants with data available at specified categories have been analyzed
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, Any increase | 2 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, No Change/Decreased | 3 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, Any increase | 4 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, Any increase | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, No Change/Decreased | 5 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, No Change/Decreased | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, No Change/Decreased | 4 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, Any increase | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, No Change/Decreased | 4 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, No Change/Decreased | 5 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, Any increase | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, Any increase | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, No Change/Decreased | 4 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, Any increase | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, No Change/Decreased | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, Any increase | 2 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, No Change/Decreased | 3 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, Any increase | 4 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, Any increase | 4 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, No Change/Decreased | 4 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, No Change/Decreased | 6 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, Any increase | 2 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, No Change/Decreased | 8 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, Any increase | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, Any increase | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, No Change/Decreased | 10 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, Any increase | 4 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, No Change/Decreased | 7 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, Any increase | 2 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, No Change/Decreased | 9 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, No Change/Decreased | 5 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, Any increase | 2 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, No Change/Decreased | 10 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, No Change/Decreased | 9 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, Any increase | 6 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, Any increase | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, Any increase | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, No Change/Decreased | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, No Change/Decreased | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, Any increase | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, No Change/Decreased | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, Any increase | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, Any increase | 1 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, No Change/Decreased | 3 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, No Change/Decreased | 4 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, Any increase | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, No Change/Decreased | 4 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, Any increase | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, Any increase | 1 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, No Change/Decreased | 14 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, Any increase | 2 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, No Change/Decreased | 14 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, Any increase | 1 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, No Change/Decreased | 13 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, Any increase | 1 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, No Change/Decreased | 3 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, Any increase | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, Any increase | 1 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, No Change/Decreased | 3 Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, No Change/Decreased | 4 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, No Change/Decreased | 2 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, No Change/Decreased | 2 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, Any increase | 1 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, Any increase | 1 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, Any increase | 0 Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, No Change/Decreased | 3 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, Any increase | 1 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, No Change/Decreased | 3 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, No Change/Decreased | 5 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, Any increase | 3 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, No Change/Decreased | 2 Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, Any increase | 4 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, Any increase | 6 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, No Change/Decreased | 28 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, Any increase | 1 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, No Change/Decreased | 23 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, Any increase | 9 Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, No Change/Decreased | 33 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, No Change/Decreased | 7 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, Any increase | 5 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, Any increase | 6 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, No Change/Decreased | 8 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, Any increase | 6 Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, No Change/Decreased | 7 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, Any increase | 6 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, No Change/Decreased | 16 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, Any increase | 10 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, Any increase | 7 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, No Change/Decreased | 12 Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, No Change/Decreased | 15 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, No Change/Decreased | 1 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, Any increase | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, No Change/Decreased | 1 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, Any increase | 1 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, Any increase | 0 Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, No Change/Decreased | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, No Change/Decreased | 3 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, Any increase | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, No Change/Decreased | 4 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, No Change/Decreased | 4 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, Any increase | 0 Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, Any increase | 1 Participants |
Secondary
Part 1A: Area Under the Concentration-time Curve From Time 0 to 504 Hours After Dosing [AUC (0-504h)] of Feladilimab
Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method.
Time frame: Pre-dose; end of infusion (EOI); 0.5, 1, 2, 4, 6, 8, 24, 48-72, 96-120 hours post-EOI; week 1; week 2; Pre-dose and 0.5 hours post-EOI in week 3; week 4; week 5; Pre-dose and 0.5 hours post-EOI in week 6, 9, 12 15; Pre-dose in week 21 and 33
Population: Pharmacokinetic Population. As pre-specified in the protocol, only specified treatment arms were planned for this outcome measure and hence there are 0 participants analyzed for rest of the arms.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Part 1A: Fela 0.030 mg/kg | Part 1A: Area Under the Concentration-time Curve From Time 0 to 504 Hours After Dosing [AUC (0-504h)] of Feladilimab | 134.6206 Hour*microgram/millilitre (h*ug/mL) | — |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Area Under the Concentration-time Curve From Time 0 to 504 Hours After Dosing [AUC (0-504h)] of Feladilimab | 373.6877 Hour*microgram/millilitre (h*ug/mL) | Geometric Coefficient of Variation 23.2053 |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Area Under the Concentration-time Curve From Time 0 to 504 Hours After Dosing [AUC (0-504h)] of Feladilimab | 1156.5768 Hour*microgram/millilitre (h*ug/mL) | Geometric Coefficient of Variation 6.8031 |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Area Under the Concentration-time Curve From Time 0 to 504 Hours After Dosing [AUC (0-504h)] of Feladilimab | 4839.0026 Hour*microgram/millilitre (h*ug/mL) | — |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Area Under the Concentration-time Curve From Time 0 to 504 Hours After Dosing [AUC (0-504h)] of Feladilimab | 11368.0960 Hour*microgram/millilitre (h*ug/mL) | — |
Secondary
Part 1A: Disease Control Rate (DCR)
DCR was defined as percentage of participants with best overall response of irCR or irPR at any time + ir stable disease (irSD) meeting the minimum time criteria from the start of treatment until ir disease progression (irPD) or death due to any cause or the start of new anticancer therapy/crossover. irCR is defined as disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \<10 mm. irPR defined as at least 30% decrease in the sum of diameters of target lesions, taking as a reference, the baseline sum of the diameters. irSD defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease. IrPD defined as the date of radiological disease progression based on imaging data per irRECIST. A one-week visit window was considered in the duration of irSD, i.e. a minimum of 8 weeks (irSD\>=9 weeks) and 17 weeks (irSD\>=18 weeks) were considered.
Time frame: Up to approximately 367 weeks
Population: All Treated population
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Disease Control Rate (DCR) | >=9 Weeks | 0 Percentage of Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Disease Control Rate (DCR) | >=18 Weeks | 0 Percentage of Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Disease Control Rate (DCR) | >=9 Weeks | 0 Percentage of Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Disease Control Rate (DCR) | >=18 Weeks | 0 Percentage of Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Disease Control Rate (DCR) | >=9 Weeks | 0 Percentage of Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Disease Control Rate (DCR) | >=18 Weeks | 0 Percentage of Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Disease Control Rate (DCR) | >=9 Weeks | 43 Percentage of Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Disease Control Rate (DCR) | >=18 Weeks | 14 Percentage of Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Disease Control Rate (DCR) | >=9 Weeks | 29 Percentage of Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Disease Control Rate (DCR) | >=18 Weeks | 17 Percentage of Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Disease Control Rate (DCR) | >=18 Weeks | 24 Percentage of Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Disease Control Rate (DCR) | >=9 Weeks | 28 Percentage of Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Disease Control Rate (DCR) | >=18 Weeks | 13 Percentage of Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Disease Control Rate (DCR) | >=9 Weeks | 33 Percentage of Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Disease Control Rate (DCR) | >=9 Weeks | 22 Percentage of Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Disease Control Rate (DCR) | >=18 Weeks | 7 Percentage of Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Disease Control Rate (DCR) | >=9 Weeks | 29 Percentage of Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Disease Control Rate (DCR) | >=18 Weeks | 0 Percentage of Participants |
Secondary
Part 1A: Duration of Response (DOR)
DOR was defined as the interval of time in months from the date of the first documented evidence of a response (confirmed CR or PR) to the date of first documented evidence of disease progression according to radiological response from investigator assessment per RECIST v1.1, or date of last adequate assessment of response or the date of death due to any cause (whichever occurs earlier). CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 mm. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters. Disease progression was defined as the date of radiological disease progression based on imaging data per RECIST v1.1.
Time frame: Up to approximately 367 weeks
Population: All Treated Population with a confirmed CR or PR. Only responders were included for the analysis.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Part 1A: Fela 0.100 mg/kg | Part 1A: Duration of Response (DOR) | 10.3 Months |
Secondary
Part 1A: Maximum Observed Plasma Concentration (Cmax) and Minimum Observed Plasma Concentration (Ctau) of Feladilimab
Blood samples were collected for Pharmacokinetic (PK) analysis. PK analysis was calculated based on standard non-compartmental method.
Time frame: Pre-dose; end of infusion (EOI); 0.5, 1, 2, 4, 6, 8, 24, 48-72, 96-120 hours POST EOI; week 1; week 2; Pre-dose and 0.5 hours POST EOI in week 3; week 4; week 5; Pre-dose and 0.5 hours POST EOI in week 6, 9, 12 15; Pre-dose in week 21 and 33
Population: Pharmacokinetic Population included as all participants from the all treated population for whom a PK sample was obtained and analyzed. Only those participants with data available at specified categories have been analyzed
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Maximum Observed Plasma Concentration (Cmax) and Minimum Observed Plasma Concentration (Ctau) of Feladilimab | Ctau, Cycle 1 | NA Microgram/millilitre (ug/mL) | — |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Maximum Observed Plasma Concentration (Cmax) and Minimum Observed Plasma Concentration (Ctau) of Feladilimab | Ctau, Cycle 6 | NA Microgram/millilitre (ug/mL) | — |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Maximum Observed Plasma Concentration (Cmax) and Minimum Observed Plasma Concentration (Ctau) of Feladilimab | Cmax, Cycle 1 | 0.0887 Microgram/millilitre (ug/mL) | — |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Maximum Observed Plasma Concentration (Cmax) and Minimum Observed Plasma Concentration (Ctau) of Feladilimab | Cmax, Cycle 1 | NA Microgram/millilitre (ug/mL) | — |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Maximum Observed Plasma Concentration (Cmax) and Minimum Observed Plasma Concentration (Ctau) of Feladilimab | Ctau, Cycle 6 | NA Microgram/millilitre (ug/mL) | — |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Maximum Observed Plasma Concentration (Cmax) and Minimum Observed Plasma Concentration (Ctau) of Feladilimab | Ctau, Cycle 1 | NA Microgram/millilitre (ug/mL) | — |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Maximum Observed Plasma Concentration (Cmax) and Minimum Observed Plasma Concentration (Ctau) of Feladilimab | Cmax, Cycle 1 | 0.2038 Microgram/millilitre (ug/mL) | Geometric Coefficient of Variation 12.6253 |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Maximum Observed Plasma Concentration (Cmax) and Minimum Observed Plasma Concentration (Ctau) of Feladilimab | Cmax, Cycle 1 | 1.7433 Microgram/millilitre (ug/mL) | Geometric Coefficient of Variation 90.594 |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Maximum Observed Plasma Concentration (Cmax) and Minimum Observed Plasma Concentration (Ctau) of Feladilimab | Ctau, Cycle 6 | 0.2426 Microgram/millilitre (ug/mL) | — |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Maximum Observed Plasma Concentration (Cmax) and Minimum Observed Plasma Concentration (Ctau) of Feladilimab | Ctau, Cycle 1 | 0.2868 Microgram/millilitre (ug/mL) | Geometric Coefficient of Variation 62.218 |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Maximum Observed Plasma Concentration (Cmax) and Minimum Observed Plasma Concentration (Ctau) of Feladilimab | Cmax, Cycle 1 | 2.3041 Microgram/millilitre (ug/mL) | Geometric Coefficient of Variation 14.0076 |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Maximum Observed Plasma Concentration (Cmax) and Minimum Observed Plasma Concentration (Ctau) of Feladilimab | Ctau, Cycle 6 | 0.3510 Microgram/millilitre (ug/mL) | — |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Maximum Observed Plasma Concentration (Cmax) and Minimum Observed Plasma Concentration (Ctau) of Feladilimab | Cmax, Cycle 1 | 6.4643 Microgram/millilitre (ug/mL) | Geometric Coefficient of Variation 23.7989 |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Maximum Observed Plasma Concentration (Cmax) and Minimum Observed Plasma Concentration (Ctau) of Feladilimab | Ctau, Cycle 1 | 1.0533 Microgram/millilitre (ug/mL) | Geometric Coefficient of Variation 9.2565 |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Maximum Observed Plasma Concentration (Cmax) and Minimum Observed Plasma Concentration (Ctau) of Feladilimab | Cmax, Cycle 1 | 18.3809 Microgram/millilitre (ug/mL) | Geometric Coefficient of Variation 24.4093 |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Maximum Observed Plasma Concentration (Cmax) and Minimum Observed Plasma Concentration (Ctau) of Feladilimab | Ctau, Cycle 1 | 4.3093 Microgram/millilitre (ug/mL) | Geometric Coefficient of Variation 21.6033 |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Maximum Observed Plasma Concentration (Cmax) and Minimum Observed Plasma Concentration (Ctau) of Feladilimab | Ctau, Cycle 6 | 11.9562 Microgram/millilitre (ug/mL) | — |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Maximum Observed Plasma Concentration (Cmax) and Minimum Observed Plasma Concentration (Ctau) of Feladilimab | Ctau, Cycle 1 | 11.3112 Microgram/millilitre (ug/mL) | Geometric Coefficient of Variation 85.3459 |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Maximum Observed Plasma Concentration (Cmax) and Minimum Observed Plasma Concentration (Ctau) of Feladilimab | Cmax, Cycle 1 | 74.7985 Microgram/millilitre (ug/mL) | Geometric Coefficient of Variation 16.0934 |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Maximum Observed Plasma Concentration (Cmax) and Minimum Observed Plasma Concentration (Ctau) of Feladilimab | Ctau, Cycle 1 | 38.0810 Microgram/millilitre (ug/mL) | Geometric Coefficient of Variation 22.3643 |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Maximum Observed Plasma Concentration (Cmax) and Minimum Observed Plasma Concentration (Ctau) of Feladilimab | Ctau, Cycle 6 | 35.9660 Microgram/millilitre (ug/mL) | — |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Maximum Observed Plasma Concentration (Cmax) and Minimum Observed Plasma Concentration (Ctau) of Feladilimab | Cmax, Cycle 1 | 193.7782 Microgram/millilitre (ug/mL) | Geometric Coefficient of Variation 17.1955 |
Secondary
Part 1A: Number of Participants With Positive Results in Anti-drug Antibody (ADA) Test by Feladilimab Dose Level
Serum samples collected and tested for the presence of ADA with a screening assay.
Time frame: Up to approximately 367 weeks
Population: All Treated population
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Number of Participants With Positive Results in Anti-drug Antibody (ADA) Test by Feladilimab Dose Level | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Number of Participants With Positive Results in Anti-drug Antibody (ADA) Test by Feladilimab Dose Level | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Number of Participants With Positive Results in Anti-drug Antibody (ADA) Test by Feladilimab Dose Level | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Number of Participants With Positive Results in Anti-drug Antibody (ADA) Test by Feladilimab Dose Level | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Number of Participants With Positive Results in Anti-drug Antibody (ADA) Test by Feladilimab Dose Level | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Number of Participants With Positive Results in Anti-drug Antibody (ADA) Test by Feladilimab Dose Level | 3 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Number of Participants With Positive Results in Anti-drug Antibody (ADA) Test by Feladilimab Dose Level | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Number of Participants With Positive Results in Anti-drug Antibody (ADA) Test by Feladilimab Dose Level | 0 Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Number of Participants With Positive Results in Anti-drug Antibody (ADA) Test by Feladilimab Dose Level | 0 Participants |
Secondary
Part 1A: Overall Response Rate (ORR)
ORR was defined as the percentage of participants with immune-related confirmed complete response (irCR) or ir confirmed partial response (irPR) per Immune-related Response Evaluation Criteria in Solid Tumors Criteria (irRECIST). irCR is defined as disappearance of all target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 millimeters (mm). irPR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.
Time frame: Up to approximately 367 weeks
Population: All Treated population
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Overall Response Rate (ORR) | 0 Percentage of Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Overall Response Rate (ORR) | 0 Percentage of Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Overall Response Rate (ORR) | 0 Percentage of Participants |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Overall Response Rate (ORR) | 0 Percentage of Participants |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Overall Response Rate (ORR) | 8 Percentage of Participants |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Overall Response Rate (ORR) | 0 Percentage of Participants |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Overall Response Rate (ORR) | 0 Percentage of Participants |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Overall Response Rate (ORR) | 0 Percentage of Participants |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Overall Response Rate (ORR) | 0 Percentage of Participants |
Secondary
Part 1A: Overall Survival (OS)
OS was defined as the interval between the date of first assigned study therapy/randomization and date of death due to any cause.
Time frame: Up to approximately 367 weeks
Population: All Treated population
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Overall Survival (OS) | 4.3 Months |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Overall Survival (OS) | 12.6 Months |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Overall Survival (OS) | 14.0 Months |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Overall Survival (OS) | 4.9 Months |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Overall Survival (OS) | 6.7 Months |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Overall Survival (OS) | 9.1 Months |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Overall Survival (OS) | 9.1 Months |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Overall Survival (OS) | 6.7 Months |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Overall Survival (OS) | 7.3 Months |
Secondary
Part 1A: Progression-free Survival (PFS)
PFS was defined as the interval between the date of first dose of study treatment (or date of randomization for randomized cohorts) and the date of disease progression according to radiological response from investigator assessment, or death due to any cause, whichever occurs earlier. Disease progression was defined as the date of radiological disease progression based on imaging data per RECIST v1.1
Time frame: Up to approximately 367 weeks
Population: All Treated
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1A: Progression-free Survival (PFS) | 1.2 Months |
| Part 1A: Fela 0.003 mg/kg | Part 1A: Progression-free Survival (PFS) | 1.9 Months |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Progression-free Survival (PFS) | 2.1 Months |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Progression-free Survival (PFS) | 2.1 Months |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Progression-free Survival (PFS) | 2.0 Months |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Progression-free Survival (PFS) | 1.9 Months |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Progression-free Survival (PFS) | 2.1 Months |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Progression-free Survival (PFS) | 1.9 Months |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Progression-free Survival (PFS) | 1.9 Months |
Secondary
Part 1A: Receptor Occupancy of Feladilimab
Blood samples were collected to assess the cluster of differentiation 4 (CD4+) and cluster of differentiation 8 (CD8+) receptor occupancy by Feladilimab as a pharmacodynamic analysis. It was assessed using validated flow cytometry assay.
Time frame: Up to approximately 367 weeks
Population: All treated population. As pre-specified in the protocol, only specified treatment arms were planned and hence there are 0 participants analyzed for rest of the arms.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Part 1A: Fela 0.010 mg/kg | Part 1A: Receptor Occupancy of Feladilimab | %CD4+ | 74.643 percent receptor occupancy | — |
| Part 1A: Fela 0.010 mg/kg | Part 1A: Receptor Occupancy of Feladilimab | %CD8+ | 70.043 percent receptor occupancy | — |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Receptor Occupancy of Feladilimab | %CD4+ | 25.406 percent receptor occupancy | Geometric Coefficient of Variation 21.423 |
| Part 1A: Fela 0.030 mg/kg | Part 1A: Receptor Occupancy of Feladilimab | %CD8+ | 16.646 percent receptor occupancy | Geometric Coefficient of Variation 283.345 |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Receptor Occupancy of Feladilimab | %CD4+ | 90.229 percent receptor occupancy | Geometric Coefficient of Variation 9.932 |
| Part 1A: Fela 0.100 mg/kg | Part 1A: Receptor Occupancy of Feladilimab | %CD8+ | 76.985 percent receptor occupancy | Geometric Coefficient of Variation 16.349 |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Receptor Occupancy of Feladilimab | %CD4+ | 96.559 percent receptor occupancy | Geometric Coefficient of Variation 2.934 |
| Part 1A: Fela 0.300 mg/kg | Part 1A: Receptor Occupancy of Feladilimab | %CD8+ | 80.933 percent receptor occupancy | Geometric Coefficient of Variation 23.48 |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Receptor Occupancy of Feladilimab | %CD4+ | 94.007 percent receptor occupancy | Geometric Coefficient of Variation 7.904 |
| Part 1A: Fela 1.000 mg/kg | Part 1A: Receptor Occupancy of Feladilimab | %CD8+ | 88.546 percent receptor occupancy | Geometric Coefficient of Variation 10.383 |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Receptor Occupancy of Feladilimab | %CD4+ | 99.553 percent receptor occupancy | Geometric Coefficient of Variation 1.559 |
| Part 1A: Fela 3.000 mg/kg | Part 1A: Receptor Occupancy of Feladilimab | %CD8+ | 95.934 percent receptor occupancy | Geometric Coefficient of Variation 7.156 |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Receptor Occupancy of Feladilimab | %CD4+ | 96.030 percent receptor occupancy | Geometric Coefficient of Variation 6.652 |
| Part 1A: Fela 10.000 mg/kg | Part 1A: Receptor Occupancy of Feladilimab | %CD8+ | 82.965 percent receptor occupancy | Geometric Coefficient of Variation 29.404 |
Secondary
Part 1A: Time to Overall Response (TTR)
TTR was defined as the time from date of first dose of study treatment/randomization to the date of first documented confirmed (=4 weeks) CR or PR. CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 mm. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.
Time frame: Up to approximately 367 weeks
Population: All Treated Population with a confirmed CR or PR. Only responders were included for the analysis.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Part 1A: Fela 0.100 mg/kg | Part 1A: Time to Overall Response (TTR) | 2.3 Months |
Secondary
Part 1B: AUC (0-504 h) of Feladilimab
Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method.
Time frame: Pre-dose; end of infusion (EOI); 0.5, 1, 2, 4, 6, 8, 24, 48-72, 96-120 hours post-EOI; week 1; week 2; Pre-dose and 0.5 hours post-EOI in week 3; week 4; week 5; Pre-dose and 0.5 hours post-EOI in week 6, 9, 12 15; Pre-dose in week 21, 33 and 45
Population: Pharmacokinetic Population. Only those participants with data available at specified categories have been analyzed
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: AUC (0-504 h) of Feladilimab | JAPAN PK/PD | 1237.7314 h*ug/mL | Geometric Coefficient of Variation 9.6008 |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: AUC (0-504 h) of Feladilimab | MSI-H/DMMR | 1048.2771 h*ug/mL | Geometric Coefficient of Variation 24.6105 |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: AUC (0-504 h) of Feladilimab | BLADDER/UROTHELIAL | 632.0762 h*ug/mL | — |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: AUC (0-504 h) of Feladilimab | MELANOMA | 1206.7402 h*ug/mL | Geometric Coefficient of Variation 18.6679 |
| Part 1A: Fela 0.003 mg/kg | Part 1B: AUC (0-504 h) of Feladilimab | MELANOMA | 4048.7261 h*ug/mL | Geometric Coefficient of Variation 29.9449 |
| Part 1A: Fela 0.003 mg/kg | Part 1B: AUC (0-504 h) of Feladilimab | MSI-H/DMMR | 5952.2979 h*ug/mL | Geometric Coefficient of Variation 59.1357 |
| Part 1A: Fela 0.003 mg/kg | Part 1B: AUC (0-504 h) of Feladilimab | NSCLC | 4731.8292 h*ug/mL | Geometric Coefficient of Variation 31.1548 |
| Part 1A: Fela 0.003 mg/kg | Part 1B: AUC (0-504 h) of Feladilimab | VIRAL-POSITIVE | 4337.5163 h*ug/mL | Geometric Coefficient of Variation 26.459 |
| Part 1A: Fela 0.003 mg/kg | Part 1B: AUC (0-504 h) of Feladilimab | BLADDER/UROTHELIAL | 5026.8004 h*ug/mL | Geometric Coefficient of Variation 24.5736 |
| Part 1A: Fela 0.003 mg/kg | Part 1B: AUC (0-504 h) of Feladilimab | CERVICAL | 5222.1970 h*ug/mL | Geometric Coefficient of Variation 5.6103 |
| Part 1A: Fela 0.003 mg/kg | Part 1B: AUC (0-504 h) of Feladilimab | JAPAN PK/PD | 4525.7373 h*ug/mL | Geometric Coefficient of Variation 5.5353 |
| Part 1A: Fela 0.010 mg/kg | Part 1B: AUC (0-504 h) of Feladilimab | BIOMARKER | 1076.8681 h*ug/mL | Geometric Coefficient of Variation 27.3988 |
Secondary
Part 1B: Cmax and Ctau of Feladilimab
Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method.
Time frame: Pre-dose; end of infusion (EOI); 0.5, 1, 2, 4, 6, 8, 24, 48-72, 96-120 hours post-EOI; week 1; week 2; Pre-dose and 0.5 hours post-EOI in week 3; week 4; week 5; Pre-dose and 0.5 hours post-EOI in week 6, 9, 12 15; Pre-dose in week 21, 33 and 45
Population: Pharmacokinetic Population. Only those participants with data available at specified categories have been analyzed
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Cmax and Ctau of Feladilimab | NSCLC, Ctau, Cycle 1 | 1.4713 ug/mL | Geometric Coefficient of Variation 39.3325 |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Cmax and Ctau of Feladilimab | MELANOMA, Ctau, Cycle 1 | 1.2025 ug/mL | Geometric Coefficient of Variation 33.0632 |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Cmax and Ctau of Feladilimab | JAPAN PK/PD, Cmax, Cycle 1 | 5.8973 ug/mL | Geometric Coefficient of Variation 10.9555 |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Cmax and Ctau of Feladilimab | MELANOMA, Ctau, Cycle 6 | 2.6320 ug/mL | Geometric Coefficient of Variation 46.3462 |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Cmax and Ctau of Feladilimab | BLADDER/UROTHELIAL, Cmax, Cycle 1 | 3.2855 ug/mL | Geometric Coefficient of Variation 98.7868 |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Cmax and Ctau of Feladilimab | MSI-H/DMMR, Cmax, Cycle 1 | 5.4181 ug/mL | Geometric Coefficient of Variation 38.5999 |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Cmax and Ctau of Feladilimab | JAPAN PK/PD, Ctau, Cycle 1 | 1.2533 ug/mL | Geometric Coefficient of Variation 9.3514 |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Cmax and Ctau of Feladilimab | MSI-H/DMMR, Ctau, Cycle 1 | 0.9976 ug/mL | Geometric Coefficient of Variation 41.4153 |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Cmax and Ctau of Feladilimab | NSCLC, Ctau, Cycle 6 | 4.2630 ug/mL | — |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Cmax and Ctau of Feladilimab | MSI-H/DMMR, Ctau, Cycle 6 | 2.5409 ug/mL | Geometric Coefficient of Variation 61.5161 |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Cmax and Ctau of Feladilimab | BLADDER/UROTHELIAL, Ctau, Cycle 1 | 0.5029 ug/mL | Geometric Coefficient of Variation 151.5778 |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Cmax and Ctau of Feladilimab | NSCLC, Cmax, Cycle 1 | 8.4009 ug/mL | Geometric Coefficient of Variation 38.8531 |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Cmax and Ctau of Feladilimab | MELANOMA, Cmax, Cycle 1 | 6.2711 ug/mL | Geometric Coefficient of Variation 24.529 |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Cmax and Ctau of Feladilimab | MSI-H/DMMR, Cmax, Cycle 1 | 25.6766 ug/mL | Geometric Coefficient of Variation 27.3384 |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Cmax and Ctau of Feladilimab | MSI-H/DMMR, Ctau, Cycle 1 | 5.1437 ug/mL | Geometric Coefficient of Variation 46.0134 |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Cmax and Ctau of Feladilimab | MSI-H/DMMR, Ctau, Cycle 6 | 9.7769 ug/mL | Geometric Coefficient of Variation 143.2225 |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Cmax and Ctau of Feladilimab | NSCLC, Cmax, Cycle 1 | 24.2697 ug/mL | Geometric Coefficient of Variation 29.1958 |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Cmax and Ctau of Feladilimab | VIRAL-POSITIVE, Ctau, Cycle 6 | 11.0416 ug/mL | Geometric Coefficient of Variation 36.7974 |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Cmax and Ctau of Feladilimab | BLADDER/UROTHELIAL, Cmax, Cycle 1 | 25.8491 ug/mL | Geometric Coefficient of Variation 15.5203 |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Cmax and Ctau of Feladilimab | BLADDER/UROTHELIAL, Ctau, Cycle 1 | 5.3950 ug/mL | Geometric Coefficient of Variation 39.3125 |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Cmax and Ctau of Feladilimab | BLADDER/UROTHELIAL, Ctau, Cycle 6 | 13.6665 ug/mL | Geometric Coefficient of Variation 21.8363 |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Cmax and Ctau of Feladilimab | CERVICAL, Cmax, Cycle 1 | 27.2607 ug/mL | Geometric Coefficient of Variation 28.7319 |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Cmax and Ctau of Feladilimab | CERVICAL, Ctau, Cycle 1 | 3.8347 ug/mL | Geometric Coefficient of Variation 51.9848 |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Cmax and Ctau of Feladilimab | CERVICAL, Ctau, Cycle 6 | 12.7002 ug/mL | Geometric Coefficient of Variation 14.071 |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Cmax and Ctau of Feladilimab | JAPAN PK/PD, Cmax, Cycle 1 | 22.4768 ug/mL | Geometric Coefficient of Variation 11.3862 |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Cmax and Ctau of Feladilimab | JAPAN PK/PD, Ctau, Cycle 1 | 5.1381 ug/mL | Geometric Coefficient of Variation 12.9597 |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Cmax and Ctau of Feladilimab | JAPAN PK/PD, Ctau, Cycle 6 | 10.9800 ug/mL | — |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Cmax and Ctau of Feladilimab | MELANOMA, Cmax, Cycle 1 | 23.9959 ug/mL | Geometric Coefficient of Variation 23.9522 |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Cmax and Ctau of Feladilimab | MELANOMA, Ctau, Cycle 1 | 4.3924 ug/mL | Geometric Coefficient of Variation 55.2035 |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Cmax and Ctau of Feladilimab | MELANOMA, Ctau, Cycle 6 | 11.2405 ug/mL | Geometric Coefficient of Variation 32.8873 |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Cmax and Ctau of Feladilimab | NSCLC, Ctau, Cycle 6 | 8.6574 ug/mL | Geometric Coefficient of Variation 62.7001 |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Cmax and Ctau of Feladilimab | VIRAL-POSITIVE, Cmax, Cycle 1 | 24.2995 ug/mL | Geometric Coefficient of Variation 25.3201 |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Cmax and Ctau of Feladilimab | VIRAL-POSITIVE, Ctau, Cycle 1 | 5.0751 ug/mL | Geometric Coefficient of Variation 45.1953 |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Cmax and Ctau of Feladilimab | NSCLC, Ctau, Cycle 1 | 5.4292 ug/mL | Geometric Coefficient of Variation 55.3073 |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Cmax and Ctau of Feladilimab | BIOMARKER, Ctau, Cycle 6 | 2.0597 ug/mL | Geometric Coefficient of Variation 61.8911 |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Cmax and Ctau of Feladilimab | BIOMARKER, Cmax, Cycle 1 | 6.9732 ug/mL | Geometric Coefficient of Variation 25.8747 |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Cmax and Ctau of Feladilimab | BIOMARKER, Ctau, Cycle 1 | 1.1411 ug/mL | Geometric Coefficient of Variation 45.6223 |
Secondary
Part 1B: Disease Control Rate (DCR)
DCR was defined as percentage of participants with best overall response of irCR or irPR at any time + irSD meeting the minimum time criteria from the start of treatment until irPD or death due to any cause or the start of new anticancer therapy/crossover. irCR is defined as disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \<10 mm. irPR defined as at least 30% decrease in the sum of diameters of target lesions, taking as a reference, the baseline sum of the diameters. irSD defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease. IrPD defined as the date of radiological disease progression based on imaging data per irRECIST. A one-week visit window was considered in the duration of irSD, i.e. a minimum of 8 weeks (irSD\>=9 weeks) and 17 weeks (irSD\>=18 weeks) were considered.
Time frame: Up to approximately 367 weeks
Population: All Treated population
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Disease Control Rate (DCR) | >=9 Weeks | 38 Percentage of Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Disease Control Rate (DCR) | >=18 Weeks | 23 Percentage of Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Disease Control Rate (DCR) | >=9 Weeks | 39 Percentage of Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Disease Control Rate (DCR) | >=18 Weeks | 23 Percentage of Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Disease Control Rate (DCR) | >=9 Weeks | 39 Percentage of Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Disease Control Rate (DCR) | >=18 Weeks | 19 Percentage of Participants |
Secondary
Part 1B: Duration of Response (DOR)
DOR was defined as the interval of time in months from the date of the first documented evidence of a response (confirmed CR or PR) to the date of first documented evidence of disease progression according to radiological response from investigator assessment per RECIST v1.1, or date of last adequate assessment of response or the date of death due to any cause (whichever occurs earlier). CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 mm. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters. Disease progression is defined as the date of radiological disease progression based on imaging data per RECIST v1.1.
Time frame: Up to approximately 367 weeks
Population: All Treated Population with a confirmed CR or PR.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Duration of Response (DOR) | 7.3 Months |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Duration of Response (DOR) | 11.8 Months |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Duration of Response (DOR) | 7.2 Months |
Secondary
Part 1B: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that, at any dose results in death, Is life-threatening, Requires inpatient hospitalization or prolongation of existing hospitalization, Results in persistent disability/incapacity or Is a congenital anomaly/birth defect, Other situations which involve medical or scientific judgment or is associated with liver injury and impaired liver function. SAEs are subset of AEs. A summary of number of participants with any AEs and SAEs is presented. AEs were coded using the MedDRA dictionary.
Time frame: Up to approximately 367 weeks
Population: All Treated population
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any AEs | 34 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any SAEs | 9 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any AEs | 111 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any SAEs | 44 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any AEs | 55 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any SAEs | 19 Participants |
Secondary
Part 1B: Number of Participants With Dose Modifications of Feladilimab
Number of participants with dose modifications (including dose delays, dose escalation and infusion interruptions) were reported for Feladilimab.
Time frame: Up to approximately 367 weeks
Population: All treated population
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Dose Modifications of Feladilimab | Infusion interruptions | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Dose Modifications of Feladilimab | Dose delays | 4 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Dose Modifications of Feladilimab | Dose escalations | 4 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Dose Modifications of Feladilimab | Dose escalations | 3 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Dose Modifications of Feladilimab | Infusion interruptions | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Dose Modifications of Feladilimab | Dose delays | 17 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Dose Modifications of Feladilimab | Dose delays | 5 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Dose Modifications of Feladilimab | Infusion interruptions | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Dose Modifications of Feladilimab | Dose escalations | 0 Participants |
Secondary
Part 1B: Number of Participants With Positive Results in ADA Test by Feladilimab Dose Level
Serum samples collected and tested for the presence of ADA with a screening assay.
Time frame: Up to approximately 367 weeks
Population: All Treated population
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Positive Results in ADA Test by Feladilimab Dose Level | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Positive Results in ADA Test by Feladilimab Dose Level | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Positive Results in ADA Test by Feladilimab Dose Level | 1 Participants |
Secondary
Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline
Normal ranges were 6 to 8.3 grams/L (protein); 100 to 250 international units (IU)/L (Lactate Dehydrogenase(LDH)); 2.3 - 4.1 picomoles/L (Free Triiodothyronine(T3)); 4.6 to 11.2 picomoles/L (Free Thyroxine(T4)); 0 and 0.04 microgram (ug)/L (Troponin I); 0 - 0.01 ug/L (Troponin T); 0.45 to 4.5 milliunits (Mu)/L (Thyrotropin(TSH)); and 6 to 24 millimoles/L (Urea). Participants were counted in worst case category that their value changes to low, normal or no change \[NC\] or high), unless there is NC in their category. Participants whose laboratory value category was unchanged (e.g. High to High) or whose value became normal, were recorded in To Normal or No Change category. Participants were counted twice if participant had values that changed To Low and To High, so percentages may not add to 100%
Time frame: Up to approximately 367 weeks
Population: All Treated Population. Only those participants with data available at specified categories have been analyzed.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Low | 2 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To High | 6 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To Low | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Normal or No Change | 27 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To High | 5 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To High | 2 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To High | 2 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Normal or No Change | 34 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To Normal or No Change | 12 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To Low | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Lactate Dehydrogenase (IU/L), To Normal or No Change | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Normal or No Change | 23 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To High | 2 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Normal or No Change | 26 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Lactate Dehydrogenase (IU/L), To Low | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Low | 5 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Lactate Dehydrogenase (IU/L), To High | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Low | 3 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Normal or No Change | 23 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Low | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To High | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To High | 2 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Low | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To Normal or No Change | 18 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Low | 4 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Low | 22 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Normal or No Change | 80 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To High | 11 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Low | 15 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Normal or No Change | 74 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To High | 16 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Low | 14 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Normal or No Change | 78 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To High | 12 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To Low | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To Normal or No Change | 27 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To High | 6 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To Low | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To Normal or No Change | 35 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To High | 8 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Normal or No Change | 82 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To High | 19 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Low | 10 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Normal or No Change | 53 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To High | 30 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To High | 4 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Low | 2 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To Normal or No Change | 30 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Normal or No Change | 37 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Lactate Dehydrogenase (IU/L), To Normal or No Change | 3 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To High | 2 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Low | 10 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To High | 4 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Low | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Normal or No Change | 45 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To High | 9 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Normal or No Change | 41 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Low | 9 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Normal or No Change | 28 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To Low | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To High | 2 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To High | 9 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To Normal or No Change | 15 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Normal or No Change | 44 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Lactate Dehydrogenase (IU/L), To High | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To High | 4 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Low | 5 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Lactate Dehydrogenase (IU/L), To Low | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To Low | 0 Participants |
Secondary
Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters
Blood samples were collected for analysis of clinical chemistry parameters. Laboratory parameters were graded according to CTCAE v4.03. Grade (G) 0: None; G1: mild; G2: moderate; G3: severe or medically significant; G4: life-threatening consequences. Higher grade indicates greater severity and increase in grade was defined relative to Baseline grade. Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Only grade change data is presented for Baseline (B) and Worst-Case Post-Baseline (WCPB) as G0, G1, G2, G3, G4, and missing (M) here as Parameter name, B GX, WCPB GX where X=grade digit.
Time frame: Baseline (Day 1) and up to approximately 367 weeks
Population: All Treated Population. Only those participants with data available at specified categories have been analyzed.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 1 | 4 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 2 | 2 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 2 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 2 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 0 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 2 | 2 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 1 | 2 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 2 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Missing, Grade 0 | 3 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Missing, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Missing, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Missing, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Missing, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 1 | 2 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 3 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 0 | 2 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 2 | 2 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 2 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 1 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 0 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 1 | 11 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 1 | 5 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 1 | 4 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 1 | 7 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 1 | 9 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 2 | 2 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 1 | 3 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 2 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 2 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 0 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 4 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 3 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 1 | 7 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 4 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 4 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 3 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 4 | 2 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 2 | 3 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Missing, Grade 0 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Missing, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 1 | 2 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Missing, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Missing, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 2 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 3 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Missing, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 1 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 1 | 4 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 1 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 0 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 0 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 2 | 9 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 3 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 1 | 18 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 1 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Missing, Grade 0 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Missing, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Missing, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Missing, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Missing, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 1 | 2 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 3 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 4 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 0 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 4 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 0 | 2 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 2 | 4 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 1 | 24 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 3 | 4 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 4 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 0 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 3 | 2 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 1 | 5 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 1 | 9 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 3 | 2 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 4 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Missing, Grade 0 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Missing, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Missing, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Missing, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Missing, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 0 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 2 | 2 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 1 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 2 | 7 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 3 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 0 | 2 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 1 | 4 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 2 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 4 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Missing, Grade 0 | 2 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Missing, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Missing, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Missing, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 1 | 5 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 2 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 3 | 2 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 3 | 3 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 4 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 1 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Missing, Grade 0 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Missing, Grade 1 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Missing, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Missing, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Missing, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 1 | 12 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 2 | 12 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 0 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 2 | 5 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 3 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 0 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 2 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 3 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 3 | 2 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Missing, Grade 0 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Missing, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Missing, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Missing, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Missing, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 1 | 20 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 2 | 3 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 2 | 2 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 3 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 0 | 2 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 3 | 2 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Missing, Grade 0 | 2 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Missing, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Missing, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Missing, Grade 3 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Missing, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 1 | 11 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 3 | 2 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 1 | 7 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 4 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 1 | 19 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 2 | 5 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 3 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 0 | 2 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 0 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 1 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 3 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 4 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 2 | 2 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 3 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Missing, Grade 0 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Missing, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Missing, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Missing, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Missing, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 2 | 4 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 4 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 1 | 25 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 1 | 7 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 2 | 2 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 0 | 2 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Missing, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 1 | 38 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 2 | 8 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 3 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Missing, Grade 0 | 3 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 0 | 2 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Missing, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 2 | 4 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 1 | 15 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 1 | 8 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 1 | 6 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 1 | 6 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 0 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 3 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Missing, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 3 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 1 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 3 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 2 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 0 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 1 | 19 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 3 | 2 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 2 | 2 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 1 | 6 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 2 | 2 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 3 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 0 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 1 | 4 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 4 | 3 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Missing, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Missing, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Missing, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 3 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Missing, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Missing, Grade 0 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 2 | 2 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 1 | 10 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 1 | 9 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 2 | 3 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Missing, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 0 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Missing, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Missing, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 2 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Missing, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 2 | 2 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 0 | 2 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 4 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Missing, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 3 | 3 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 1 | 3 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 3 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 1 | 8 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 1 | 3 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Missing, Grade 0 | 2 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 2 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 0 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Missing, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Missing, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 3 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Missing, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Missing, Grade 0 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 3 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 4 | 2 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 0 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Missing, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Missing, Grade 1 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 1 | 12 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 3 | 3 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 3 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 4 | 2 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 0 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 4 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 2 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 4 | 0 Participants |
Secondary
Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters
Blood samples were collected for analysis of hematology parameters. Laboratory parameters were graded according to CTCAE v4.03. Grade (G) 0: None; G1: mild; G2: moderate; G3: severe or medically significant; G4: life-threatening consequences. Higher grade indicates greater severity and increase in grade was defined relative to Baseline grade. Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Only grade change data is presented for Baseline (B) and Worst-Case Post-Baseline (WCPB) as G0, G1, G2, G3, G4, and missing (M) here as Parameter name, B GX, WCPB GX where X=grade digit.
Time frame: Baseline (Day 1) and up to approximately 367 weeks
Population: All Treated Population. Only those participants with data available at specified categories have been analyzed.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 3 | 3 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 2 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 0 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 2 | 5 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 3 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 0 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 1 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 1 | 2 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 2 | 6 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 1 | 4 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 1 | 4 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 2 | 2 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 2 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 3 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 1 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Missing, Grade 0 | 6 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Missing, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Missing, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Missing, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Missing, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 1 | 6 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 3 | 2 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 3 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 0 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Missing, Grade 0 | 2 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Missing, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Missing, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Missing, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Missing, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 1 | 9 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 4 | 2 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 0 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 2 | 2 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 1 | 22 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 2 | 10 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 3 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 3 | 8 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 4 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 1 | 22 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 0 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 2 | 15 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 3 | 4 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 3 | 2 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 2 | 7 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 3 | 4 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Missing, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Missing, Grade 1 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Missing, Grade 2 | 3 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Missing, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Missing, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 2 | 4 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 3 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 2 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 0 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Missing, Grade 0 | 3 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Missing, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Missing, Grade 2 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Missing, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Missing, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 1 | 4 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 3 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 4 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 2 | 20 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 3 | 3 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 1 | 7 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 2 | 5 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 3 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 0 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 2 | 8 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 3 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 3 | 4 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 3 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 1 | 8 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 2 | 6 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 2 | 7 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 3 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 3 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 1 | 2 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 2 | 3 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 1 | 2 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 4 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 1 | 3 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 2 | 2 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 2 | 2 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 2 | 0 Participants |
Secondary
Part 1B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline
Normal ranges were 0.01 to 0.3\*10\^9 cells/L (basophils), 0 to 500 cells /L (eosinophils), 41 to 50 percentage of RBC in blood (hematocrit), 2 to 8 percentage of WBC (monocytes), and Women: 4.2 to 5.4 million RBC/ mcL of blood and Men: 4.7 to 6.1 million RBC/ mcL (erythrocyte count). Participants were counted in worst case category that their value changes to low, normal or no change \[NC\] or high), unless there is NC in their category. Participants whose laboratory value category was unchanged (e.g. High to High) or whose value became normal, were recorded in To Normal or No Change category. Participants were counted twice if participant had values that changed To Low and To High, so percentages may not add to 100%.
Time frame: Up to approximately 367 weeks
Population: All Treated Population. Only those participants with data available at specified categories have been analyzed.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To High | 7 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To High | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Normal or No Change | 29 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Low | 8 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Normal or No Change | 35 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Low | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Normal or No Change | 28 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Low | 8 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To High | 2 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Low | 5 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To High | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Low | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Normal or No Change | 27 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Normal or No Change | 29 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To High | 8 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To High | 20 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Low | 3 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Normal or No Change | 101 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To High | 3 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Low | 11 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Normal or No Change | 85 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To High | 18 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Low | 33 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Normal or No Change | 74 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To High | 7 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Low | 3 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Normal or No Change | 92 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Low | 25 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Normal or No Change | 85 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To High | 4 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To High | 6 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Normal or No Change | 45 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Normal or No Change | 43 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Normal or No Change | 46 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Low | 7 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To High | 15 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To High | 2 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Low | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Low | 12 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Normal or No Change | 38 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Normal or No Change | 55 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To High | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Low | 20 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To High | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Low | 0 Participants |
Secondary
Part 1B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline
Urine samples were collected to assess urine glucose, ketones and occult blood using dipstick method. The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as negative, trace, 1+, 2+, 3+ indicating proportional concentrations in the urine sample. Baseline (Day 1) was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Result for urinalysis parameters were recorded as no change/decreased and any increase.
Time frame: Up to approximately 367 weeks
Population: All treated population. Only those participants with data available at specified categories have been analyzed
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, No Change/Decreased | 36 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, Any Increase | 2 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, No Change/Decreased | 29 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, Any Increase | 9 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, No Change/Decreased | 24 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, Any Increase | 12 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, Any Increase | 40 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, No Change/Decreased | 104 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, Any Increase | 37 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, No Change/Decreased | 70 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, Any Increase | 9 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, No Change/Decreased | 76 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, Any Increase | 2 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, No Change/Decreased | 46 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, Any Increase | 19 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, Any Increase | 12 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, No Change/Decreased | 56 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, No Change/Decreased | 39 Participants |
Secondary
Part 1B: Overall Response Rate (ORR)
ORR was defined as the percentage of participants with a confirmed irCR or confirmed irPR per irRECIST. irCR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. irPR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.
Time frame: Up to approximately 367 weeks
Population: All Treated population
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Overall Response Rate (ORR) | 5 Percentage of Participants |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Overall Response Rate (ORR) | 4 Percentage of Participants |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Overall Response Rate (ORR) | 8 Percentage of Participants |
Secondary
Part 1B: Overall Survival (OS)
OS was defined as the interval between the date of first assigned study therapy/randomization and date of death due to any cause.
Time frame: Up to approximately 367 weeks
Population: All Treated
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Overall Survival (OS) | 10.5 Months |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Overall Survival (OS) | 9.4 Months |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Overall Survival (OS) | 7.8 Months |
Secondary
Part 1B: Progression-free Survival (PFS)
PFS was defined as the interval between the date of first dose of study treatment (or date of randomization for randomized cohorts) and the date of disease progression according to radiological response from investigator assessment, or death due to any cause, whichever occurs earlier. Disease progression was defined as the date of radiological disease progression based on imaging data per RECIST v1.1.
Time frame: Up to approximately 367 weeks
Population: All Treated
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Progression-free Survival (PFS) | 2.1 Months |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Progression-free Survival (PFS) | 2.1 Months |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Progression-free Survival (PFS) | 2.1 Months |
Secondary
Part 1B: Receptor Occupancy of Feladilimab
Blood samples were collected to assess the cluster of differentiation 4 (CD4+) and cluster of differentiation 8 (CD8+) receptor occupancy by Feladilimab as a pharmacodynamic analysis. It was assessed using validated flow cytometry assay.
Time frame: Up to approximately 367 weeks
Population: All treated population.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Receptor Occupancy of Feladilimab | %CD4+ | 96.520 percent receptor occupancy | Geometric Coefficient of Variation 4.258 |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Receptor Occupancy of Feladilimab | %CD8+ | 90.111 percent receptor occupancy | Geometric Coefficient of Variation 11.7 |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Receptor Occupancy of Feladilimab | %CD4+ | 99.179 percent receptor occupancy | Geometric Coefficient of Variation 3.926 |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Receptor Occupancy of Feladilimab | %CD8+ | 96.160 percent receptor occupancy | Geometric Coefficient of Variation 9.429 |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Receptor Occupancy of Feladilimab | %CD4+ | 98.128 percent receptor occupancy | Geometric Coefficient of Variation 2.192 |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Receptor Occupancy of Feladilimab | %CD8+ | 81.219 percent receptor occupancy | Geometric Coefficient of Variation 21.037 |
Secondary
Part 1B: Time to Overall Response (TTR)
TTR was defined as the time from date of first dose of study treatment/randomization to the date of first documented confirmed (=4 weeks) CR or PR. CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 mm. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.
Time frame: Up to approximately 367 weeks
Population: All Treated Population with a confirmed CR or PR. Only responders are included in the analysis
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 1B: Time to Overall Response (TTR) | 3.0 Months |
| Part 1A: Fela 0.003 mg/kg | Part 1B: Time to Overall Response (TTR) | 3.0 Months |
| Part 1A: Fela 0.010 mg/kg | Part 1B: Time to Overall Response (TTR) | 3.8 Months |
Secondary
Part 2A: AUC (0-504 h) of GSK3174998
Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method.
Time frame: Pre-dose and 24 hours post-EOI on day 1; week 1; week 2; Pre-dose in week 3; week 4; week 5; Pre-dose in week 9, 15, 18, 21, 33, 45, 57, 69, 81 and 93
Population: Pharmacokinetic Population. Data is presented for participants who received feladilimab in combination with GSK3174998. As pre-specified in the protocol, only specified treatment arms were planned and hence there are 0 participants analyzed for rest of the arms.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Part 1A: Fela 0.003 mg/kg | Part 2A: AUC (0-504 h) of GSK3174998 | 1038.4544 h*ug/mL | — |
| Part 1A: Fela 0.010 mg/kg | Part 2A: AUC (0-504 h) of GSK3174998 | 953.0313 h*ug/mL | Geometric Coefficient of Variation 9.2381 |
| Part 1A: Fela 0.030 mg/kg | Part 2A: AUC (0-504 h) of GSK3174998 | 703.8874 h*ug/mL | Geometric Coefficient of Variation 2.7723 |
| Part 1A: Fela 0.100 mg/kg | Part 2A: AUC (0-504 h) of GSK3174998 | 4606.4365 h*ug/mL | Geometric Coefficient of Variation 21.6164 |
Secondary
Part 2A: AUC (0-504h) of Pembrolizumab
Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method.
Time frame: Pre-dose and 24 hours post-EOI on day 1; week 1; week 2; Pre-dose in week 3; week 4; week 5; Pre-dose in week 9, 15, 18, 21, 33, 45, 57, 69, 81 and 93
Population: Pharmacokinetic Population. Data is presented for participants who received feladilimab in combination with Pembrolizumab. As pre-specified in the protocol, only specified treatment arms were planned and hence there are 0 participants analyzed for rest of the arms.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: AUC (0-504h) of Pembrolizumab | 11363.9193 h*ug/mL | — |
| Part 1A: Fela 0.030 mg/kg | Part 2A: AUC (0-504h) of Pembrolizumab | 11556.7001 h*ug/mL | — |
| Part 1A: Fela 0.100 mg/kg | Part 2A: AUC (0-504h) of Pembrolizumab | 19158.7768 h*ug/mL | — |
| Part 1A: Fela 0.300 mg/kg | Part 2A: AUC (0-504h) of Pembrolizumab | 17928.7606 h*ug/mL | Geometric Coefficient of Variation 32.2374 |
Secondary
Part 2A: Cmax and Ctau of GSK3174998
Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method.
Time frame: Pre-dose and 24 hours post-EOI on day 1; week 1; week 2; Pre-dose in week 3; week 4; week 5; Pre-dose in week 9, 15, 18, 21, 33, 45, 57, 69, 81 and 93
Population: Pharmacokinetic Population. Data is presented for participants who received feladilimab in combination with GSK3174998. As pre-specified in the protocol, only specified treatment arms were planned and hence there are 0 participants analyzed for rest of the arms. Only those participants with data available at specified categories have been analyzed.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Part 1A: Fela 0.003 mg/kg | Part 2A: Cmax and Ctau of GSK3174998 | Cmax, Cycle 1 | 5.1078 ug/mL | Geometric Coefficient of Variation 27.704 |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Cmax and Ctau of GSK3174998 | Ctau, Cycle 1 | 0.6700 ug/mL | — |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Cmax and Ctau of GSK3174998 | Ctau, Cycle 1 | 0.6484 ug/mL | Geometric Coefficient of Variation 52.4342 |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Cmax and Ctau of GSK3174998 | Ctau, Cycle 6 | 0.5663 ug/mL | Geometric Coefficient of Variation 94.4364 |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Cmax and Ctau of GSK3174998 | Cmax, Cycle 1 | 6.6367 ug/mL | Geometric Coefficient of Variation 47.593 |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Cmax and Ctau of GSK3174998 | Cmax, Cycle 1 | 5.5967 ug/mL | Geometric Coefficient of Variation 10.5455 |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Cmax and Ctau of GSK3174998 | Ctau, Cycle 1 | 0.5893 ug/mL | Geometric Coefficient of Variation 72.0699 |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Cmax and Ctau of GSK3174998 | Cmax, Cycle 1 | 22.7767 ug/mL | Geometric Coefficient of Variation 13.7397 |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Cmax and Ctau of GSK3174998 | Ctau, Cycle 1 | 4.5862 ug/mL | Geometric Coefficient of Variation 50.0449 |
Secondary
Part 2A: Ctau of Pembrolizumab
Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method.
Time frame: Pre-dose and 24 hours post-EOI on day 1; week 1; week 2; Pre-dose in week 3; week 4; week 5; Pre-dose in week 9, 15, 18, 21, 33, 45, 57, 69, 81 and 93
Population: Pharmacokinetic Population. Data is presented for participants who received feladilimab in combination with Pembrolizumab. Only those participants with data available at specified categories have been analyzed
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Ctau of Pembrolizumab | Cycle 6 | 35.1000 ug/mL | — |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Ctau of Pembrolizumab | Cycle 1 | 10.8032 ug/mL | Geometric Coefficient of Variation 55.7461 |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Ctau of Pembrolizumab | Cycle 1 | 19.2951 ug/mL | Geometric Coefficient of Variation 41.016 |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Ctau of Pembrolizumab | Cycle 6 | 62.3000 ug/mL | — |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Ctau of Pembrolizumab | Cycle 1 | 16.7039 ug/mL | Geometric Coefficient of Variation 47.934 |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Ctau of Pembrolizumab | Cycle 1 | 13.9035 ug/mL | Geometric Coefficient of Variation 31.906 |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Ctau of Pembrolizumab | Cycle 6 | 35.3321 ug/mL | Geometric Coefficient of Variation 21.9877 |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Ctau of Pembrolizumab | Cycle 1 | 12.9277 ug/mL | Geometric Coefficient of Variation 42.3634 |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Ctau of Pembrolizumab | Cycle 6 | 35.6000 ug/mL | — |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Ctau of Pembrolizumab | Cycle 6 | 35.6444 ug/mL | Geometric Coefficient of Variation 63.8554 |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Ctau of Pembrolizumab | Cycle 1 | 15.1724 ug/mL | Geometric Coefficient of Variation 40.5 |
Secondary
Part 2A: Disease Control Rate (DCR)
DCR was defined as percentage of participants with best overall response of irCR or irPR at any time + irSD meeting the minimum time criteria from the start of treatment until irPD or death due to any cause or the start of new anticancer therapy/crossover. irCR defined as disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \<10 mm. irPR defined as at least 30% decrease in the sum of diameters of target lesions, taking as a reference, the baseline sum of the diameters. irSD defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease. IrPD defined as the date of radiological disease progression based on imaging data per irRECIST. A one-week visit window was considered in the duration of irSD, i.e. a minimum of 8 weeks (irSD\>=9 weeks) and 17 weeks (irSD\>=18 weeks) were considered.
Time frame: Up to approximately 367 weeks
Population: All Treated population
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Disease Control Rate (DCR) | >=18 Weeks | 20 Percentage of Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Disease Control Rate (DCR) | >=9 Weeks | 20 Percentage of Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Disease Control Rate (DCR) | >=9 Weeks | 40 Percentage of Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Disease Control Rate (DCR) | >=18 Weeks | 0 Percentage of Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Disease Control Rate (DCR) | >=18 Weeks | 20 Percentage of Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Disease Control Rate (DCR) | >=9 Weeks | 40 Percentage of Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Disease Control Rate (DCR) | >=9 Weeks | 38 Percentage of Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Disease Control Rate (DCR) | >=18 Weeks | 25 Percentage of Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Disease Control Rate (DCR) | >=18 Weeks | 27 Percentage of Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Disease Control Rate (DCR) | >=9 Weeks | 27 Percentage of Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Disease Control Rate (DCR) | >=9 Weeks | 55 Percentage of Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Disease Control Rate (DCR) | >=18 Weeks | 36 Percentage of Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Disease Control Rate (DCR) | >=18 Weeks | 0 Percentage of Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Disease Control Rate (DCR) | >=9 Weeks | 0 Percentage of Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Disease Control Rate (DCR) | >=18 Weeks | 0 Percentage of Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Disease Control Rate (DCR) | >=9 Weeks | 0 Percentage of Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Disease Control Rate (DCR) | >=9 Weeks | 19 Percentage of Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Disease Control Rate (DCR) | >=18 Weeks | 13 Percentage of Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Disease Control Rate (DCR) | >=18 Weeks | 0 Percentage of Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Disease Control Rate (DCR) | >=9 Weeks | 25 Percentage of Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Disease Control Rate (DCR) | >=18 Weeks | 33 Percentage of Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Disease Control Rate (DCR) | >=9 Weeks | 33 Percentage of Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Disease Control Rate (DCR) | >=9 Weeks | 67 Percentage of Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Disease Control Rate (DCR) | >=18 Weeks | 67 Percentage of Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Disease Control Rate (DCR) | >=18 Weeks | 44 Percentage of Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Disease Control Rate (DCR) | >=9 Weeks | 58 Percentage of Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Disease Control Rate (DCR) | >=18 Weeks | 62 Percentage of Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Disease Control Rate (DCR) | >=9 Weeks | 77 Percentage of Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Disease Control Rate (DCR) | >=9 Weeks | 86 Percentage of Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Disease Control Rate (DCR) | >=18 Weeks | 73 Percentage of Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Disease Control Rate (DCR) | >=9 Weeks | 0 Percentage of Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Disease Control Rate (DCR) | >=18 Weeks | 0 Percentage of Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Disease Control Rate (DCR) | >=18 Weeks | 50 Percentage of Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Disease Control Rate (DCR) | >=9 Weeks | 50 Percentage of Participants |
Secondary
Part 2A: Duration of Response (DOR)
DOR was defined as the interval of time in months from the date of the first documented evidence of a response (confirmed CR or PR) to the date of first documented evidence of disease progression according to radiological response from investigator assessment per RECIST v1.1, or date of last adequate assessment of response or the date of death due to any cause (whichever occurs earlier). CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 mm. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters. Disease progression is defined as the date of radiological disease progression based on imaging data per RECIST v1.1.
Time frame: Up to approximately 367 weeks
Population: All Treated Population with a confirmed CR or PR. Only responders are included in the analysis.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Duration of Response (DOR) | NA Months |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Duration of Response (DOR) | 4.1 Months |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Duration of Response (DOR) | 14.3 Months |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Duration of Response (DOR) | NA Months |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Duration of Response (DOR) | 13.8 Months |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Duration of Response (DOR) | NA Months |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Duration of Response (DOR) | 4.5 Months |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Duration of Response (DOR) | 22.5 Months |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Duration of Response (DOR) | NA Months |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Duration of Response (DOR) | 6.0 Months |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Duration of Response (DOR) | NA Months |
Secondary
Part 2A: Number of Participants With Positive Results in ADA in GSK3174998
Serum samples collected and tested for the presence of ADA with a screening assay.
Time frame: Up to approximately 367 weeks
Population: All Treated population. Only participants who received GSK3174998 with Feladilimab were included in this analysis.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Positive Results in ADA in GSK3174998 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Positive Results in ADA in GSK3174998 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Positive Results in ADA in GSK3174998 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Positive Results in ADA in GSK3174998 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Positive Results in ADA in GSK3174998 | 0 Participants |
Secondary
Part 2A: Number of Participants With Positive Results in ADA in Pembrolizumab
Serum samples collected and tested for the presence of ADA with a screening assay.
Time frame: Up to approximately 367 weeks
Population: All Treated population. Only participants who received 200 mg Pembrolizumab with Feladilimab were included in this analysis.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Positive Results in ADA in Pembrolizumab | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Positive Results in ADA in Pembrolizumab | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Positive Results in ADA in Pembrolizumab | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Positive Results in ADA in Pembrolizumab | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Positive Results in ADA in Pembrolizumab | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Positive Results in ADA in Pembrolizumab | 0 Participants |
Secondary
Part 2A: Number of Participants With Positive Results in ADA Test by Feladilimab Combination With Chemotherapies Dose Level
Serum samples collected and tested for the presence of ADA with a screening assay.
Time frame: Up to approximately 367 weeks
Population: All Treated population. Only participants who received Chemotherapy with Feladilimab were included in this analysis.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Positive Results in ADA Test by Feladilimab Combination With Chemotherapies Dose Level | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Positive Results in ADA Test by Feladilimab Combination With Chemotherapies Dose Level | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Positive Results in ADA Test by Feladilimab Combination With Chemotherapies Dose Level | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Positive Results in ADA Test by Feladilimab Combination With Chemotherapies Dose Level | 0 Participants |
Secondary
Part 2A: Number of Participants With Positive Results in ADA Test by Feladilimab Dose Level in Combination With Pembrolizumab
Serum samples collected and tested for the presence of ADA with a screening assay.
Time frame: Up to approximately 367 weeks
Population: All Treated population. Only participants who received 200 mg pembrolizumab with Feladilimab were included in this analysis.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Positive Results in ADA Test by Feladilimab Dose Level in Combination With Pembrolizumab | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Positive Results in ADA Test by Feladilimab Dose Level in Combination With Pembrolizumab | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Positive Results in ADA Test by Feladilimab Dose Level in Combination With Pembrolizumab | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Positive Results in ADA Test by Feladilimab Dose Level in Combination With Pembrolizumab | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Positive Results in ADA Test by Feladilimab Dose Level in Combination With Pembrolizumab | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Number of Participants With Positive Results in ADA Test by Feladilimab Dose Level in Combination With Pembrolizumab | 0 Participants |
Secondary
Part 2A: Number of Participants With Positive Results in ADA Test by Feladilimab in Combination With GSK3174998 Dose Level
Serum samples collected and tested for the presence of ADA with a screening assay.
Time frame: Up to approximately 367 weeks
Population: All Treated population. Only participants who received GSK317499 with Feladilimab were included in this analysis.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Number of Participants With Positive Results in ADA Test by Feladilimab in Combination With GSK3174998 Dose Level | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Number of Participants With Positive Results in ADA Test by Feladilimab in Combination With GSK3174998 Dose Level | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Number of Participants With Positive Results in ADA Test by Feladilimab in Combination With GSK3174998 Dose Level | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Number of Participants With Positive Results in ADA Test by Feladilimab in Combination With GSK3174998 Dose Level | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Number of Participants With Positive Results in ADA Test by Feladilimab in Combination With GSK3174998 Dose Level | 0 Participants |
Secondary
Part 2A: Overall Response Rate (ORR)
ORR was defined as the percentage of participants with irCR or irPR per irRECIST. irCR is defined as disappearance of all target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimeters (mm). irPR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.
Time frame: Up to approximately 367 weeks
Population: All Treated population
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Overall Response Rate (ORR) | 20 Percentage of Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Overall Response Rate (ORR) | 0 Percentage of Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Overall Response Rate (ORR) | 20 Percentage of Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Overall Response Rate (ORR) | 25 Percentage of Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Overall Response Rate (ORR) | 27 Percentage of Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Overall Response Rate (ORR) | 18 Percentage of Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Overall Response Rate (ORR) | 0 Percentage of Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Overall Response Rate (ORR) | 0 Percentage of Participants |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Overall Response Rate (ORR) | 0 Percentage of Participants |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Overall Response Rate (ORR) | 0 Percentage of Participants |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Overall Response Rate (ORR) | 33 Percentage of Participants |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Overall Response Rate (ORR) | 50 Percentage of Participants |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Overall Response Rate (ORR) | 14 Percentage of Participants |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Overall Response Rate (ORR) | 46 Percentage of Participants |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Overall Response Rate (ORR) | 41 Percentage of Participants |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Overall Response Rate (ORR) | 0 Percentage of Participants |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Overall Response Rate (ORR) | 50 Percentage of Participants |
Secondary
Part 2A: Overall Survival (OS)
OS was defined as the interval between the date of first assigned study therapy/randomization and date of death due to any cause.
Time frame: Up to approximately 367 weeks
Population: All Treated
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Overall Survival (OS) | NA Months |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Overall Survival (OS) | 5.3 Months |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Overall Survival (OS) | 9.3 Months |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Overall Survival (OS) | 18.4 Months |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Overall Survival (OS) | 12.7 Months |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Overall Survival (OS) | 14.6 Months |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Overall Survival (OS) | 4.1 Months |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Overall Survival (OS) | 3.0 Months |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Overall Survival (OS) | 8.2 Months |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Overall Survival (OS) | 6.1 Months |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Overall Survival (OS) | 8.6 Months |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Overall Survival (OS) | 7.5 Months |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Overall Survival (OS) | 8.2 Months |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Overall Survival (OS) | 18.5 Months |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Overall Survival (OS) | 16.1 Months |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Overall Survival (OS) | NA Months |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Overall Survival (OS) | NA Months |
Secondary
Part 2A: Progression-free Survival (PFS)
PFS was defined as the interval between the date of first dose of study treatment (or date of randomization for randomized cohorts) and the date of disease progression according to radiological response from investigator assessment, or death due to any cause, whichever occurs earlier. Disease Progression was defined as the date of radiological disease progression based on imaging data per RECIST v1.1.
Time frame: Up to approximately 367 weeks
Population: All Treated
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Progression-free Survival (PFS) | 2.0 Months |
| Part 1A: Fela 0.003 mg/kg | Part 2A: Progression-free Survival (PFS) | 1.9 Months |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Progression-free Survival (PFS) | 1.9 Months |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Progression-free Survival (PFS) | 2.1 Months |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Progression-free Survival (PFS) | 2.1 Months |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Progression-free Survival (PFS) | 2.0 Months |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Progression-free Survival (PFS) | 1.9 Months |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Progression-free Survival (PFS) | 1.7 Months |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Progression-free Survival (PFS) | 2.0 Months |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Progression-free Survival (PFS) | 1.6 Months |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Progression-free Survival (PFS) | 2.1 Months |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Progression-free Survival (PFS) | 5.7 Months |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Progression-free Survival (PFS) | 4.5 Months |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Progression-free Survival (PFS) | 6.7 Months |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Progression-free Survival (PFS) | 7.3 Months |
| Part 2A: Fela 24 mg + Dostarlimab 500 mg + Cobolimab 300 mg | Part 2A: Progression-free Survival (PFS) | 1.9 Months |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Progression-free Survival (PFS) | NA Months |
Secondary
Part 2A: Receptor Occupancy of Feladilimab
Blood samples were collected to assess the cluster of differentiation 4 (CD4+) and cluster of differentiation 8 (CD8+) receptor occupancy by Feladilimab as a pharmacodynamic analysis. It was assessed using validated flow cytometry assay.
Time frame: Up to approximately 367 weeks
Population: All treated population. Analysis was planned for only Feladilimab and therefore arms are clubbed based on Feladilimab dosage for this endpoint. As pre-specified in the protocol, only specified treatment arms were planned and hence there are 0 participants analyzed for rest of the arms.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Receptor Occupancy of Feladilimab | %CD4+ | 87.351 percent receptor occupancy | Geometric Coefficient of Variation 4.63 |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Receptor Occupancy of Feladilimab | %CD8+ | 82.973 percent receptor occupancy | Geometric Coefficient of Variation 13.323 |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Receptor Occupancy of Feladilimab | %CD4+ | 97.962 percent receptor occupancy | Geometric Coefficient of Variation 2.282 |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Receptor Occupancy of Feladilimab | %CD8+ | 99.782 percent receptor occupancy | Geometric Coefficient of Variation 4.173 |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Receptor Occupancy of Feladilimab | %CD4+ | 98.244 percent receptor occupancy | Geometric Coefficient of Variation 1.888 |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Receptor Occupancy of Feladilimab | %CD8+ | 93.448 percent receptor occupancy | Geometric Coefficient of Variation 10.622 |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Receptor Occupancy of Feladilimab | %CD4+ | 99.364 percent receptor occupancy | Geometric Coefficient of Variation 1.333 |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Receptor Occupancy of Feladilimab | %CD8+ | 97.995 percent receptor occupancy | Geometric Coefficient of Variation 3.7 |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Receptor Occupancy of Feladilimab | %CD8+ | 100.887 percent receptor occupancy | Geometric Coefficient of Variation 2.264 |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Receptor Occupancy of Feladilimab | %CD4+ | 99.704 percent receptor occupancy | Geometric Coefficient of Variation 0.995 |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Receptor Occupancy of Feladilimab | %CD8+ | 79.261 percent receptor occupancy | Geometric Coefficient of Variation 4.878 |
| Part 1A: Fela 1.000 mg/kg | Part 2A: Receptor Occupancy of Feladilimab | %CD4+ | 93.157 percent receptor occupancy | Geometric Coefficient of Variation 1.017 |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Receptor Occupancy of Feladilimab | %CD8+ | 93.221 percent receptor occupancy | Geometric Coefficient of Variation 8.141 |
| Part 1A: Fela 3.000 mg/kg | Part 2A: Receptor Occupancy of Feladilimab | %CD4+ | 97.324 percent receptor occupancy | Geometric Coefficient of Variation 3.753 |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Receptor Occupancy of Feladilimab | %CD4+ | 99.887 percent receptor occupancy | Geometric Coefficient of Variation 0.176 |
| Part 1A: Fela 10.000 mg/kg | Part 2A: Receptor Occupancy of Feladilimab | %CD8+ | 96.540 percent receptor occupancy | Geometric Coefficient of Variation 4.157 |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Receptor Occupancy of Feladilimab | %CD4+ | 96.417 percent receptor occupancy | Geometric Coefficient of Variation 7.179 |
| Part 2A: Fela 80 mg + GSK3174998 24 mg | Part 2A: Receptor Occupancy of Feladilimab | %CD8+ | 94.960 percent receptor occupancy | Geometric Coefficient of Variation 7.366 |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Receptor Occupancy of Feladilimab | %CD4+ | 94.324 percent receptor occupancy | Geometric Coefficient of Variation 36.547 |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Receptor Occupancy of Feladilimab | %CD8+ | 101.528 percent receptor occupancy | Geometric Coefficient of Variation 18.835 |
Secondary
Part 2A: Time to Overall Response (TTR)
TTR was defined as the time from date of first dose of study treatment/randomization to the date of first documented confirmed (=4 weeks) CR or PR. CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 mm. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.
Time frame: Up to approximately 367 weeks
Population: All Treated Population with a confirmed CR or PR. Only responders were included for the analysis.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2A: Time to Overall Response (TTR) | 2.1 Months |
| Part 1A: Fela 0.010 mg/kg | Part 2A: Time to Overall Response (TTR) | 2.0 Months |
| Part 1A: Fela 0.030 mg/kg | Part 2A: Time to Overall Response (TTR) | 2.8 Months |
| Part 1A: Fela 0.100 mg/kg | Part 2A: Time to Overall Response (TTR) | 3.0 Months |
| Part 1A: Fela 0.300 mg/kg | Part 2A: Time to Overall Response (TTR) | 11.0 Months |
| Part 2A: Fela 80 mg + GSK3174998 80 mg | Part 2A: Time to Overall Response (TTR) | 2.1 Months |
| Part 2A: Fela 24 mg + Chemotherapy | Part 2A: Time to Overall Response (TTR) | 1.6 Months |
| Part 2A: Fela 80 mg + Chemotherapy | Part 2A: Time to Overall Response (TTR) | 2.1 Months |
| Part 2A: Fela 24 mg + 200 mg Pembro + Chemotherapy | Part 2A: Time to Overall Response (TTR) | 1.6 Months |
| Part 2A: Fela 80 mg + 200 mg Pembro + Chemotherapy | Part 2A: Time to Overall Response (TTR) | 2.1 Months |
| Part 2A: Fela 24 mg + Bintrafusp Alfa 2400 mg | Part 2A: Time to Overall Response (TTR) | 2.1 Months |
Secondary
Part 2B: AUC (0-1008 h) of Feladilimab
Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method.
Time frame: Pre-dose; EOI; 0.5, 1, 2, 4, 6, 8, 24, 48-72, 96-120 hours post-EOI; week 1; week 2; Pre-dose and 0.5 hours post-EOI in week 3; week 4; week 5; Pre-dose and 0.5, 4 hours post-EOI in week 6, 9, 12 and15; Pre-dose in week 18, 21, 33, 45, 57, 69, 81 and 93
Population: Pharmacokinetic Population. Data is presented for participants who received feladilimab in combination with 400 mg Pembro. Only those participants with data available at specified categories have been analyzed.
| Arm | Measure | Value (GEOMETRIC_MEAN) |
|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: AUC (0-1008 h) of Feladilimab | 3829.5867 h*ug/mL |
| Part 1A: Fela 0.003 mg/kg | Part 2B: AUC (0-1008 h) of Feladilimab | 22182.5834 h*ug/mL |
Secondary
Part 2B: AUC (0-504 h) of Feladilimab
Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method.
Time frame: Pre-dose; EOI; 0.5, 1, 2, 4, 6, 8, 24, 48-72, 96-120 hours post-EOI; week 1; week 2; Pre-dose and 0.5 hours post-EOI in week 3; week 4; week 5; Pre-dose and 0.5, 4 hours post-EOI in week 6, 9, 12 and15; Pre-dose in week 18, 21, 33, 45, 57, 69, 81 and 93
Population: Pharmacokinetic Population. Data is presented for participants who received feladilimab in combination with 200 mg Pembro. Only those participants with data available at specified categories have been analyzed.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: AUC (0-504 h) of Feladilimab | HNSCC RANDOMIZED | 294.2888 h*ug/mL | Geometric Coefficient of Variation 46.7592 |
| Part 1A: Fela 0.003 mg/kg | Part 2B: AUC (0-504 h) of Feladilimab | CERVICAL | 1254.7759 h*ug/mL | Geometric Coefficient of Variation 39.2813 |
| Part 1A: Fela 0.003 mg/kg | Part 2B: AUC (0-504 h) of Feladilimab | HNSCC RANDOMIZED | 1500.4305 h*ug/mL | — |
| Part 1A: Fela 0.003 mg/kg | Part 2B: AUC (0-504 h) of Feladilimab | BLADDER/UROTHELIAL | 1205.2673 h*ug/mL | Geometric Coefficient of Variation 24.3543 |
| Part 1A: Fela 0.003 mg/kg | Part 2B: AUC (0-504 h) of Feladilimab | JAPAN PK/PD | 1367.0149 h*ug/mL | Geometric Coefficient of Variation 359.19195 |
| Part 1A: Fela 0.003 mg/kg | Part 2B: AUC (0-504 h) of Feladilimab | MELANOMA | 1082.3162 h*ug/mL | Geometric Coefficient of Variation 48.1386 |
| Part 1A: Fela 0.003 mg/kg | Part 2B: AUC (0-504 h) of Feladilimab | MSI-H/DMMR | 1264.0452 h*ug/mL | Geometric Coefficient of Variation 280.10101 |
| Part 1A: Fela 0.003 mg/kg | Part 2B: AUC (0-504 h) of Feladilimab | NSCLC | 1318.6658 h*ug/mL | Geometric Coefficient of Variation 664.64033 |
| Part 1A: Fela 0.003 mg/kg | Part 2B: AUC (0-504 h) of Feladilimab | VIRAL-POSITIVE | 1415.2121 h*ug/mL | Geometric Coefficient of Variation 355.2595 |
| Part 1A: Fela 0.010 mg/kg | Part 2B: AUC (0-504 h) of Feladilimab | NSCLC | 3071.5346 h*ug/mL | Geometric Coefficient of Variation 1879.01269 |
| Part 1A: Fela 0.010 mg/kg | Part 2B: AUC (0-504 h) of Feladilimab | HNSCC RANDOMIZED | 4225.4602 h*ug/mL | Geometric Coefficient of Variation 33.1105 |
| Part 1A: Fela 0.010 mg/kg | Part 2B: AUC (0-504 h) of Feladilimab | MELANOMA | 4098.4237 h*ug/mL | Geometric Coefficient of Variation 45.2413 |
| Part 1A: Fela 0.010 mg/kg | Part 2B: AUC (0-504 h) of Feladilimab | JAPAN PK/PD | 4258.3090 h*ug/mL | Geometric Coefficient of Variation 280.08094 |
| Part 1A: Fela 0.030 mg/kg | Part 2B: AUC (0-504 h) of Feladilimab | HNSCC RANDOMIZED | 13829.6005 h*ug/mL | Geometric Coefficient of Variation 18.4367 |
| Part 1A: Fela 0.030 mg/kg | Part 2B: AUC (0-504 h) of Feladilimab | JAPAN PK/PD | 13890.8203 h*ug/mL | — |
Secondary
Part 2B: AUC (0-504h) of Pembrolizumab
Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method.
Time frame: Pre-dose; EOI; 0.5, 1, 2, 4, 6, 8, 24, 48-72, 96-120 hours post-EOI; week 1; week 2; Pre-dose and 0.5 hours post-EOI in week 3; week 4; week 5; Pre-dose and 0.5, 4 hours post-EOI in week 6, 9, 12 and15; Pre-dose in week 18, 21, 33, 45, 57, 69, 81 and 93
Population: Pharmacokinetic Population. As pre-specified in the protocol, PK data were not collected and analyzed for Pembrolizumab. Therefore, this PK parameter was not reported in this study.
Secondary
Part 2B: Cmax and Ctau of Feladilimab
Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method.
Time frame: Pre-dose; EOI; 0.5, 1, 2, 4, 6, 8, 24, 48-72, 96-120 hours post-EOI; week 1; week 2; Pre-dose and 0.5 hours post-EOI in week 3; week 4; week 5; Pre-dose and 0.5, 4 hours post-EOI in week 6, 9, 12 and15; Pre-dose in week 18, 21, 33, 45, 57, 69, 81 and 93
Population: Pharmacokinetic Population. Data is presented for participants who received feladilimab in combination with Pembro. Only those participants with data available at specified categories have been analyzed.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Cmax and Ctau of Feladilimab | HNSCC RANDOMIZED, Ctau, Cycle 1 | 0.3314 ug/mL | Geometric Coefficient of Variation 75.4863 |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Cmax and Ctau of Feladilimab | HNSCC RANDOMIZED, Ctau, Cycle 6 | 0.4949 ug/mL | Geometric Coefficient of Variation 141.2509 |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Cmax and Ctau of Feladilimab | HNSCC RANDOMIZED, Cmax, Cycle 1 | 2.2993 ug/mL | Geometric Coefficient of Variation 35.489 |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Cmax and Ctau of Feladilimab | CERVICAL, Cmax, Cycle 1 | 7.8457 ug/mL | Geometric Coefficient of Variation 25.6236 |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Cmax and Ctau of Feladilimab | CERVICAL, Ctau, Cycle 1 | 1.1026 ug/mL | Geometric Coefficient of Variation 86.6644 |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Cmax and Ctau of Feladilimab | CERVICAL, Ctau, Cycle 6 | 3.5457 ug/mL | Geometric Coefficient of Variation 51.5684 |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Cmax and Ctau of Feladilimab | BLADDER/UROTHELIAL, Cmax, Cycle 1 | 7.0435 ug/mL | Geometric Coefficient of Variation 16.095 |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Cmax and Ctau of Feladilimab | BLADDER/UROTHELIAL, Ctau, Cycle 1 | 1.1346 ug/mL | Geometric Coefficient of Variation 49.2057 |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Cmax and Ctau of Feladilimab | BLADDER/UROTHELIAL, Ctau, Cycle 6 | 2.5980 ug/mL | Geometric Coefficient of Variation 39.5677 |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Cmax and Ctau of Feladilimab | HNSCC RANDOMIZED, Cmax, Cycle 1 | 6.8500 ug/mL | — |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Cmax and Ctau of Feladilimab | HNSCC RANDOMIZED, Ctau, Cycle 1 | 1.2350 ug/mL | — |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Cmax and Ctau of Feladilimab | JAPAN PK/PD, Cmax, Cycle 1 | 7.8198 ug/mL | Geometric Coefficient of Variation 7.7572 |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Cmax and Ctau of Feladilimab | JAPAN PK/PD, Ctau, Cycle 1 | 0.8800 ug/mL | Geometric Coefficient of Variation 77.4102 |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Cmax and Ctau of Feladilimab | MELANOMA, Cmax, Cycle 1 | 8.3936 ug/mL | Geometric Coefficient of Variation 43.1529 |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Cmax and Ctau of Feladilimab | MELANOMA, Ctau, Cycle 1 | 1.4839 ug/mL | Geometric Coefficient of Variation 42.9808 |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Cmax and Ctau of Feladilimab | MELANOMA, Ctau, Cycle 6 | 3.2491 ug/mL | Geometric Coefficient of Variation 66.9061 |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Cmax and Ctau of Feladilimab | MSI-H/DMMR, Cmax, Cycle 1 | 7.4487 ug/mL | Geometric Coefficient of Variation 20.891 |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Cmax and Ctau of Feladilimab | MSI-H/DMMR, Ctau, Cycle 1 | 1.2458 ug/mL | Geometric Coefficient of Variation 75.5891 |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Cmax and Ctau of Feladilimab | MSI-H/DMMR, Ctau, Cycle 6 | 3.3140 ug/mL | Geometric Coefficient of Variation 32.6114 |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Cmax and Ctau of Feladilimab | NSCLC, Cmax, Cycle 1 | 8.1306 ug/mL | Geometric Coefficient of Variation 47.5103 |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Cmax and Ctau of Feladilimab | NSCLC, Ctau, Cycle 1 | 1.0848 ug/mL | Geometric Coefficient of Variation 63.6879 |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Cmax and Ctau of Feladilimab | NSCLC, Ctau, Cycle 6 | 3.0399 ug/mL | Geometric Coefficient of Variation 53.4515 |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Cmax and Ctau of Feladilimab | VIRAL-POSITIVE, Cmax, Cycle 1 | 7.5533 ug/mL | Geometric Coefficient of Variation 20.0814 |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Cmax and Ctau of Feladilimab | VIRAL-POSITIVE, Ctau, Cycle 1 | 1.0357 ug/mL | Geometric Coefficient of Variation 66.5632 |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Cmax and Ctau of Feladilimab | VIRAL-POSITIVE, Ctau, Cycle 6 | 1.9175 ug/mL | Geometric Coefficient of Variation 77.2467 |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Cmax and Ctau of Feladilimab | MELANOMA, Cmax, Cycle 1 | 25.7542 ug/mL | Geometric Coefficient of Variation 12.1953 |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Cmax and Ctau of Feladilimab | HNSCC RANDOMIZED, Cmax, Cycle 1 | 21.7283 ug/mL | Geometric Coefficient of Variation 27.2945 |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Cmax and Ctau of Feladilimab | JAPAN PK/PD, Ctau, Cycle 1 | 4.3511 ug/mL | Geometric Coefficient of Variation 28.127 |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Cmax and Ctau of Feladilimab | CERVICAL, Ctau, Cycle 1 | 8.3270 ug/mL | — |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Cmax and Ctau of Feladilimab | NSCLC, Cmax, Cycle 1 | 16.0295 ug/mL | Geometric Coefficient of Variation 88.7297 |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Cmax and Ctau of Feladilimab | HNSCC RANDOMIZED, Ctau, Cycle 1 | 4.3179 ug/mL | Geometric Coefficient of Variation 32.9785 |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Cmax and Ctau of Feladilimab | JAPAN PK/PD, Cmax, Cycle 1 | 21.5695 ug/mL | Geometric Coefficient of Variation 8.906 |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Cmax and Ctau of Feladilimab | MELANOMA, Ctau, Cycle 1 | 4.2946 ug/mL | Geometric Coefficient of Variation 47.1494 |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Cmax and Ctau of Feladilimab | MELANOMA, Ctau, Cycle 6 | 8.3404 ug/mL | Geometric Coefficient of Variation 58.4213 |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Cmax and Ctau of Feladilimab | NSCLC, Ctau, Cycle 1 | 2.7263 ug/mL | Geometric Coefficient of Variation 66.3138 |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Cmax and Ctau of Feladilimab | HNSCC RANDOMIZED, Ctau, Cycle 6 | 15.0674 ug/mL | Geometric Coefficient of Variation 100.4531 |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Cmax and Ctau of Feladilimab | CERVICAL, Cmax, Cycle 1 | 31.0460 ug/mL | — |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Cmax and Ctau of Feladilimab | CERVICAL, Ctau, Cycle 6 | 19.2960 ug/mL | — |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Cmax and Ctau of Feladilimab | HNSCC RANDOMIZED, Ctau, Cycle 6 | 78.2867 ug/mL | Geometric Coefficient of Variation 251.8571 |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Cmax and Ctau of Feladilimab | JAPAN PK/PD, Cmax, Cycle 1 | 69.9207 ug/mL | Geometric Coefficient of Variation 31.4654 |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Cmax and Ctau of Feladilimab | JAPAN PK/PD, Ctau, Cycle 1 | 15.7566 ug/mL | Geometric Coefficient of Variation 16.444 |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Cmax and Ctau of Feladilimab | JAPAN PK/PD, Ctau, Cycle 6 | 37.7140 ug/mL | — |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Cmax and Ctau of Feladilimab | HNSCC RANDOMIZED, Ctau, Cycle 1 | 14.0320 ug/mL | Geometric Coefficient of Variation 34.624 |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Cmax and Ctau of Feladilimab | HNSCC RANDOMIZED, Cmax, Cycle 1 | 71.1264 ug/mL | Geometric Coefficient of Variation 25.9928 |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Cmax and Ctau of Feladilimab | HNSCC_CPS<1, Ctau, Cycle 1 | 1.4240 ug/mL | — |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Cmax and Ctau of Feladilimab | HNSCC_CPS<1, Cmax, Cycle 1 | 11.7572 ug/mL | Geometric Coefficient of Variation 72.5188 |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Cmax and Ctau of Feladilimab | HNSCC Q6W, Cmax, Cycle 1 | 12.7362 ug/mL | Geometric Coefficient of Variation 35.6947 |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Cmax and Ctau of Feladilimab | HNSCC Q6W, Cmax, Cycle 1 | 70.9208 ug/mL | Geometric Coefficient of Variation 22.9901 |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Cmax and Ctau of Feladilimab | HNSCC Q6W, Ctau, Cycle 1 | 6.6970 ug/mL | — |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Cmax and Ctau of Feladilimab | HNSCC_CPS<1, Cmax, Cycle 1 | 39.4240 ug/mL | — |
Secondary
Part 2B: Cmax and Ctau of Pembrolizumab
Blood samples were collected for PK analysis. PK analysis was calculated based on standard non-compartmental method.
Time frame: Pre-dose; EOI; 0.5, 1, 2, 4, 6, 8, 24, 48-72, 96-120 hours post-EOI; week 1; week 2; Pre-dose and 0.5 hours post-EOI in week 3; week 4; week 5; Pre-dose and 0.5, 4 hours post-EOI in week 6, 9, 12 and15; Pre-dose in week 18, 21, 33, 45, 57, 69, 81 and 93
Population: Pharmacokinetic Population. As pre-specified in the protocol, PK data were not collected and analyzed for Pembrolizumab. Therefore, this PK parameter was not reported in this study.
Secondary
Part 2B: Disease Control Rate (DCR)
DCR was defined as the percentage of participants with a best overall response of irCR or irPR at any time plus irSD meeting the minimum time criteria from the start of treatment until irPD or death due to any cause or the start of new anticancer therapy/crossover. irCR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. irPR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters. irSD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease. irPD is defined as the date of radiological disease progression based on imaging data per irRECIST. A one-week visit window was considered in the duration of irSD, i.e. a minimum of 8 weeks (irSD\>=9 weeks) and 17 weeks (irSD\>=18 weeks) were considered.
Time frame: Up to approximately 367 weeks
Population: All Treated population
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Disease Control Rate (DCR) | >=9 Weeks | 29 Percentage of Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Disease Control Rate (DCR) | >=18 Weeks | 21 Percentage of Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Disease Control Rate (DCR) | >=9 Weeks | 58 Percentage of Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Disease Control Rate (DCR) | >=18 Weeks | 39 Percentage of Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Disease Control Rate (DCR) | >=9 Weeks | 43 Percentage of Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Disease Control Rate (DCR) | >=18 Weeks | 27 Percentage of Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Disease Control Rate (DCR) | >=9 Weeks | 57 Percentage of Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Disease Control Rate (DCR) | >=18 Weeks | 35 Percentage of Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Disease Control Rate (DCR) | >=9 Weeks | 50 Percentage of Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Disease Control Rate (DCR) | >=18 Weeks | 25 Percentage of Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Disease Control Rate (DCR) | >=9 Weeks | 33 Percentage of Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Disease Control Rate (DCR) | >=18 Weeks | 33 Percentage of Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Disease Control Rate (DCR) | >=18 Weeks | 0 Percentage of Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Disease Control Rate (DCR) | >=9 Weeks | 0 Percentage of Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Disease Control Rate (DCR) | >=9 Weeks | 0 Percentage of Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Disease Control Rate (DCR) | >=18 Weeks | 0 Percentage of Participants |
Secondary
Part 2B: Duration of Response (DOR)
DOR was defined as the interval of time in months from the date of the first documented evidence of a response (confirmed CR or PR) to the date of first documented evidence of disease progression according to radiological response from investigator assessment per RECIST v1.1, or date of last adequate assessment of response or the date of death due to any cause (whichever occurs earlier). CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters. Disease progression is defined as the date of radiological disease progression based on imaging data per RECIST v1.1
Time frame: Up to approximately 367 weeks
Population: All Treated Population with a confirmed CR or PR. Only responders were included for the analysis.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Duration of Response (DOR) | 6.1 Months |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Duration of Response (DOR) | 13.8 Months |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Duration of Response (DOR) | 18.7 Months |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Duration of Response (DOR) | 24.6 Months |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Duration of Response (DOR) | 11.5 Months |
Secondary
Part 2B: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, Results in persistent disability/incapacity or is a congenital anomaly/birth defect, other situations which involve medical or scientific judgment or is associated with liver injury and impaired liver function. SAEs are subset of AEs. A summary of number of participants with any AEs and SAEs is presented. AEs were coded using the MedDRA dictionary.
Time frame: Up to approximately 367 weeks
Population: All Treated population
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any AEs | 13 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any SAEs | 3 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any AEs | 250 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any SAEs | 126 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any AEs | 43 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any SAEs | 17 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any AEs | 23 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any SAEs | 7 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any AEs | 4 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any SAEs | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any AEs | 5 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any SAEs | 2 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any SAEs | 2 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any AEs | 4 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any AEs | 1 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) | Any SAEs | 1 Participants |
Secondary
Part 2B: Number of Participants With Dose Modifications of Feladilimab
Number of participants with dose modifications (including dose delays, dose escalations, and infusion interruptions) were reported for Feladilimab.
Time frame: Up to approximately 367 weeks
Population: All treated population
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Dose Modifications of Feladilimab | Dose delays | 2 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Dose Modifications of Feladilimab | Infusion interruptions | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Dose Modifications of Feladilimab | Dose escalations | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Dose Modifications of Feladilimab | Infusion interruptions | 8 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Dose Modifications of Feladilimab | Dose escalations | 10 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Dose Modifications of Feladilimab | Dose delays | 31 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Dose Modifications of Feladilimab | Infusion interruptions | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Dose Modifications of Feladilimab | Dose delays | 5 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Dose Modifications of Feladilimab | Dose escalations | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Dose Modifications of Feladilimab | Dose delays | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Dose Modifications of Feladilimab | Dose escalations | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Dose Modifications of Feladilimab | Infusion interruptions | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Dose Modifications of Feladilimab | Dose escalations | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Dose Modifications of Feladilimab | Dose delays | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Dose Modifications of Feladilimab | Infusion interruptions | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Dose Modifications of Feladilimab | Dose escalations | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Dose Modifications of Feladilimab | Dose delays | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Dose Modifications of Feladilimab | Infusion interruptions | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Dose Modifications of Feladilimab | Dose escalations | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Dose Modifications of Feladilimab | Dose delays | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Dose Modifications of Feladilimab | Infusion interruptions | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Dose Modifications of Feladilimab | Dose delays | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Dose Modifications of Feladilimab | Dose escalations | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Dose Modifications of Feladilimab | Infusion interruptions | 0 Participants |
Secondary
Part 2B: Number of Participants With Positive Results in ADA in Pembrolizumab
Serum samples collected and tested for the presence of ADA with a screening assay.
Time frame: Up to approximately 367 weeks
Population: All Treated population
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Positive Results in ADA in Pembrolizumab | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Positive Results in ADA in Pembrolizumab | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Positive Results in ADA in Pembrolizumab | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Positive Results in ADA in Pembrolizumab | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Positive Results in ADA in Pembrolizumab | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Positive Results in ADA in Pembrolizumab | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Positive Results in ADA in Pembrolizumab | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Positive Results in ADA in Pembrolizumab | 0 Participants |
Secondary
Part 2B: Number of Participants With Positive Results in ADA Test by Feladilimab Dose Level
Serum samples collected and tested for the presence of ADA with a screening assay.
Time frame: Up to approximately 367 weeks
Population: All Treated population
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Positive Results in ADA Test by Feladilimab Dose Level | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Positive Results in ADA Test by Feladilimab Dose Level | 5 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Positive Results in ADA Test by Feladilimab Dose Level | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Positive Results in ADA Test by Feladilimab Dose Level | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Positive Results in ADA Test by Feladilimab Dose Level | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Positive Results in ADA Test by Feladilimab Dose Level | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Positive Results in ADA Test by Feladilimab Dose Level | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Positive Results in ADA Test by Feladilimab Dose Level | 0 Participants |
Secondary
Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline
Normal ranges were 0.1 to 0.3 micromoles (umol)/liter (L) (direct bilirubin); 6 to 8.3 grams/L (protein); 100 to 250 international units (IU)/L (Lactate Dehydrogenase(LDH)); 2.3 - 4.1 picomoles/L (Free Triiodothyronine(T3)); 4.6 to 11.2 picomoles/L (Free Thyroxine(T4)); 0 and 0.04 microgram (ug)/L (Troponin I); 0 - 0.01 ug/L (Troponin T); 0.45 to 4.5 milliunits (Mu)/L (Thyrotropin(TSH)); 24-204 ug/L (creatine kinase); and 6 to 24 millimoles/L (Urea). Participants were counted in worst case category that their value changes to low, normal or no change \[NC\] or high), unless there is NC in their category. Participants whose laboratory value category was unchanged (e.g. High to High) or whose value became normal, were recorded in To Normal or No Change category. Participants were counted twice if participant had values that changed To Low and To High, so percentages may not add to 100%.
Time frame: Up to approximately 367 weeks
Population: All Treated Population. Only those participants with data available at specified categories have been analyzed.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To High | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To Low | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Normal or No Change | 10 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Normal or No Change | 12 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Normal or No Change | 9 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Normal or No Change | 11 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Low | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Low | 2 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To High | 2 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Low | 2 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To High | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To Normal or No Change | 7 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To High | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Normal or No Change | 10 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To High | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Low | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Low | 3 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To High | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Lactate Dehydrogenase (IU/L), To High | 2 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To High | 38 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To Normal or No Change | 109 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To High | 15 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To High | 34 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Low | 37 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Low | 41 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Normal or No Change | 179 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Low | 33 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Normal or No Change | 160 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To High | 25 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Lactate Dehydrogenase (IU/L), To Low | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Low | 22 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To High | 53 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To High | 31 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To High | 13 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To Normal or No Change | 44 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Low | 30 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Normal or No Change | 183 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To Low | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To Low | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Normal or No Change | 137 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Normal or No Change | 180 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Lactate Dehydrogenase (IU/L), To Normal or No Change | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To High | 8 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To Normal or No Change | 18 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To High | 2 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Lactate Dehydrogenase (IU/L), To Normal or No Change | 2 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To Low | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Direct Bilirubin (umol/L), To Normal or No Change | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Lactate Dehydrogenase (IU/L), To High | 2 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Direct Bilirubin (umol/L), To High | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Low | 9 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To High | 6 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Normal or No Change | 27 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Normal or No Change | 27 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Creatine Kinase MB (ug/L), To Low | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Low | 3 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To High | 7 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Creatine Kinase MB (ug/L), To Normal or No Change | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Normal or No Change | 29 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Low | 7 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Creatine Kinase MB (ug/L), To High | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Low | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Normal or No Change | 29 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To High | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To High | 2 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Lactate Dehydrogenase (IU/L), To Low | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To Normal or No Change | 6 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Low | 6 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Direct Bilirubin (umol/L), To Low | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To Low | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To High | 3 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Normal or No Change | 30 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Low | 2 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Lactate Dehydrogenase (IU/L), To Low | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Lactate Dehydrogenase (IU/L), To Normal or No Change | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Lactate Dehydrogenase (IU/L), To High | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Normal or No Change | 18 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To High | 4 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Low | 5 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Normal or No Change | 12 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To High | 3 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Low | 3 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Normal or No Change | 16 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To High | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To Low | 2 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To Normal or No Change | 12 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To High | 2 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To Low | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To Normal or No Change | 4 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To High | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Low | 2 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Normal or No Change | 12 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To High | 6 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Low | 5 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Normal or No Change | 10 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To High | 4 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To High | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Low | 3 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To High | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Low | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Normal or No Change | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Normal or No Change | 3 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To High | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Normal or No Change | 3 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Low | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To Low | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Low | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To High | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To Low | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Normal or No Change | 2 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To High | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To Normal or No Change | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To Normal or No Change | 3 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To High | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Normal or No Change | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To High | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Low | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To High | 2 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To Low | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To High | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Normal or No Change | 3 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To Normal or No Change | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin T (ug/L), To High | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Normal or No Change | 5 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Low | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Low | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Low | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Normal or No Change | 4 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To High | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To High | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Low | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Normal or No Change | 4 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To Low | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To High | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To Normal or No Change | 2 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Normal or No Change | 3 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Normal or No Change | 2 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To High | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To High | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To High | 2 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To Normal or No Change | 3 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To Low | 2 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Normal or No Change | 2 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To High | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Normal or No Change | 4 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Urea (mmol/L), To Low | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To High | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Triiodothyronine, Free (pmol/L), To High | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Low | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyroxine, Free (pmol/L), To Low | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Low | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Troponin I (ug/L), To Low | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Thyrotropin (mU/L), To Normal or No Change | 3 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Normal or No Change | 1 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To High | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline | Protein (g/L), To Low | 0 Participants |
Secondary
Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters
Blood samples were collected for analysis of clinical chemistry parameters. Laboratory parameters were graded according to CTCAE v4.03. Grade (G) 0: None; G1: mild; G2: moderate; G3: severe or medically significant; G4: life-threatening consequences. Higher grade indicates greater severity and increase in grade was defined relative to Baseline grade. Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Only grade change data is presented for Baseline (B) and Worst-Case Post-Baseline (WCPB) as G0, G1, G2, G3, G4, and missing (M) here as Parameter name, B GX, WCPB GX where X=grade digit.
Time frame: Baseline (Day 1) and up to approximately 367 weeks
Population: All Treated Population. Only those participants with data available at specified categories have been analyzed.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 1 | 2 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 2 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 1 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 1 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 1 | 2 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 3 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 3 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 3 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 1 | 2 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 2 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 1 | 6 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 1 | 4 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 2 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 1 | 2 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 1 | 4 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 1 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 2 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 2 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 1 | 3 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 2 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 1 | 4 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 1 | 26 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 0 | 5 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 2 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 2 | 22 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 0 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 0 | 2 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 3 | 4 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 4 | 4 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 3 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Missing, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Missing, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Missing, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 3 | 2 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 3 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 0 | 3 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 0 | 5 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 1 | 65 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Missing, Grade 0 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Missing, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 2 | 12 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 2 | 4 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 2 | 11 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 2 | 7 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Missing, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Missing, Grade 1 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 3 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Missing, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Missing, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 1 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Missing, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 3 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 1 | 50 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Missing, Grade 4 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Missing, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Missing, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 4 | 10 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Missing, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Missing, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 1 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 1 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 0 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 1 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 2 | 10 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 1 | 9 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 4 | 2 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 0 | 6 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 0 | 3 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 2 | 10 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 3 | 2 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 0 | 2 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 3 | 2 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 4 | 9 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 2 | 9 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 1 | 52 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 3 | 4 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 1 | 50 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 2 | 6 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 3 | 2 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 4 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 0 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 2 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 1 | 9 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 2 | 5 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 3 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 4 | 8 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 0 | 4 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 2 | 3 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 3 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Missing, Grade 0 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Missing, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Missing, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Missing, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Missing, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 1 | 91 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 2 | 13 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 4 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 1 | 2 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 1 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 4 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 3 | 4 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Missing, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Missing, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Missing, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 1 | 47 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 3 | 5 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 2 | 11 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 2 | 7 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 3 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 3 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 3 | 3 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 4 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 3 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Missing, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Missing, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Missing, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Missing, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Missing, Grade 4 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 1 | 34 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 0 | 2 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 2 | 4 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 3 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 2 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 1 | 3 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 2 | 5 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 1 | 12 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 2 | 7 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 2 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 3 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Missing, Grade 0 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Missing, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 1 | 24 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 0 | 2 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 2 | 12 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 4 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 1 | 30 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 4 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 1 | 45 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 2 | 8 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 3 | 2 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 0 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 3 | 4 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 0 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 3 | 10 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 3 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 4 | 6 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 1 | 18 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 4 | 2 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 4 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 2 | 3 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 1 | 6 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 3 | 2 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 3 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 0 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 3 | 3 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 1 | 7 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 3 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 1 | 4 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 1 | 8 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 0 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 1 | 3 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Cpk Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Cpk Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Cpk Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Cpk Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Cpk Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 3 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Cpk Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Cpk Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Cpk Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Cpk Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Cpk Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Cpk Increased, Missing, Grade 0 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Cpk Increased, Missing, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Cpk Increased, Missing, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Cpk Increased, Missing, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Cpk Increased, Missing, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 2 | 6 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 1 | 12 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 1 | 8 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 1 | 5 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 1 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 1 | 7 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 2 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 3 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Cpk Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Cpk Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Cpk Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Cpk Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 1 | 2 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Cpk Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 0 | 2 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Cpk Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Cpk Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Cpk Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 2 | 3 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Cpk Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 4 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 2 | 3 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 1 | 5 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 3 | 2 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 3 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 1 | 11 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 0 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 4 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Cpk Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 4 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 0 | 3 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 4 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 3 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 2 | 2 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 1 | 7 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 1 | 4 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 2 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 2 | 3 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 4 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 3 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 1 | 2 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 2 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 2 | 2 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 0 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 1 | 2 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 2 | 2 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 3 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 1 | 6 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 1 | 2 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 4 | 3 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 1 | 8 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 0 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 1 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 2 | 4 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 4 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 2 | 2 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 1 | 4 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 4 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 1 | 9 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 3 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 2 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 2 | 2 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 3 | 2 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 1 | 4 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 1 | 6 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 1 | 6 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 2 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 3 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 3 | 2 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 1 | 4 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 0 | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 3 | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 0 | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 2 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 3 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 1 | 3 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 2 | 2 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 1 | 2 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 1 | 2 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 3 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 1 | 2 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 3 | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 3 | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 0 | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 1 | 2 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 1 | 2 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 1 | 2 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 2 | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 1 | 2 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 2 | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 2 | 2 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 0 | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 0 | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Missing, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 1 | 2 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Chronic Kidney Disease , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 0 | 1 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypercalcemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperkalemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Creatinine Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | ALT Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Blood Bilirubin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AST Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyponatremia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypernatremia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoalbuminemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypoglycemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypokalemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hyperglycemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | Hypocalcemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters | AP Increased, Grade 4, Grade 2 | 0 Participants |
Secondary
Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters
Blood samples were collected for analysis of hematology parameters. Laboratory parameters were graded according to CTCAE v4.03. Grade (G) 0: None; G1: mild; G2: moderate; G3: severe or medically significant; G4: life-threatening consequences. Higher grade indicates greater severity and increase in grade was defined relative to Baseline grade. Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Only grade change data is presented for Baseline (B) and Worst-Case Post-Baseline (WCPB) as G0, G1, G2, G3, G4, and missing (M) here as Parameter name, B GX, WCPB GX where X=grade digit.
Time frame: Baseline (Day 1) and up to approximately 367 weeks
Population: All Treated Population. Only those participants with data available at specified categories have been analyzed.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 2 | 3 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 3 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 2 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 1 | 3 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 2 | 3 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 2 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 1 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 2 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 1 | 4 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 1 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 2 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 4 | 1 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 3 | 16 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 3 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 0 | 5 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 3 | 3 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 2 | 9 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 1 | 71 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 0 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 4 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 1 | 19 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 2 | 4 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 3 | 2 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 1 | 40 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 2 | 24 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 3 | 6 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 0 | 2 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 2 | 42 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 4 | 2 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 1 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 3 | 7 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 4 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 0 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 2 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Missing, Grade 0 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Missing, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Missing, Grade 2 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Missing, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Missing, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 2 | 9 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 3 | 4 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 3 | 5 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 0 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Missing, Grade 0 | 2 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Missing, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Missing, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Missing, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Missing, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 1 | 3 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 2 | 2 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 3 | 10 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 4 | 2 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 0 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 3 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 2 | 3 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 3 | 2 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 2 | 44 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 1 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 1 | 5 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 0 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 0 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 4 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Missing, Grade 0 | 2 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Missing, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 0 | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Missing, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Missing, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Missing, Grade 4 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 1 | 21 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 4 | 8 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 0 | 2 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 2 | 5 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 2 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 4 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 1 | 3 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 2 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 2 | 4 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 1 | 13 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 1 | 3 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 3 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 3 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 3 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 4 | 2 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 2 | 3 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 1 | 7 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 3 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 2 | 3 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 1 | 2 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 3 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 2 | 9 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 3 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 1 | 4 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 1 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 0 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 3 | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 2 | 7 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 3 | 3 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 2 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 3 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 3 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 1 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 1 | 5 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 3 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 3 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 2 | 2 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 0 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 2 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 2 | 4 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 2 | 4 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 3 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 0 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 2 | 5 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 2 | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 3 | 2 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 2 | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 1 | 2 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 2 | 2 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 1 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 3 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Missing, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Missing, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Missing, Grade 2 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Missing, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Missing, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Missing, Grade 0 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Missing, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Missing, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Missing, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Missing, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Missing, Grade 0 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Missing, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Missing, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Missing, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Missing, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 1 | 2 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 3 | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 3 | 2 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 1 | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 2 | 2 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 2 | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Neutrophil Count Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Increased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 1, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 1, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Lymphocyte Count Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Hemoglobin Increased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 4, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 3, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Anemia , Grade 0, Grade 2 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 1 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Leukocytosis , Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 2, Grade 0 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | White Blood Cell Decreased, Grade 0, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 4 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 3 | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters | Platelet Count Decreased, Grade 1, Grade 2 | 0 Participants |
Secondary
Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline
Normal ranges were 0.01 to 0.3\*10\^9 cells/L (basophils), 0 to 500 cells/L(eosinophils), 41 to 50 percentage of RBC in blood (hematocrit), 1,000 - 4,800 lymphocytes per microliter (µL) of blood (lymphocytes), 80-100 fl (erythrocytes, mean corpuscular volume), 2 to 8 percentage of WBC (monocytes), 40 to 60 cells/mcL (neutrophils) and Women: 4.2 to 5.4 million RBC/ mcL of blood and Men: 4.7 to 6.1 million RBC/ mcL (erythrocytes count). Participants were counted in worst case category that their value changes to low, normal or no change \[NC\] or high), unless there is NC in their category. Participants whose laboratory value category was unchanged (e.g. High to High) or whose value became normal, were recorded in To Normal or No Change category. Participants were counted twice if participant had values that changed To Low and To High, so percentages may not add to 100%.
Time frame: Up to approximately 367 weeks
Population: All Treated Population. Only those participants with data available at specified categories have been analyzed.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Low | 4 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To High | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Low | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To High | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Normal or No Change | 10 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Low | 4 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To High | 3 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To High | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Normal or No Change | 14 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Low | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Low | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Normal or No Change | 11 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Normal or No Change | 14 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Normal or No Change | 10 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To High | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, Mean Corpuscular Volume, To High | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Lymphocytes, To Normal or No Change | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To High | 12 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Lymphocytes, To Low | 2 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Normal or No Change | 224 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Normal or No Change | 180 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Low | 66 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To High | 10 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Low | 7 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Neutrophils, To High | 2 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Low | 22 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Neutrophils, To Normal or No Change | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Neutrophils, To Low | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Normal or No Change | 192 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To High | 12 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To High | 63 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Normal or No Change | 181 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To High | 39 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Low | 8 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Low | 73 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Lymphocytes, To High | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, Mean Corpuscular Volume, To Normal or No Change | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, Mean Corpuscular Volume, To Low | 0 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Normal or No Change | 169 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Lymphocytes, To Low | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To High | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Lymphocytes, To Normal or No Change | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To High | 12 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Low | 13 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Low | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Low | 2 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Normal or No Change | 22 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Low | 2 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To High | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Normal or No Change | 39 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Neutrophils, To Low | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To High | 3 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To High | 13 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Neutrophils, To Normal or No Change | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Lymphocytes, To High | 0 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Normal or No Change | 29 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Low | 18 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Normal or No Change | 29 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Neutrophils, To High | 1 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Normal or No Change | 27 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To High | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Low | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Normal or No Change | 22 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To High | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Low | 1 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Normal or No Change | 20 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To High | 2 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Low | 7 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Normal or No Change | 16 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Low | 0 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Normal or No Change | 15 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To High | 8 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Low | 6 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Normal or No Change | 16 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To High | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Low | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Low | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Low | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Normal or No Change | 2 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To High | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Low | 4 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Normal or No Change | 3 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Normal or No Change | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Normal or No Change | 4 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Normal or No Change | 4 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To High | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To High | 2 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Low | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To High | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To High | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Normal or No Change | 6 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Low | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Low | 3 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To High | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To High | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To High | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Low | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To High | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Low | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Low | 3 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Normal or No Change | 3 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Normal or No Change | 5 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Normal or No Change | 6 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To High | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Normal or No Change | 3 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Normal or No Change | 5 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Low | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To High | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Low | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Normal or No Change | 4 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Normal or No Change | 5 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To High | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Low | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To High | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Normal or No Change | 5 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Low | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To High | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Normal or No Change | 5 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Low | 0 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To High | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Low | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Low | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To High | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Normal or No Change | 1 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To High | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To High | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Normal or No Change | 1 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Normal or No Change | 1 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Eosinophils, To Normal or No Change | 1 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To Low | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To Normal or No Change | 1 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Basophils, To High | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Hematocrit, To Low | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Erythrocytes, To Low | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline | Monocytes, To High | 0 Participants |
Secondary
Part 2B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline
Urine samples were collected to assess urine glucose, ketones and occult blood using dipstick method. The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as negative, trace, 1+, 2+, 3+ indicating proportional concentrations in the urine sample. Baseline (Day 1) was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Result for urinalysis parameters were recorded as no change/decreased and any increase.
Time frame: Up to approximately 367 weeks
Population: All treated population. Only those participants with data available at specified categories have been analyzed.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, Any increase | 3 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, No Change/Decreased | 14 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, Any increase | 0 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, No Change/Decreased | 13 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, No Change/Decreased | 8 Participants |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, Any increase | 1 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, No Change/Decreased | 183 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, No Change/Decreased | 228 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, Any increase | 70 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, Any increase | 107 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, Any increase | 24 Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, No Change/Decreased | 129 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, No Change/Decreased | 28 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, No Change/Decreased | 31 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, Any increase | 2 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, Any increase | 13 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, Any increase | 12 Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, No Change/Decreased | 42 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, No Change/Decreased | 15 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, No Change/Decreased | 21 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, Any increase | 2 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, No Change/Decreased | 16 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, Any increase | 7 Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, Any increase | 7 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, No Change/Decreased | 3 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, Any increase | 0 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, Any increase | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, No Change/Decreased | 4 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, Any increase | 1 Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, No Change/Decreased | 3 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, No Change/Decreased | 4 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, Any increase | 1 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, Any increase | 0 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, No Change/Decreased | 2 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, No Change/Decreased | 5 Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, Any increase | 3 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, Any increase | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, No Change/Decreased | 4 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, No Change/Decreased | 5 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, No Change/Decreased | 4 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, Any increase | 1 Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, Any increase | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, Any increase | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Ketones, No Change/Decreased | 1 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, Any increase | 0 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Occult Blood, No Change/Decreased | 1 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, No Change/Decreased | 1 Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline | Glucose, Any increase | 0 Participants |
Secondary
Part 2B: Overall Response Rate (ORR)
ORR was defined as the percentage of participants with a confirmed irCR or confirmed irPR per irRECIST. irCR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. irPR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.
Time frame: Up to approximately 367 weeks
Population: All Treated population
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Overall Response Rate (ORR) | 7 Percentage of Participants |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Overall Response Rate (ORR) | 20 Percentage of Participants |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Overall Response Rate (ORR) | 18 Percentage of Participants |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Overall Response Rate (ORR) | 30 Percentage of Participants |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Overall Response Rate (ORR) | 0 Percentage of Participants |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Overall Response Rate (ORR) | 17 Percentage of Participants |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Overall Response Rate (ORR) | 0 Percentage of Participants |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Overall Response Rate (ORR) | 0 Percentage of Participants |
Secondary
Part 2B: Overall Survival (OS)
OS was defined as the interval between the date of first assigned study therapy/randomization and date of death due to any cause.
Time frame: Up to approximately 367 weeks
Population: All Treated
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Overall Survival (OS) | 8.9 Months |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Overall Survival (OS) | 12.5 Months |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Overall Survival (OS) | 12.1 Months |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Overall Survival (OS) | 10.8 Months |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Overall Survival (OS) | NA Months |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Overall Survival (OS) | NA Months |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Overall Survival (OS) | 4.7 Months |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Overall Survival (OS) | 1.1 Months |
Secondary
Part 2B: Progression-free Survival (PFS)
PFS was defined as the interval between the date of first dose of study treatment (or date of randomization for randomized cohorts) and the date of disease progression according to radiological response from investigator assessment, or death due to any cause, whichever occurs earlier. Disease progression was defined as the date of radiological disease progression based on imaging data per RECIST v1.1.
Time frame: Up to approximately 367 weeks
Population: All Treated
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Progression-free Survival (PFS) | 2.6 Months |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Progression-free Survival (PFS) | 3.9 Months |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Progression-free Survival (PFS) | 2.3 Months |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Progression-free Survival (PFS) | 4.4 Months |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Progression-free Survival (PFS) | 2.1 Months |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Progression-free Survival (PFS) | 3.1 Months |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Progression-free Survival (PFS) | 1.5 Months |
| Part 1A: Fela 3.000 mg/kg | Part 2B: Progression-free Survival (PFS) | 0.8 Months |
Secondary
Part 2B: Receptor Occupancy of Feladilimab
Blood samples were collected to assess the cluster of differentiation 4 (CD4+) and cluster of differentiation 8 (CD8+) receptor occupancy by Feladilimab as a pharmacodynamic analysis. It was assessed using validated flow cytometry assay.
Time frame: Up to approximately 367 weeks
Population: All treated population. As pre-specified in the protocol, only specified treatment arms were planned and hence there are 0 participants analyzed for rest of the arms.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Receptor Occupancy of Feladilimab | %CD4+ | 95.795 percent receptor occupancy | Geometric Coefficient of Variation 4.267 |
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Receptor Occupancy of Feladilimab | %CD8+ | 89.773 percent receptor occupancy | Geometric Coefficient of Variation 8.36 |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Receptor Occupancy of Feladilimab | %CD4+ | 95.750 percent receptor occupancy | Geometric Coefficient of Variation 8.757 |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Receptor Occupancy of Feladilimab | %CD8+ | 93.581 percent receptor occupancy | Geometric Coefficient of Variation 9.049 |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Receptor Occupancy of Feladilimab | %CD4+ | 99.004 percent receptor occupancy | Geometric Coefficient of Variation 1.658 |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Receptor Occupancy of Feladilimab | %CD8+ | 96.900 percent receptor occupancy | Geometric Coefficient of Variation 4.013 |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Receptor Occupancy of Feladilimab | %CD4+ | 99.988 percent receptor occupancy | Geometric Coefficient of Variation 0.827 |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Receptor Occupancy of Feladilimab | %CD8+ | 102.610 percent receptor occupancy | Geometric Coefficient of Variation 9.138 |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Receptor Occupancy of Feladilimab | %CD4+ | 87.194 percent receptor occupancy | — |
| Part 1A: Fela 0.100 mg/kg | Part 2B: Receptor Occupancy of Feladilimab | %CD8+ | 57.856 percent receptor occupancy | — |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Receptor Occupancy of Feladilimab | %CD4+ | 101.663 percent receptor occupancy | Geometric Coefficient of Variation 2.364 |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Receptor Occupancy of Feladilimab | %CD8+ | 106.059 percent receptor occupancy | Geometric Coefficient of Variation 14.555 |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Receptor Occupancy of Feladilimab | %CD4+ | 100.790 percent receptor occupancy | Geometric Coefficient of Variation 1.198 |
| Part 1A: Fela 1.000 mg/kg | Part 2B: Receptor Occupancy of Feladilimab | %CD8+ | 103.802 percent receptor occupancy | Geometric Coefficient of Variation 6.179 |
Secondary
Part 2B: Time to Overall Response (TTR)
TTR was defined as the time from date of first dose of study treatment/randomization to the date of first documented confirmed (=4 weeks) CR or PR. CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 mm. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.
Time frame: Up to approximately 367 weeks
Population: All Treated Population with a confirmed CR or PR. Only responders were included for the analysis.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Part 1A: Feladilimab (Fela) 0.001 Milligram/Kilogram (mg/kg) | Part 2B: Time to Overall Response (TTR) | 2.1 Months |
| Part 1A: Fela 0.003 mg/kg | Part 2B: Time to Overall Response (TTR) | 2.1 Months |
| Part 1A: Fela 0.010 mg/kg | Part 2B: Time to Overall Response (TTR) | 2.0 Months |
| Part 1A: Fela 0.030 mg/kg | Part 2B: Time to Overall Response (TTR) | 2.1 Months |
| Part 1A: Fela 0.300 mg/kg | Part 2B: Time to Overall Response (TTR) | 2.2 Months |